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  Abstract 
 
ii 
Approximately 340 million people worldwide have Type 2 Diabetes Mellitus (T2DM), 
making identification of the aetiological processes underlying this disease imperative. 
Endoplasmic reticulum (ER) stress has emerged as a potential mechanism driving the 
pathogenesis of obesity and T2DM. Palmitate, the predominant saturated fatty acid elevated 
in the blood plasma of obese individuals, induces ER stress and insulin resistance in skeletal 
muscle. However, the interaction between ER stress, lipid metabolism and T2DM remains 
poorly understood. This thesis uses lipidomic tools to investigate skeletal muscle ER stress in 
cell culture and animal models. Chronic palmitate treatment of both mouse C2C12 and 
human primary myotubes induced ER stress, concurrent with the cytosolic phospholipase A2-
dependent release of polyunsaturated fatty acids (PUFAs) from phosphatidylcholines (PCs). 
This phenotype was also observed in skeletal muscle from mouse models of diet-induced 
obesity and T2DM patients. Palmitate-stimulated catabolism of PUFA-containing PCs was 
concomitant with increases in bioactive eicosanoid secretion, which was shown to be 
important in the control of ER stress, inflammatory signalling and macrophage activation. 
This provides a novel link between palmitate and the control of ER stress and inflammation 
in metabolic disease.  
Previous work has suggested that the propagation of ER stress signalling between cells may 
result from the secretion of a, as yet undefined, cell non-autonomous signal. In this thesis, 
long-chain ceramides (40:1 and 42:1) were identified as signals transmitting the induction of 
ER stress between myotubes via exosome-mediated transport. Long-chain ceramide 
concentrations were increased in skeletal muscle and blood plasma from in vivo models of 
obesity and were elevated in the muscle of T2DM patients. Muscle synthesis of long chain 
ceramides in response to palmitate was found to occur via the de novo pathway and was 
linked to ER stress by Perk, an important unfolded protein response kinase. This work 
identifies ceramides as cell non-autonomous signals that propagate ER stress activation 
following exposure to palmitate, providing a novel mechanism for stress signalling in obesity 
and insulin resistance. 
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Introduction 
 
1.1 The metabolic syndrome 
The metabolic syndrome describes a collection of risk factors for cardiovascular disease and 
type 2 diabetes mellitus (T2DM) 1. The World Health Organisation (WHO) definition of the 
metabolic syndrome states that patients must exhibit insulin resistance, a condition 
characterised by an inhibited response to insulin, and then two further risk factors, which may 
include: obesity, defined as the accumulation of white adipose tissue (WAT) and reflected in 
a body mass index (BMI) above 30; hyperglycaemia, referring to raised fasting blood glucose 
levels resulting from insulin resistance; dyslipidaemia, indicated by raised plasma 
triacylglyceride (TG) levels above 150 mg/dL, low high-density lipoprotein (HDL) 
cholesterol levels (below 35 mg/dL in men and 39 mg/dL in women) and an increase in low 
density lipoproteins (LDLs); and hypertension – raised blood pressure above 140/90 mm Hg 
2,3. The risk factors are interdependent and underpinned by common mechanisms and 
features.  
The International Diabetes Federation (IDF) estimates that approximately 20-25% of the 
world’s adult population suffer from the metabolic syndrome 4. The prevalence of the 
metabolic syndrome is associated with increases in age and BMI, with 42% of individuals 
aged over 70 suffering from the metabolic syndrome and 60% of obese adults 5,6. 
Furthermore, an increase in body weight of 2.25 kg over a period of 16 years increased risk 
for the development of the metabolic syndrome by 20% in men and 37% in women. 
Similarly, a 2.25 kg decrease in body weight reduced risk by 48% in men and 40% in women 
7.  
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1.1.1 Type 2 diabetes mellitus 
The numbers of individuals suffering from T2DM is increasing at an alarming rate, putting 
pressure on healthcare systems across the world 8. In 2011, an estimated 366 million people 
worldwide suffered from diabetes, with the numbers suffering from T2DM rising to 439 
million by 2030 9. T2DM arises from an interaction between lifestyle and genetic factors, 
with the former including physical inactivity, diet, smoking and a high consumption of 
alcohol 10. As with the metabolic syndrome, obesity is an important risk factor in the 
development of T2DM. Studies in the US highlight that 55% of individuals suffering from 
T2DM are obese, and 85% are overweight 11. Diagnosis of T2DM relies on raised fasting 
plasma glucose levels of >7 mmol/L or plasma glucose levels of >11.1 mmol/L 2 hours after 
an oral dose of glucose, termed an oral glucose tolerance test (OGTT) 12.  
T2DM is characterised by insulin resistance, a state defined as an inability for peripheral 
tissues, such as skeletal muscle, adipose and liver tissues, to respond correctly to insulin 13. In 
the healthy state, insulin is secreted in response to raised blood glucose levels, and binds to 
insulin receptors on peripheral tissues (Figure 1.1). This stimulates autophosphorylation of 
tyrosine residues on the receptor, which, in turn, are recognised by adapter proteins, including 
insulin receptor substrate (IRS) proteins 14. Phosphorylation of IRS proteins stimulates the 
phosphoinositide 3-kinase (PI3K) pathway, leading to the activation of AKT (also known as 
protein kinase B) 15. AKT phosphorylates and inactivates glycogen synthase kinase 3 
(GSK3), increasing glucose storage in the form of glycogen 16. Activation of this pathway 
also stimulates the translocation of glucose transporter type 4 (GLUT4) channels, increasing 
glucose uptake from the blood into cells of peripheral tissues 17. GLUT4 translocation is also 
increased by the insulin-mediated activation of a second pathway. Binding of insulin to its 
receptor activates the CBL-CAP complex that interacts with a membrane domain enriched in 
caveolin 18. The complex then activates the G-protein TC10, which stimulates GLUT4 
translocation and glucose uptake 19. 
As well as the activation of glucose uptake and storage, insulin also inhibits the production 
and release of glucose in the liver. Insulin increases transcription of glycolytic genes, such as 
glucokinase and pyruvate kinase, and decreases expression of phosphoenolpyruvate 
carboxylase, which mediates the rate-limiting step in gluconeogenesis 20,21. In this way, liver 
cells switch from glucose synthesis to utilisation.   
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Insulin signalling also regulates lipid, as well as carbohydrate, metabolism. AKT activates 
mammalian target of rapamycin complex 1 (mTORC1), which is important in the regulation 
of sterol regulatory element-binding protein 1 (SREBP1) 22,23. SREBP1 is a transcription 
factor that increases expression of genes associated with lipid synthesis, such as stearoyl-CoA 
desaturase 1 (SCD1) and fatty acid synthase (FAS) 24.  
Furthermore, insulin reduces rates of lipolysis - the hydrolysis of TGs to produce fatty acids -  
in adipose tissue, decreasing plasma fatty acid levels 25. The regulation of lipolysis controls 
the availability of fatty acids to peripheral tissues such as skeletal muscle and the liver 
depending on their metabolic requirement 26. The catabolism of TGs is catalysed by 3 
enzymes: adipose triacylglyceride lipase (ATGL), which converts TG to diacylglycerides 
(DG); hormone-sensitive lipase (HSL), which converts DG to monoacylglycerol (MG); and 
monoacylglycerol lipase (MGL), which hydrolyses MGs 27. Insulin signalling decreases 
expression of both ATGL and HSL, reducing the rate of lipolysis 28,29. Insulin also reduces 
the activity of both enzymes via the activation of AKT 30.   
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1.1.2 Insulin and skeletal muscle 
The tissue of focus in this thesis is skeletal muscle, the primary site for glucose uptake from 
the blood in healthy individuals 31. In fasting conditions, insulin concentrations in the blood 
are low, and so plasma free fatty acid (FFA) concentrations are high as a result of uninhibited 
adipose lipolysis 32. In these conditions, skeletal muscle is dependent on fatty acid oxidation 
for ATP generation, but this shifts following feeding. Increases in blood glucose stimulate the 
release of insulin, inhibiting adipose lipolysis and reducing plasma FFA concentrations. 
Insulin stimulates skeletal muscle glucose uptake and utilisation, while muscle fatty acid 
oxidation reduces as a consequence of diminishing plasma FFA concentrations. In this way, 
Figure 1.1: The insulin signalling pathway. Insulin binds to the insulin receptor (IR), 
stimulating its phosphorylation and the recruitment of IRS proteins. Phosphorylated IRS 
is recognised by the PI3-K heterodimer, leading to the triphosphorylation of 
phosphatidylinositol (PI) and the formation of the second messenger phosphatidylinositol 
3,4,5-phosphate (PIP3). PIP3 activates AKT, which is important in stimulating the 
recruitment of GLUT4-containing vesicles to the plasma membrane to enhance glucose 
uptake. AKT also phosphorylates GSK3, increasing glycogen synthesis, and mTORC1 to 
increase fatty acid synthesis. Separately, phosphorylation of the insulin receptor 
stimulates, via the CBL/CAP heterodimer, the recruitment of a multi-protein complex to 
microdomains in the plasma membrane. TC10 then also increases the recruitment of 
GLUT4 to the plasma membrane 405.  
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insulin switches the skeletal muscle fuel source from fatty acids to glucose in healthy 
individuals. In response to insulin, approximately 70% of glucose is converted to glycogen, 
with the remaining fraction oxidised 33. Insulin is a crucial hormone in the regulation of 
skeletal muscle metabolism, and so resistance to insulin signalling has profound metabolic 
consequences, leading ultimately to T2DM. One study by DeFronzo and colleagues 
highlighted impairment of skeletal muscle insulin sensitivity in T2DM patients 34. Total 
glucose metabolism was reduced by 38% in T2DM patients, while glucose uptake in the leg 
(primarily by skeletal muscle) was 45% lower in patients compared to healthy controls. The 
importance of skeletal muscle in glucose disposal places the tissue at the centre of blood 
glucose homeostasis. Detailed understanding of mechanisms underpinning insulin resistance 
is, therefore, imperative to improve therapeutics for T2DM patients.  
 
1.1.3 Mechanisms of insulin resistance 
Obesity is the leading risk factor for T2DM, thought to be, in part, as a result of adipose 
dysfunction and the ‘overspill’ of lipids into other tissues (ectopic lipid deposition). Obesity 
is associated with an increase in basal lipolysis in adipose tissue, which is reduced following 
weight loss 35,36. Dysfunctional lipolysis is enhanced in insulin resistance, preventing the 
insulin-induced reduction in lipolytic activity in adipocytes 37,38. Elevated lipolysis results in 
an increase in release of FFAs from the adipose tissue, with research showing that obese 
individuals have increased concentrations of FFAs in their plasma 39. The theory of 
lipotoxicity links raised plasma FFAs with insulin resistance in peripheral tissues. 
 
1.1.4 Lipotoxicity and metabolic dysfunction 
Lipotoxicity is defined as the inappropriate accumulation of lipids in peripheral tissues, 
leading to cellular dysfunction and insulin resistance 40,41. This mechanism was initially 
suggested by Randle and colleagues in a study showing intracellular glucose-6-phosphate 
increases as a result of incubating rodent heart with fatty acids 42. They postulated that this 
was a result of decreased glycolysis, although further studies have indicated that lipid-
induced insulin resistance may arise due to impaired insulin signalling and, as a consequence, 
reduced glucose uptake 43,44. A number of studies have investigated this phenomenon. 
Increasing plasma FFA concentrations for 9 healthy volunteers decreased glucose uptake and 
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glycogen synthesis in skeletal muscle by 46% and 50%, respectively 45. In a separate study, 
plasma free fatty acid concentrations were increased by infusion of three different 
concentrations of Liposyn, a fat emulsion administered intravenously, in healthy individuals. 
Insulin-stimulated glucose uptake was decreased dose-responsively with increases in plasma 
FFA concentrations, while skeletal muscle markers of insulin resistance, such as a reduction 
in phosphorylation of the insulin receptor and Akt, were increased 46. Similarly, acutely 
lowering plasma FFA levels with Acipimox, an inhibitor of lipolysis, improved insulin 
sensitivity and insulin-stimulated glucose uptake in obese individuals 47. 
Fatty acids, the building blocks of more complex lipids, comprise a hydrocarbon chain of 
varying length and saturation, bonded to a carboxylic acid group. Unsaturated fatty acids 
contain one or more carbon-carbon double bonds (C=C). Differences in fatty acid chain 
length and saturation can have a profound effect on the shape and structure of the complex 
lipid they are a part of. For example, increases in the proportion of saturated fatty acids in 
membrane phospholipids can decrease the fluidity of the membrane 48. Fatty acids are also 
substrates for mitochondrial β-oxidation, producing acetyl CoA that feeds in to the 
tricarboxylic acid cycle, and NADH and FADH2 that transport electrons to the electron 
transport chain 49. Metabolism of fatty acids is also important in the generation of signalling 
molecules, such as eicosanoids – a group of bioactive lipids formed by the oxidation of 
polyunsaturated fatty acids (PUFAs) 50.  However, research suggests not all fatty acids are 
equal in metabolic disease, with saturated fatty acids in the plasma, such as palmitate, the 
predominant drivers of fatty acid-induced lipotoxicity 51. Exposure of immortalized mouse 
C2C12 myotubes to palmitate reduced insulin-stimulated glycogen synthesis and inhibited 
phosphorylation and activation of AKT and GSK3, while the monounsaturated fatty acid 
oleate had no effect 52. In a separate study, treatment of rat L6 myotubes with palmitate 
decreased insulin signalling and glucose uptake, while exposure to the monounsaturated fatty 
acid palmitoleate showed increases in glucose uptake and glycogen synthesis 53. Co-treatment 
of skeletal muscle cells with oleate and palmitate ameliorated palmitate-induced insulin 
resistance and inflammation 54. Similarly diets enriched in the polyunsaturated fatty acid 
linolenic or oleic acid improved high fat diet-induced insulin resistance in mice 55,56.  
Mechanisms underpinning lipotoxicity implicate the synthesis of bioactive lipid intermediates 
including ceramides and DGs 57. Ceramides and DGs accumulate in adipocytes, myocytes 
and hepatocytes following acute exposure to palmitate, inducing insulin resistance via protein 
kinase C (PKC) isoforms 52,58–61. Evidence supporting a role for DGs in the development of 
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insulin resistance is convincing in liver tissue, with DG levels and PKCε activity correlating 
negatively with insulin sensitivity, while knockdown of PKCε in the liver protects against 
lipid-induced insulin resistance 62. Mechanisms underpinning the link between DG 
concentrations, PKC activation and insulin resistance centre on the phosphorylation of IRS-1 
(Figure 1.2A) 63. Activation of PKCθ leads to phosphorylation of IRS1 on serine 307, via c-
JUN N-terminal kinase (JNK), and serine 1101 64,65. This inhibits tyrosine phosphorylation 
and prevents activation of PI3K, thereby reducing insulin sensitivity. Similarly, PKCε has 
been shown to phosphorylate serine 636 and 639 to inhibit IRS1 activation 66. The 
importance of PKC-mediated IRS1 phosphorylation was highlighted in a study in which 
serine 302, 307 and 612 were all mutated to alanine, preventing inhibitory phosphorylation 67. 
These mice were partially protected from diet-induced insulin resistance.  
However, the importance of DG signalling in the control of skeletal muscle insulin sensitivity 
is questioned since DG content fails to correlate with insulin resistance in a number of 
different studies 68–70. Instead, research points to ceramides as the important lipotoxic 
mediators in skeletal muscle. Ceramides accumulate in the skeletal muscle of mice fed a high 
fat diet, and plasma concentrations correlate with insulin resistance in T2DM patients 71,72. 
Targeting serine palmitoyl transferase (SPT), which catalyses the first step in ceramide 
biosynthesis, with myriocin, improves insulin sensitivity in mice fed a high fat diet 73. 
Mechanisms underpinning ceramide-induced insulin resistance focus on the inhibition of 
AKT/PKB activity, a key player in the insulin signalling pathway, through activation of 
PKCζ or the phosphatase PP2A (Figure 1.2B) 63. Ceramides bind PKCζ, and the activated 
kinase then phosphorylates AKT on threonine 34 74,75. This prevents recruitment of AKT to 
the plasma membrane upon insulin receptor activation. Furthermore, myriocin treatment also 
alleviated PKB inhibition following palmitate treatment 52,74. PP2A, on the other hand, is a 
phosphatase that dephosphorylates AKT, preventing its activation. Ceramides can bind 
allosterically and activate PP2A, while inhibition of PP2A with okadaic acid ameliorated 
palmitate-induced insulin resistance in C2C12 myotubes 76. Ceramides can also negatively 
impact on the insulin signalling pathway through the kinases JNK and inhibitor of nuclear 
factor kappa-B kinase subunit β (IKKβ), which phosphorylate IRS1 on serine 312 77. 
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Figure 1.2: (A) Diacylglyceride (DG)-mediated lipotoxicity. DGs can activate PKCθ and 
PKCε, which phosphorylate and inhibit activation of IRS1 proteins. This disrupts 
downstream signalling from the insulin receptor. (B) Ceramide-induced lipotoxicity. 
Ceramide-mediated inhibition of the insulin signalling pathway occurs through multiple 
mechanisms. Ceramides activate both PP2A and PKCζ, which inhibit AKT activity. 
Activation of JNK and IKKβ, on the other hand, leads to the inhibition of IRS1. Both 
DGs and ceramides can also increase IKKβ activity, which leads to the degradation of 
IKB and activation of the NF-κB complex, comprising p50 and p65. NF-κB can then 
translocate to the nucleus and increase the transcription of pro-inflammatory genes 405.  
A 
B 
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1.1.5 Lipotoxicity and Chronic Inflammation 
Lipotoxicity is closely integrated with chronic inflammation, now considered a hallmark of 
metabolic disease 78. Obese individuals have increased plasma concentrations of pro-
inflammatory cytokines such as tumour necrosis factor α (TNFα), interleukins (ILs) 1 and 6, 
and C-C motif chemokine ligand 2 (CCL2, also known as monocyte chemoattractant protein 
1) 79. Furthermore, lipid/heparin infusion, which raised plasma FFA concentrations, increased 
the activity of pro-inflammatory nuclear factor-kappa B (NF-κB) in skeletal muscle and liver 
80,81. Palmitate increases the levels of pro-inflammatory cytokines such as TNFα and IL-6 in 
cultured adipocytes, myocytes and hepatocytes, while knockdown of TNFα ameliorates 
palmitate-induced insulin resistance in C2C12 cells 82–84. Plasma ceramides contained in LDL 
increase skeletal muscle inflammation, and palmitate-induced synthesis of ceramides is 
dependent on the inflammatory Toll-like receptor 4 (TLR4) 85,86. Furthermore, ceramides and 
DGs can activate IKKβ, which triggers the degradation of IKB and the translocation of the 
NF-κB complex to the nucleus (Figure 1.2) 77,80. Activated NF-κB increases the expression 
of pro-inflammatory cytokines that include TNFα, IL-1β and IL-6 87.  
Immune cells, particularly macrophages, respond to these cytokine signalling cues, 
infiltrating peripheral tissues 88–91. This environment can then alter the phenotype of 
accumulating macrophages, with consequences for insulin resistance 92. The concept of 
macrophage activation (also termed polarisation) and its associated nomenclature is 
controversial 93. Traditionally, the activation of macrophages is considered as classical (M1) 
or alternative (M2) 94. Classical activation is defined as a pro-inflammatory phenotype, 
characterised by increases in inflammatory cytokines such as TNFα and IL6, as well as an 
increase in nitric oxide (NO). Alternatively activated macrophages are considered anti-
inflammatory with decreased cytokine secretion and increased activity of arginase 1, reducing 
nitric oxide availability. However, the concept of only two distinct macrophage activation 
states is now considered an oversimplification 95. Instead, macrophages are now considered 
across a spectrum of phenotypes, and the M1 and M2 definitions better describe properties of 
pathways that interact to give the macrophage phenotype.  
The importance of macrophage phenotype in the development of insulin resistance has been 
highlighted in a number of studies. CD11c+ proinflammatory macrophages accumulated in 
the skeletal muscle of mice fed a high fat diet, correlating with insulin resistance, while 
CCL2-KO mice did not have increased macrophage numbers and maintained insulin 
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sensitivity  91. Overexpression of CCL2 in murine adipose tissue increased macrophage 
infiltration and induced insulin resistance, while expression of a mutant CCL2 ameliorated 
diet-induced insulin resistance 96. The secretion of pro-inflammatory cytokines from activated 
macrophages can induce insulin resistance in adipocytes, highlighting the role these cytokines 
play in bi-directional cross-talk between peripheral tissues and the immune system (Figure 
1.3). For example, IL-1β, secreted from pro-inflammatory macrophages, induces insulin 
resistance in human primary adipocytes, concurrent with an increase in synthesis and 
secretion of IL-6 and CCL2 97. Conversely, macrophages that exhibit a predominantly M2 
phenotype confer protection against the development of insulin resistance 98. Furthermore, 
palmitate can directly activate immune cells, further enhancing lipid-induced inflammation 
99,100. Macrophages treated with palmitate have increased CD11b expression, as well as 
higher reactive oxygen species and disrupted oxidative phosphorylation 101. In a separate 
study, palmitate treatment increased secretion of pro-inflammatory cytokines from 
macrophages, including TNFα and IL-6 102. Conditioned media from these palmitate-treated 
macrophages was also capable of inducing insulin resistance in myotubes, highlighting that 
the deleterious effects of palmitate on insulin sensitivity in peripheral tissues result from the 
direct lipotoxic insult, as well as a changing inflammatory environment.  
Figure 1.3: Macrophage cross-talk in metabolic disease. Palmitate treatment increase the 
secretion of pro-inflammatory cytokines from insulin-sensitive cells such as myotubes, 
adipocytes and hepatocytes. Macrophages respond to these signalling cues, infiltrating 
peripheral tissues. The increase in cytokine secretion, coupled with exposure to palmitate, 
also induces a switch in macrophage polarisation towards a pro-inflammatory phenotype. 
Activated macrophages increase expression and secretion of pro-inflammatory cytokines 
that can act on peripheral tissues, disrupting insulin signalling and further enhancing the 
activation of inflammatory pathways 405.  
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The evidence supporting roles for lipotoxicity and inflammation in the development of 
insulin resistance is strong. Nonetheless, it is one contributing mechanism in a complex 
multi-factorial disease. With the prevalence of obesity and T2DM on the rise, impacting the 
quality of life of those affected and increasing the burden on health services, there is a 
growing need to determine the mechanisms underpinning other aspects of these diseases. 
Endoplasmic reticulum (ER) stress has recently emerged as a potentially important 
mechanism that drives the pathological changes associated with aspects of the metabolic 
syndrome 103,104.  
 
1.2 The endoplasmic reticulum 
The ER is the largest organelle in the cell and responsible for numerous cellular functions 
including protein folding, oligomer assembly, protein modifications, lipid metabolism, and 
calcium storage, as well as directing proteins into the secretory pathway 105. It is composed of 
membrane-bound branching tubules and flattened sacs, with a membrane that is continuous 
with the nuclear envelope and encloses the ER lumen 106. The structure of the ER is dynamic, 
with this diverse set of roles performed in distinct microdomains specialised for each function 
107.  
One of the primary functions of the ER is the control of protein homeostasis, including the 
regulation of protein synthesis and folding. ER-bound ribosomes synthesise integral 
membrane and secretory proteins, with nascent protein chains co-translationally translocated 
across the ER membrane 108. Integral membrane proteins contain a stretch of hydrophobic 
residues that delay translation during translocation and anchor it in the ER membrane, before 
the completion of synthesis 109. Following translocation, secretory proteins are folded into 
their native structure and modified, such as with N-linked glycosylation or the formation of 
disulphide bonds 110. Chaperones, co-chaperones and protein disulphide isomerases aid in this 
process, providing an environment favourable to protein folding 110. Recent studies have also 
shown the accumulation of mRNAs encoding cytosolic proteins on ribosomes attached to the 
ER, implicating the ER in the translation of a portion of cytosolic proteins 111,112.   
In addition to protein synthesis, the ER is crucial to the biogenesis of lipids, particularly 
membrane lipids. The synthesis of glycerolipids, including phosphatidylcholines (PCs), 
phosphatidylethanolamines (PEs), phosphatidylinositols (PIs) and phosphatidylserines (PSs) 
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all take place in the ER, as well as the synthesis of sphingolipids such as ceramides 113. 
Furthermore, the mevalonate pathway, leading to the synthesis of cholesterol and other 
sterols, also takes place in the ER 114,115. ER-synthesised lipids are then distributed 
throughout the cell via vesicles or lipid-protein transporters 116. Lipids can be modified in 
other cellular compartments, such as the conversion of ceramides to glucosyl- and lactosyl-
ceramides, or sphingomyelin, in the Golgi following the transport of ceramides by the 
ceramide transfer protein (CERT) 117.  
Beyond protein and lipid synthesis, the ER is also an essential store of calcium ions (Ca2+), 
with concentrations much higher in the lumen of the ER compared to the cytosol (100-800 
µM vs. 100 nM) 118–120. Ca2+ is an important mediator of inositol 1,4,5-triphosphate (IP3) 
secondary messenger signalling pathways and crucial in the regulation of protein function 
and localisation 121. Chaperones bind Ca2+ as a cofactor and the ion is required for the correct 
functioning of the proteins 122. It is therefore crucial that ion levels are tightly regulated by 
the ER, ensuring fidelity of signalling pathways and protein folding. Calcium concentrations 
are regulated by ER calcium channels, ryanodine receptors, which are activated in response 
to elevated Ca2+, and IP3 receptors, which are stimulated by IP3 following phospholipase C 
activation 123.  
 
1.2.1 The unfolded protein response  
With such a crucial role in cellular function and protein homeostasis, it’s important that the 
ER can adapt to changing environments that place stress upon the organelle. In particular ER 
stress arises from the accumulation of unfolded proteins and triggers the unfolded protein 
response (UPR), a protective signalling cascade 124. Multiple stimuli have been documented 
to induce ER stress, impinging on the protein folding capabilities of the ER. These include 
glucose deprivation, exposure to high concentrations of plasma lipid, disruption of Ca2+ ion 
homeostasis, hypoxia, and changes in the redox state of the ER 125. 
Activation of the UPR improves protein folding conditions and reduces protein load on the 
ER, alleviating stress. The UPR signalling pathway consists of three distinct arms, mediated 
by protein kinase R-like endoplasmic reticulum kinase (PERK), inositol requiring enzyme 1 
(IRE1), and activating transcription factor 6 (ATF6) 126 (Figure 1.4). These three proteins are 
maintained in an inactive state by the chaperone glucose regulated protein 78 kDa (GRP78) 
(also known as BiP). GRP78 dissociates from the UPR signalling molecules to bind to 
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accumulating misfolded proteins. This triggers their activation, combining the detection of 
ER stress with the instigation of the UPR.  
Upon activation, PERK oligomerises and phosphorylates both itself and eukaryotic initiation 
factor 2α (eIF2α), inhibiting protein translation 127. By reducing protein translation the protein 
load on the stressed ER is lowered. However, some transcripts, such as the activating 
transcription factor 4 (ATF4) mRNA, contain an internal ribosome entry site (IRES) and so 
are exempt from translational repression imparted by PERK activation 128. ATF4 is a 
transcription factor whose targets include C/EBP-homologous protein (CHOP) and growth 
arrest and DNA damage-inducible 34 (GADD34) 129,130. CHOP is a pro-apoptotic 
transcription factor, implicating the PERK arm of the UPR in the regulation of programmed 
cell death following unresolved ER stress 131. Other targets of ATF4 include protein folding 
and antioxidant genes to improve the protein folding environment of the ER 132,133.  
IRE1 has both kinase and endoribonuclease functions. Following activation and 
oligomerisation, IRE1 splices x-box binding protein 1 (XBP1) mRNA, producing a basic 
leucine zipper transcription factor that increases expression of numerous UPR genes 
responsible for heightening protein folding, secretion and degradation capabilities 134,135. ER-
associated degradation (ERAD) removes misfolded proteins from the ER lumen via 
ubiquitination and proteasomal degradation 136. IRE1 also cleaves the ER-localised mRNA of 
many secretory proteins in a pathway termed regulated IRE1-dependent decay (RIDD), thus 
reducing the protein load on the ER 137.  
The activation of the IRE1 arm of the UPR is also closely integrated with nutrient 
availability, and metabolic regulation. Forced expression of spliced XBP1 increases levels of 
phosphatidylcholines, an important phospholipid of the ER membrane, and membrane 
surface area 138. XBP1 splicing is also dependent on mTORC1 pathway, which is crucial in 
nutrient sensing and energy availability 139. Inhibition of mTORC1 with rapamycin reduced 
diet-induced activation of IRE1 and XBP1 in rats 140.  
Activated ATF6 is transported to the Golgi where it is processed by two site specific serine 
proteases to release its cytosolic domain 141. The cytosolic domain then translocates to the 
nucleus, activating the transcription of UPR target genes. These genes include chaperones 
such as BiP and glucose regulated protein 94 (GRP94) that aid in protein folding by 
providing a stable environment in which to fold 142,143. ATF6 also increases the expression of 
protein disulphide isomerase (PDI), which aids in the formation of disulphide bonds in 
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secreted proteins – one of the rate-limiting steps in protein folding 144. ATF6-null mice have 
also shown the transcription factor to be important in protecting cells from chronic stresses 
145.  
Recent work has demonstrated the induction of ER stress can be controlled in an endocrine 
manner, with the activation of ER stress in one tissue leading to the induction of the UPR in a 
distal tissue 146. Studies have highlighted the ability of prostate cancer cells and mammary 
carcinoma cells to transmit ER stress to neighbouring macrophages, concomitant with a 
switch to a pro-inflammatory and pro-angiogenic macrophage phenotype 147,148 . This 
remodelling of macrophage phenotype implicates the cell non-autonomous transmission of 
ER stress in tumour progression. In a separate study, constitutive expression of spliced XBP1 
in the neuronal tissue of C. elegans induced ER stress in intestinal cells and increased 
longevity of the animals by 32% 149. This work also translates to mouse models, in which 
constitutive expression of spliced XBP1 in neurons induced ER stress in hepatocytes, whilst 
also ameliorating diet-induced adiposity and insulin resistance 150. This final study highlights 
that cell nonautonomous control of ER stress has implication for metabolic disease, but 
remains understudied at this point.  
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1.2.2 Endoplasmic reticulum stress and the metabolic syndrome 
Beyond its role in proteostasis, the ER is also an important site for lipid metabolism 151. In 
particular, the smooth ER is responsible for the synthesis of phospholipids, cholesterol and 
ceramides 152. The accumulation of lipids and dysregulation of lipid homeostasis underpins 
several cardiometabolic risk factors of the metabolic syndrome, and is a well-documented 
cause of insulin resistance 153. Thus, it’s suggested that disruption of ER homeostasis, and the 
subsequent activation of the UPR, may impact upon lipid metabolism and contribute to the 
dyslipidaemia associated with obesity and T2DM 151,154. Recent work, establishing that 
elements of the UPR can affect energy homeostasis, insulin sensitivity and lipid metabolism 
Figure 1.4: The unfolded protein response (UPR) consists of three signalling pathways, 
mediated by PERK, IRE1 and ATF6. Upon the accumulation of unfolded proteins, BiP 
dissociates from the luminal domains of PERK, IRE1, and ATF6, activating the UPR. 
PERK phosphorylates eIF2α, inhibiting translation and concomitantly activating the 
IRES-containing transcription factor, ATF4. IRE1 splices XBP1, with the spliced 
transcript producing a transcription factor that activates expression of UPR target genes. 
ATF6, upon activation, is processed in the Golgi before translocating to the nucleus and 
increasing expression of genes including XBP1, CHOP and ER chaperones 405.  
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supports this hypothesis. Mice defective for eIF2α phosphorylation exhibited hypoglycaemia, 
increased insulin sensitivity and decreased liver glycogen stores 155. When fed a high-fat diet, 
these eIF2α-null mice had reduced hepatosteatosis and greater insulin sensitivity when 
compared to the wild-type mice. Furthermore, these mice exhibited reduced liver expression 
of peroxisome proliferator-activated receptor γ (PPARγ), a ligand activated nuclear receptor 
and master regulator of lipid metabolism 156.  
ATF4 has also been shown to have an important role in metabolism. ATF4-knockout (KO) 
mice have reduced WAT, decreased lipogenic gene expression and increased β-oxidation in 
the WAT 157. These mice also had increased expression of uncoupling protein 2 (UCP2) in 
WAT and UCP1, 2 and 3 in brown adipose tissue, implying an increase in fatty acid 
utilisation and thermogenesis. Expression of ATF4 decreases insulin sensitivity in skeletal 
muscle, adipose tissue and the liver 158.  
IRE1 has been observed to participate in hepatic lipid metabolism and may have a protective 
effect against ER-stress induced hepatic steatosis 159. Hepactocyte-specific-IRE1α-KO mice 
exhibited altered lipid metabolism when treated with the canonical inducer of ER stress, 
tunicamycin. IRE1α hepatic-null mice had enhanced steatosis and reduced concentration of 
plasma lipids, accompanied by a reduction in apoB-containing lipoprotein secretion, and an 
increased expression of the lipogenic genes. These transcriptional changes fell into three 
categories, with increases in: 1) C/EBP transcription factors and PPARγ; 2) adipose 
differentiation-related protein (ADRP) and fat-storage inducing transmembrane proteins 
(FIT) 1 and 2; 3) triglyceride biosynthesis enzymes (DGAT 1 and 2, SCD1, and ACC1). 
However, it is unclear whether the lack of IRE1 per se, or prolonged ER stress as a result of 
the IRE1-KO, triggered the induction of lipogenic genes and the accumulation of lipid within 
hepatocytes.  
Furthermore, ATF6 has been proposed to antagonise sterol regulatory-element binding 
protein 2 (SREBP2)-mediated lipogenesis. Tunicamycin-induced ER stress in ATF6-KO 
mice stimulated the accumulation of neutral lipids, including TGs and cholesterol 160. These 
changes were ascribed to increased lipid droplet formation as a result of reduced fatty acid β-
oxidation, inhibited VLDL formation and an increase in expression of ADRP. In an 
analogous situation to the IRE-1 null mouse model, it is unclear whether ATF6 is directly 
protective, or the loss of the transcription factor leads to prolonged ER stress that underpins 
the metabolic dysregulation observed.  
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The interaction between ER stress and metabolic perturbation is bidirectional. While ER 
stress disrupts lipid metabolism, dysregulation of lipid metabolism can also trigger ER stress, 
thus forming a self-reinforcing circuit. Mouse models of obesity, including the leptin null 
Ob/Ob mouse, and mice fed a high-fat diet, exhibit increases in PERK and IRE-1 
phosphorylation in adipose tissue and the liver 103. Similar associations are observed in 
humans, with Boden and Merali demonstrating an upregulation of ER stress proteins in the 
adipose tissue of obese individuals compared to lean 161. There is a positive correlation 
between body mass index (BMI) and ER stress markers in human subcutaneous adipose 
tissue 162. There is also a reduction in ER stress markers in the liver and adipose tissue of 
obese patients following gastric-band surgery and weight loss 163. Treatment of humans with 
sodium phenylbutyrate (4-PBA), a chemical chaperone that improves protein folding, 
partially alleviated lipid-induced insulin resistance and beta-cell dysfunction 164.  
 
1.2.3 Free fatty acids as inducers of endoplasmic reticulum stress 
High-fat diets elevate plasma FFA concentrations 165,166, and these FFAs and dyslipidaemia 
contribute to whole-body insulin resistance 167. The treatment of cells and tissues with the 
fatty acid, palmitate, has been employed as a model to understand the underlying mechanisms 
of lipid-induced insulin resistance 168,169. ER stress has been identified as an underlying 
mechanism behind palmitate-induced insulin resistance in skeletal muscle, adipocytes and 
hepatocytes 170–172. Both overexpressing the chaperone protein, BiP, and knocking down 
expression of PERK attenuated palmitate-induced cell death in liver cells 173,174. Recent work 
has highlighted phospholipid bilayer composition as a potential mechanism linking palmitate 
loading with ER stress in liver. Overexpressing Lpcat3 increased the incorporation of 
polyunsaturated fatty acids (PUFAs) into phospholipids and ameliorated palmitate-induced 
ER stress  175. Elegant work by Fu et al. focused on the lipid content of the ER itself, 
analysing fractionated ER from lean and obese liver tissue from mice. The ER was subjected 
to comparative proteomic and lipidomic analysis, with the results highlighting a switch from 
protein to lipid synthesis in the ER. The study highlighted remodelling of ER phospholipids, 
which incorporated increased amounts of de novo synthesised saturated fatty acids in obese 
livers at the cost of polyunsaturated fatty acids from the diet. Furthermore, they demonstrated 
that an increase in the phosphatidylcholine/phosphatidylethanolamine (PC/PE) ratio disrupted 
the functioning of the sarco/endoplasmic reticulum calcium ATPase (SERCA) pump. 
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Correcting the PC/PE ratio by knocking down Pemt, which codes for 
phosphatidylethanolamine N-methyltransferase, the enzyme that converts PE to PC, in obese 
mice reduced ER stress and improved glucose homeostasis 176. This work highlights the 
potential importance of the lipidome in mediating palmitate-induced ER stress.  
Palmitate also induces ER stress in adipocytes, while treatment of adipocytes with TUDCA 
reduces palmitate-induced inflammation and improves insulin signalling 171,177. Similarly, 
inhibition of mTORC1 with rapamycin alleviated palmitate-induced ER stress in adipocytes, 
via an autophagy-dependent mechanism 178. In the same study rapamycin also decreased 
palmitate-induced inflammation, with reduced nuclear translocation of NF-κB and decreased 
secretion of CCL2 and IL6, suggesting an important role for mTOR signalling in palmitate-
induced ER stress and inflammation.  
While evidence supporting a role for palmitate-induced ER stress in the liver and adipose 
tissue is strong, the argument is unclear in skeletal muscle. Treatment of human myotubes 
with palmitate is associated with increases in UPR markers and this induction is prevented 
with overexpression of SCD1 179, which also highlights the potential benefits of fatty acid 
desaturation in palmitate-induced ER stress and lipotoxicity. Alleviating ER stress using 
oleate or AMPK/PPARδ activation also ameliorated insulin resistance and inflammation, 
further implicating ER stress as a connecting mechanism between palmitate and insulin 
resistance 54,180. However, this work is contradicted by research demonstrating that chemical 
chaperones do not improve palmitate-induced insulin resistance 181. 
With ER stress markers correlating with obesity, and cell culture and rodent experiments 
highlighting the mechanistic importance of saturated fatty acid-induced ER stress in the 
development of lipid-induced insulin resistance, it is important to dissect the effects of ER 
stress on lipid metabolism in detail. In this way, the contribution of ER stress to the 
pathologies of obesity and T2DM can be assessed, leading to the identification of potential 
novel therapeutic targets and strategies. The use of metabolomics and lipidomics can provide 
a detailed metabolic snapshot, highlighting pathway alterations following the induction of ER 
stress. This may provide novel insights into the mechanisms underpinning ER stress, 
dyslipidaemia and insulin resistance.   
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1.3 Metabolomics and lipidomics 
 
1.3.1 The omics revolution  
The term ‘omics’ refers to technologies that allow for the untargeted profiling of molecules in 
biological samples, which has led to a vast number of applications 182. This term now 
encompasses the study of genes (genomics), genetic modifications (epigenomics), mRNA 
(transcriptomics), proteins (proteomics), and metabolites (metabolomics), including the fast-
growing field of lipidomics – the study of lipid metabolism (Figure 1.5) 183. The use and 
integration of these techniques can provide insight in to disrupted biochemical pathways that 
underpin disease progression, as well as markers that delineate between healthy and diseased 
populations 184. Progress in the field has been driven by rapid advances in technology, 
highlighted by the improvements in DNA sequencing over the last 50 years and the 
subsequent impact on the field of genomics 185. First generation sequencers that used a 
modified “Sanger sequencing” technique were capable of read lengths less than one kilobase 
long. Utilised as part of a shotgun sequencing method, these machines were crucial in the 
Human Genome Project, and the sequencing of the first human genome. Now with the advent 
of third generation sequencers, read lengths are in excess of 10 kb, aiding in genome 
assembly, at a much lower cost 186. Now similar technological advances in mass spectrometry 
allow for a more cost-effective and sensitive analysis of thousands of small molecule 
metabolites and proteins 187,188.  
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Understanding of biological systems is aided by the integration of multiple omic fields, each 
adding a complimentary layer of information to help sift through compensatory changes to 
the key pathway alterations that underpin disease states 183,189,190. There are a number of 
different approaches in the design of multi-omic studies 183. The “genome-first approach” 
uses genomics for the identification of loci arising from genome-wide association studies 
(GWAS) of particular diseases. Transcriptomics, proteomics and metabolomics can then be 
used to understand the causality of these variants and particular pathways that are altered to 
drive disease. However, the “phenotype-first” approach correlates omic data with observable 
or measurable aspects of disease to provide insight into disrupted pathways. The integration 
Figure 1.5: Omic techniques profile each layer of the central dogma and have aided our 
understanding of the interaction between each stage. This is no longer considered a 
simple linear pathway that begins at the genome and ends in the products of enzyme 
catalysis. Instead metabolites and proteins feedback into each preceding level, playing 
critical regulatory roles.   
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of omic techniques is best utilised in the study of complex diseases, which have combined 
polygenic and environmental influences in their aetiology. The multi-faceted nature of 
metabolic disease makes it a prime candidate for omic analysis 1. This thesis employs mass 
spectrometry-based lipidomics combined with RT-qPCR to understand mechanisms 
underpinning metabolic disease.  
 
1.3.2 Metabolomics and lipidomics 
Metabolomics refers to the study of metabolism at a system-wide level, measuring the small 
molecule complement of a range of different samples, including cells, tissues and biofluids 
191–193. It provides a global steady-state snapshot of the metabolic profile of a biological 
system and how this changes upon a shift in conditions, improving on the canonical 
biochemistry techniques of single metabolite or enzyme analysis, and thus making it ideal for 
the study of diseases in which metabolism is disrupted. 
The analytical techniques commonly used in metabolomic studies include nuclear magnetic 
resonance (NMR) spectroscopy, and chromatography coupled mass spectrometric (MS) 
analysis, typically liquid chromatography (LC)- or gas chromatography (GC)-MS. Each 
technique provides both unique and overlapping information, with no one technique able to 
provide complete coverage of the metabolome 191. NMR spectroscopy, although highly 
quantitative, suffers from comparatively poor sensitivity, covering a smaller range of 
metabolites compared to MS 194. Thus this project makes use of MS-based platforms, 
allowing for the detection of a large number of metabolites across a broad range of 
concentrations 191.  
The term lipidomics was first coined in 2003, and describes a set of techniques for the 
profiling of lipid metabolism 195. Our understanding of lipids has evolved from the view of 
lipids as structural molecules important to the integrity of the cell to one that also places huge 
importance on the role they play in signalling and coordination of fundamental biochemical 
and cellular processes. The number of lipid species is predicted to be in the range of tens of 
thousands to hundreds of thousands 196.  With this, technological advancements have 
increased our ability to profile a vast range of lipid species using a variety of MS techniques. 
Below, the uses of GC-MS and LC-MS in lipidomics are discussed. It is important to note 
that direct infusion mass spectrometry (DI-MS), ion mobility mass spectrometry (IM-MS) 
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and mass spectrometry imaging are alternative lipidomic techniques, but are not utilised in 
this thesis and are not expanded upon here.  
 
1.3.3 Gas chromatography-mass spectrometry  
Developed over 60 years ago, GC-MS is an analytical technique employed commonly in the 
metabolomic field that aids in the separation and quantitation of analytes within a mixture 197. 
Samples are vaporised and carried by an inert gas through a column during which compounds 
are separated through their interaction with a stationary phase. Analytes are then detected by 
a coupled mass spectrometer. Since samples are vaporised, it is important that analytes are 
volatile and thermally stable. In some cases, these properties can be enhanced by 
derivatisation – the chemical modification of analytes. GC-MS has been an important 
metabolomic platform for a number of decades, crucial to the analysis of low molecular 
weight compounds such as sugars, amino acids and fatty acids 198–202. Below, the 
fundamentals of GC-MS will be discussed and its applications to lipidomic analysis in this 
thesis.   
Typically, metabolites are extracted from samples of interest and dissolved in an organic 
solution. The sample is injected on to the GC instrument where it is vaporised immediately. 
An inert carrier gas, such as helium, then carries the sample to a capillary column, coated 
with a siloxane-based stationary phase 203. Analytes interact with the stationary phase to 
varying degrees, based on chain length and desaturation, leading to their separation. The 
column is held in an oven with tight temperature control. The temperature is gradually 
increased, so analytes with lower boiling points elute first, providing an extra degree of 
separation.  
The end of the GC column is interfaced with a mass spectrometer, connected by a heated 
transfer line, for identification and quantitation of analytes. The metabolites must be ionised 
to be detected, with electron ionisation the most commonly used method (Figure 1.6). This is 
a hard ionisation technique, which takes place in a high-vacuum ion source and leads to 
extensive fragmentation of the parent ion. Analytes are ionised using a fixed electron beam 
with a voltage of 70 eV. The electron beam is generated by a filament and collected by an 
electron trap. Analytes and electrons travel at right angles to one another, and the interaction 
between the two results in the loss of an electron and the generation of a positive ion under 
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the more commonly used positive ionisation mode. A magnet, with poles at opposite ends of 
the chamber, induces a spiral in the electron beam to increase interactions between electrons 
and analytes. Electron ionisation greatly increases the energy of the molecule and so leads to 
comprehensive fragmentation of the species of interest. This is useful for identification, with 
the fragmentation pattern of each compound providing important information on the structure 
of the molecule. Numerous databases, such as the NIST/EPA/NIH standard reference 
database, contain reference fragmentation spectra to aid in identification of compounds across 
different types and designs of GC-MS.  
 
Following ionisation and fragmentation, ions are separated and detected in a mass analyser. 
In the case of this thesis, GC is coupled to a quadrupole mass analyser. Quadrupoles consist 
of four parallel rods, typically made of an inert alloy (Figure 1.7). Both a direct current (DC) 
and an alternating radio frequency (RF) potential are applied across the rods. These electric 
fields focus ions from the source to the detector. Only ions of a particular mass-to-charge 
(m/z) ratio can pass through the detector, based on the magnitude of the electric field – all 
other ions are deflected away. The detector generates an electrical signal that is proportional 
Figure 1.6: In electron ionisation, a beam of electrons is generated from a filament 
perpendicular to the direction of travel of analyte molecules. Interaction between 
electrons and analytes leads to the loss of an electron from the analyte, and the formation 
of a positive ion.  
  Chapter 1 
 
24 
 
to the abundance of the ions. By varying the RF, ions of different m/z ratios can be focused to 
the detector, resulting in a mass spectrum.  
In this thesis, GC-MS is employed for the analysis of fatty acids. Fatty acids are the key 
building blocks for lipids and, therefore, their measurement is important to understanding 
alterations in lipid metabolism. Fatty acids are commonly measured by GC-MS following 
their derivatisation to fatty acid methyl esters (FAMEs), a method first employed in 1956 202.  
The derivatisation improves the poor volatility of fatty acids that results from the polar 
carboxylic acid group 204. A number of methods have been described for this process, but this 
thesis uses boron trifluoride (BF3) in methanol as the catalyst (Figure 1.8) 
205,206. This 
derivatisation is an acid-catalysed transesterification, resulting in the hydrolysis of fatty acids 
from complex lipids. Therefore, GC-MS analysis is of the total fatty acid profile, providing a 
good overview of metabolism regardless of the complex lipid the fatty acid originated from.  
Figure 1.7: A quadrupole mass analyser, consisting of four parallel rods. DC and 
alternating radio frequency (RF) potentials are applied across the rods, focusing ions from 
the source to the detector. By varying the RF frequency, ions of a particular m/z ratio are 
focused to the detector.    
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GC-MS is a highly robust and reproducible technique for metabolomics. Fragmentation of 
ions provides a characteristic fingerprint that is important in identifying metabolites and 
providing structural information on unknown compounds. However, the requirement for 
derivatisation is a drawback, increasing the workload required for sample analysis. While 
GC-MS is an excellent technique for analysis of the total fatty acid profile in biological 
samples, the derivatisation ensures that no information on the complex lipids that the detected 
fatty acids are a part of can be inferred. Furthermore, the quadrupole mass analyser has a 
limited mass range of 50-650.  
 
1.3.4 Liquid chromatography-mass spectrometry 
To increase coverage of the lipidome, LC-MS techniques can provide complementary 
information on intact lipids. Liquid chromatography is the most commonly used separation 
technique in metabolomics, largely due to the variety in columns that facilitates the analysis 
of a large number of physicochemically diverse metabolites 207. The technique was pioneered 
in the early 1900s by a botanist, Mikhail Tswett, who used a column and different eluents to 
separate out pigments from a leaf, including the separation of chlorophylls a and b 208. The 
technique has now evolved from LC through high-performance LC (HPLC) to ultra-high-
performance LC (UHPLC) 209.  
In LC systems, solvent (the mobile phase) is pumped by a solvent delivery system at a 
specific flow rate. An autosampler then injects the sample into this flowing solvent, which 
carries the sample to the column. The column is packed with a stationary phase that mediates 
separation of species based on a variety of factors including the pressure and temperature of 
Figure 1.8: Fatty acids are hydrolysed from complex lipid and derivatised using a boron 
trifluoride (BF3)-catalysed transesterification in methanol.  
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the column, the chemical properties of the column surface and eluent solvents utilised. 
Analytes then elute from the column and are detected by a mass spectrometer.  
There are two types of solvent system that operate in LC 210. With isocratic elution, the 
solvent remains the same throughout the run. In gradient elution, however, the solvent 
composition varies during the run. The solvent is varied to increase the elution of analytes 
that interact strongly with the stationary phase. The system used in this thesis makes use of a 
binary solvent system. In this two solvent system, solvent A is a weak solvent, eluting 
compounds that weakly interact with the stationary phase, and solvent B is a stronger solvent. 
The percentage of B is then gradually increased over time. Gradient elution is extremely 
useful for separating compounds across a wide-range of polarities, such as in the profiling of 
lipid species.  
Column choice is critical in the separation of compounds. Increased column length and 
reduced particle size increase separation of compounds, but at a cost of increased pressure 
and longer run times. The choice of stationary and mobile phases are most important to 
efficient separation of analytes, with separation possible based on polarity, charge or size 211.  
The two predominant classes of chromatography used in LC – normal phase liquid 
chromatography (NPLC) and reverse phase liquid chromatography (RPLC) – rely on 
separation of analytes based on polarity. In these systems, mobile and stationary phases have 
different polarities. A compound will therefore have a differing affinity with either the mobile 
or stationary phase depending on its polarity. If a compound has a greater affinity with the 
mobile phase, it will elute faster, but elution time is slower for those compounds with greater 
affinity for the stationary phase. In NPLC, the stationary phase is polar and the mobile phase 
is non-polar, while this is reversed in RPLC. A stationary phase comprising silica is 
extremely polar and used for NPLC, while modifications of this silica group, such as the 
addition of C18 carbon chain, greatly reduce the polarity for the use in RPLC. The latter is a 
common column used for the LC-MS analysis of lipids. A third separation based on polarity 
is hydrophilic-interaction chromatography (HILIC), a variant on NPLC that uses a slightly 
more polar mobile phase to increase elution of highly polar compounds.  
Following separation by LC, analytes are detected by the coupled mass spectrometer. While 
GC-MS traditionally makes use of simple quadrupole analyser, LC-MS can incorporate a 
number of different spectrometers, each with their own advantages and disadvantages. For 
example, while robust and relatively low cost, the quadrupole has a small mass range and 
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poor resolution 212. Hybrid mass spectrometers and orbitraps may be employed instead and 
are discussed below. Other mass analysers include time of flight (ToF) and quadrupole ion 
trap, which are not expanded upon here as they are not employed in this thesis, but are well 
reviewed elsewhere 212–215. 
Most LC-MS systems rely on electrospray ionisation (ESI) to generate ions. The sample, 
dissolved in the mobile phase of the LC system, is sprayed from a thin needle into the ion 
source (Figure 1.9). A high electrical potential is applied across the needle to form charged 
droplets with the same charge as the spray needle. The mechanism underpinning the 
generation of analyte ions differs depending on the type of analyte 216. Here, the focus is on 
ion formation of low molecular weight analytes. The charged droplets are repelled from the 
spray needle, directing them towards the counter electrode. The addition of an inert gas, such 
as nitrogen, and an increase in temperature leads to the evaporation of the solvent from the 
charged droplets. With this evaporation, the droplets reduce in size until they are small 
enough that they cannot hold their charge, which is termed the Rayleigh limit 217. The 
charged droplet then undergoes Coulomb fission, which is also known as a Coulombic 
explosion, as the charge intensity results in the droplets exploding to form a number of 
smaller, more stable droplets, which can then undergo the same process, producing charged 
analytes devoid of solvent 218. These ions are then detected by the analyser.  
 
 
Figure 1.9: In electrospray ionisation, the sample is sprayed from a needle with a high 
potential difference applied to it. This results in the spray of charged droplets, containing 
the analytes (in this case in positive ion mode). Solvent evaporates until the Rayleigh 
limit is reached, and the droplet undergoes Coulomb fission, forming smaller charged 
droplets and charged analytes.     
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ESI is a soft ionisation technique, resulting in minimal fragmentation of the analyte, except 
through in-source fragmentation 219. Fragmentation results from the collision of multiple 
charged ions during their acceleration from the source to the high vacuum region of the mass 
spectrometer 220. While in some cases this can provide useful structural information, often the 
data is difficult to interpret as all ions at any given moment are subjected to fragmentation 221. 
This, therefore, makes it very difficult to assign fragments to a parent ion and elucidate 
structural information. Instead, tandem mass spectrometry (MS/MS) is used to fragment a 
specific parent ion. Analysis of the subsequent fragment ions can then give valuable insight 
into the structure of the analyte.  
MS/MS relies on the sequential connection of multiple mass analysers. One of the most 
common MS/MS systems is the triple quadrupole (QqQ), which uses three separate 
quadrupoles (Figure 1.10). The first isolates a parent (or precursor) ion of interest, which is 
then fragmented in the second analyser, termed the collision cell. The final analyser then 
detects the fragment ions. The collision cell (the second quadrupole, q) fragments precursor 
ions using collision-induced dissociation (CID). Ions are fragmented following collision with 
an inert gas, such as nitrogen or helium, which increases the internal energy of precursor ions, 
leading to fragmentation 222. However, other types of mass spectrometers have MS/MS 
capabilities. Hybrid instruments have been developed to combine benefits offered by 
different mass analysers, such as the hybrid quadrupole-time-of-flight (Q-ToF) mass 
spectrometer. This takes advantage of the selecting power and MS/MS efficiency of a 
quadrupole and the enhanced resolution and sensitivity of a ToF 223. 
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LC-MS/MS is crucial in targeted metabolomics. Targeted metabolomics is defined as the 
measurement of specified groups of chemically characterised and biochemically annotated 
metabolites 224. Conversely, untargeted metabolomics refers to the more comprehensive 
analysis of analytes in a sample, including those that are chemically unknown. Targeted 
approaches offer accurate and sensitive measurements of groups of metabolites, with 
confident annotation. Furthermore, the use of appropriate labelled internal standards – 
compounds of known concentrations added to each sample – allows for quantitative 
measurements of species of interest. The applications of targeted LC-MS/MS methods to 
lipidomics are numerous 225. Typically, methods can take advantage of structural similarities 
between members of the same lipid class. For example, a targeted method for the detection of 
ceramides can focus on the production of a fragment ion with m/z 264 225. Due to the 
increased sensitivity of a targeted approach, LC-MS/MS is often used for the measurement of 
lipid signalling molecules that are low in abundance, such as eicosanoid lipid species 226.  
However, lipidomics also relies heavily on untargeted approaches. In an untargeted approach, 
a fuller metabolic complement of a biological sample is analysed, requiring no prior 
hypothesis, unlike targeted approaches. Chromatography is not essential, with direct infusion-
mass spectrometry (DI-MS) underpinning the field of “shotgun metabolomics” 227. However, 
this thesis makes use of an untargeted LC-MS approach using chromatography to separate 
isomeric and isobaric species 225. Crucial to untargeted methods is the use of a mass analyser 
with excellent mass accuracy, such as the orbitrap mass analyser, which is used in this thesis.  
Figure 1.10: A schematic of a triple quadrupole (QqQ), with three quadrupoles joined in 
series. The first is used to select an m/z ratio of a precursor ion. This is then fragmented 
in the second quadrupole, termed the collision cell, and the m/z ratios of subsequent 
daughter ions are selected for in the third quadrupole.     
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An orbitrap comprises two electrodes (Figure 1.11). A central spindle electrode is 
surrounded by an outer electrode. Ions are injected into the orbitrap by a curved ion trap (c-
trap) and are trapped by an electrostatic field. They rotate around the central electrode and 
oscillate along its axis. The outer electrode detects the image current induced by the moving 
ions. The frequency of the oscillations is specific to the m/z ratio of the ion, while the size of 
the image current reflects the abundance of ions with that particular m/z ratio. The image 
current is then processed by a Fourier transformation, providing information on the frequency 
and amplitude of each ion. These can then be converted into the m/z ratio and intensity of 
each ion in the mass spectrum 228,229. Advantages of the orbitrap over other mass analysers 
include high mass accuracy and resolution, imperative for untargeted lipidomics.  
To complement the untargeted approach, data-dependent acquisition (DDA) can be used to 
fragment species of interest via CID. Targeted approaches using triple quadrupole 
instruments require the input of apriori defined precursor ions of interest. DDA, however, 
fragments the most intense ion in a particular scan, therefore requiring no prior hypothesis. 
Interpretation of the fragmentation spectrum then provides structural information for a 
Figure 1.11: An orbitrap is composed of two electrodes. Ions spin around and oscillate 
along the central electrode. The image current is then detected by the outer detector 
electrode, which is then processed by a Fourier transformation.  
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precursor ion. This method can be enhanced by the use of a parent ion list, so that only 
particular species of interest are fragmented – a method more similar to a targeted analysis.  
One of the drawbacks of untargeted metabolomics is the intensity of data processing required 
to identify and annotate lipid features from a vast dataset. This thesis makes use of XCMS, 
within R, for data processing 230,231. First, the algorithm extracts features from background 
noise. This is done using a peak width threshold, based on the full width at half maximum 
(FWHM), in seconds. Peak quality can be ensured using a signal to noise ratio threshold. 
Following identification, peaks representing the same species are matched across all samples. 
Setting a minimum fraction of samples that a peak must be found in can be used to improve 
the quality of a peak group. The peak matching process is then used to correct retention time 
drift between samples. This is an iterative process, with peak matching repeated and 
improved following retention time alignment. Peaks won’t be present in all samples if either 
the peak matching has not worked correctly or if the analyte is not present in the sample. 
Therefore, the algorithm then fills in these blanks by returning to the raw data and integrating 
the correct region of the chromatogram for the particular m/z value. Peaks can then be 
annotated with comparison to databases, such as the LipidMaps database 232. In untargeted 
metabolomics, annotations are based on similar accurate mass, with retention time providing 
complementary information.  
 
1.4 Gene expression analysis  
To integrate lipidomic data with functional readouts of gene expression, reverse transcription-
quantitative polymerase chain reaction (RT-qPCR) was used. RT-qPCR is a sensitive and 
quick method for the quantification of specific mRNAs of interest 233. Complementary DNA 
(cDNA) is synthesised from purified RNA using a reverse transcriptase enzyme and a set of 
primers (Figure 1.12). Primers can either be an oligo of deoxythymine, which binds to the 
polyadenosine tail of mRNA species, or random short primers (typically 6-9 bases) that 
anneal to multiple points along the RNA transcript. Reverse transcriptase enzymes are 
thermostable, allowing cDNA synthesis to take place at high temperatures, increasing cDNA 
yield and transcription of RNAs with extensive secondary structure.  
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Following synthesis of cDNA, the product is amplified by PCR using gene-specific primers 
(Figure 1.13). Use of both forward and reverse primers ensures the synthesis of double 
stranded DNA (dsDNA) products, which are detected by the binding of a fluorescent dye, 
such as SYBR-Green 234. Upon binding to dsDNA, fluorescence increases and is detected by 
a fluorescence detector. The cycle threshold (CT) value gives the cycle number for the 
fluorescence to increase above the background threshold. For relative quantification of gene 
transcription, the transcription of a gene of interest is normalised to the expression of a 
housekeeping gene, such as the ribosomal 18s gene, to correct for any sample to sample 
variation in RNA purification or cDNA synthesis 235. Commonly, the ΔΔCT-method is used 
to look at differences in transcription between control and treated samples. In this method, the 
CT-value for the housekeeping gene is subtracted from the CT-value of the gene of interest in 
each sample, giving a ΔCT-value. The ΔCT-value from a treated sample is then subtracted 
Figure 1.12: The synthesis of cDNA can use oligo(dT) primers that anneal to the poly(A) 
tail of mRNA molecules or random short primers. Once the primers have annealed, 
reverse transcriptase synthesises a DNA strand complementary to the mRNA.    
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from the ΔCT-value of a control sample to give the ΔΔCT-value for that sample. The fold 
change in gene expression can then be calculated by 2(-ΔΔCt).  
RT-qPCR is used throughout this thesis as a method of measuring the induction of ER stress. 
Activation of the UPR results in the upregulation of a number of transcripts encoding 
transcription factors, such as ATF3 and ATF4, chaperones, including HSPA5 (also known as 
BiP) and proteins involved in protein degradation, such as EDEM1 236. RT-qPCR of these 
transcripts provides a rapid and sensitive readout for activation of the UPR and the induction 
of ER stress 236–239.  
Figure 1.13: In RT-qPCR, cDNA is denatured to separate the two strands. Primers can 
then anneal to each strand and are extended by DNA polymerase, forming double 
stranded molecules. SYBR Green is a fluorescent dye that binds only to dsDNA, 
detecting the amplification of DNA in each cycle.  
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1.5 Project aims 
ER stress has been implicated as a potential mechanism unifying lipotoxicity and 
inflammation in the development of insulin resistance. However, the role of lipotoxicity-
induced ER stress in skeletal muscle, in the setting of the metabolic syndrome, remains 
poorly defined. This thesis aims to understand the interaction between chronic ER stress and 
lipid metabolism in the context of obesity and T2DM using a multi-platform lipidomic 
approach combined with RT-qPCR and applied to skeletal muscle cell biology, murine and 
clinical studies. Mouse skeletal myotubes will be exposed to palmitate to model raised 
plasma FFAs observed in the plasma of obese individuals. GC-MS analysis of FAMEs and 
LC-MS open profiling of intact lipids will be used to understand the effects of palmitate on 
both the total fatty acid profile and individual complex lipid species within palmitate exposed 
myotubes. RT-qPCR will be used to confirm the induction of ER stress.  
Key metabolic alteration will then be investigated in primary human skeletal myocytes and in 
vivo models of obesity. These models include dietary mouse models of obesity and human 
skeletal muscle biopsies from diabetic and non-diabetic patients undergoing routine 
pacemaker surgery. Pharmacological inhibition in skeletal myocytes in vitro will then be used 
to probe the mechanisms and functional consequences of observed lipid changes, with 
particular focus on the induction of ER stress.   
Finally, following the demonstration of cell non-autonomous signalling in the propagation of 
ER stress, this thesis also seeks to integrate lipid-induced ER stress with intercellular 
signalling, combining in vitro techniques with the lipidomic profiling of culture media.  
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Aim Chapter number 
To establish a model of chronic palmitate-induced ER stress in 
mouse C2C12 myotubes, and profile the lipidomic effects of 
palmitate using GC-MS and LC-MS.  
Chapter 3 
To translate lipidomic findings from palmitate-induced ER stress 
in C2C12 myotubes to human primary human skeletal muscle cells 
and in vivo models of obesity. 
Chapter 3 
To assess the dependence of lipid alterations on ER stress using 
chemical inducers and pharmacological inhibition of the UPR. 
Chapter 3 
To use pharmacological inhibition to identify the mechanisms 
underpinning the metabolic perturbations identified in Chapter 3. 
Chapter 4 
To use pharmacological inhibition and co-culture assays to 
understand the functional consequences of palmitate-induced 
metabolic alterations. 
Chapter 4 
To identify the presence of cell non-autonomous signals that 
propagate the induction of ER stress between C2C12 myotubes 
and human primary skeletal myocytes. 
Chapter 5 
To use pharmacological inhibition to interrogate the mechanisms 
underpinning the generation of non-cell autonomous ER stress 
propagating signals. 
Chapter 6 
 
  
 
Chapter 2  
 
Materials and Methods 
 
2.1 Cell and tissue culture techniques 
 
2.1.1 C2C12 myoblast culture and differentiation 
C2C12 myoblasts were purchased from Sigma Aldrich. The vial was thawed for 
approximately 1 minute in a water bath set to 37 ºC. Cells were suspended in 10 mL of 
Dulbecco’s Modified Eagle Medium (DMEM; D6429, Sigma Aldrich) supplemented with 
10% fetal bovine serum (FBS, Sigma Aldrich, F7524) and 1% penicillin-streptomycin (P/S, 
Sigma Aldrich, P4333), termed “growth media”. Cells were centrifuged (220g, 5 minutes) 
and the supernatant discarded. The cell pellet was then resuspended in 15 mL growth media 
and transferred to a T75 flask (Corning, 658175).  
At 70% cell confluence, the culture media was aspirated and 5 mL of a trypsin-EDTA 
solution (Thermo Fisher Scientific, 25300054), warmed to 37 ºC, was added to detach the 
cells from the flask. Once cells were in suspension, 10 mL of growth media was added to 
inactivate the trypsin. Cells were centrifuged (220g, 5 minutes) and the supernatant 
discarded. The cell pellet was resuspended in growth media, and approximately 2 x 106 cells 
were plated in T75 flasks for further subculture, or 1 x 105 cells were plated per well of a 12-
well plate. Experiments were conducted in 12-well collagen I-coated plates (Corning Biocoat, 
734-0295), with 1 mL of the cell suspension added per well, except for eicosanoid analysis in 
chapter 4, which was conducted in collage I-coated T75 flasks (Corning Biocoat, 734-0290). 
Once confluent within plates, differentiation was induced by changing the culture media to 
DMEM containing 10% horse serum (HS, Sigma-Aldrich, H1270), 1% P/S and 850 nM 
insulin (Sigma Aldrich, I9278), termed “differentiation media”. Cells were differentiated for 
6 days. During differentiation cells were treated with either 200 µM palmitate, or the BSA 
vehicle control, to set up a chronic model of ER stress. Media was changed every day during 
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differentiation. Furthermore, cells were co-treated with pharmacological inhibitors, as 
detailed in the relevant chapter specific method section (AMG PERK 44 (Tocris Bioscience, 
5517) Chapters 3 and 6; 4µ8c (Tocris Bioscience, 4479) Chapters 3 and 6; tunicamycin from 
Streptomyces (Sigma Aldrich, T7765) Chapter 3; PD146176 (Sigma Aldrich, P4620) Chapter 
4; NCTT-956 (Sigma Aldrich, SML0499) Chapter 4; AACOCF3 (Abcam, ab120350) 
Chapter 4; Fumonisin B1 (Tocris Bioscience, 3103) Chapter 6; Fenretinide (Tocris 
Bioscience, 1396) Chapter 6; Myriocin (Sigma Aldrich, M1177) Chapter 6).  
To develop a stock of C2C12 myoblasts, cells that had undergone 4 passages were lifted from 
the bottom of flasks using 5 mL of trypsin, diluted in 10 mL of growth media and centrifuged 
(220g, 5 minutes). The supernatant was discarded and the pellet resuspended in growth media 
containing 10% DMSO (Sigma Aldrich, D8418) for freezing. Each flask provided two vials 
of cells for freezing. Cells were stored at -80 ºC overnight, and then in liquid nitrogen for 
long-term storage.  
 
2.1.2 Primary human skeletal muscle cell culture and differentiation 
Primary human skeletal muscle cells (HSKMCs) were purchased from Cell Applications 
(S150a-05a). The vial was thawed for approximately 1 minute in a water bath set to 37 ºC. 
HSKMCs were then suspended in 15 mL of Skeletal Muscle Cell Growth Medium (Cell 
Applications, 151-500) and transferred to a T75 flask.  
Cells were subcultured once they reached 90% confluence. They were detached from the 
flask using 5 mL of trypsin. Trypsin was then inactivated using a trypsin inhibitor solution 
(Sigma Aldrich). The cell suspension was transferred to a 50 mL falcon tube and centrifuged 
(220g, 5 minutes). Flasks were subcultured in a 1:3 ratio. The cell pellet was resuspended in 
45 mL of Skeletal Muscle Cell Growth Medium and 15 mL of the cell suspension was 
transferred to each flask (approximately 2.5 x 106 cells).  
Experiments were conducted in collagen I-coated 12-well plates. Cells were detached from a 
T75 flask with trypsin as previously described, and the pellet was resuspended in 75 mL of 
Skeletal Muscle Cell Growth Media. One mL (approximately 1 x 105 cells) of the cell 
suspension was added to each well. Once confluent, HSKMCs were differentiated for 6 days 
using Skeletal Muscle Differentiation Media (Cell Applications, 151D-250). During 
differentiation cells were treated with either 100 µM palmitate, or the BSA vehicle control, to 
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set up a chronic model of ER stress. Media was changed every 2 days during differentiation. 
Furthermore, cells were co-treated with pharmacological inhibitors, as detailed in the relevant 
chapter specific method section (tunicamycin from Streptomyces chapter 3; PD146176 
chapter 4; NCTT-956 chapter 4; AACOCF3 chapter 4).  
To create a stock of primary HSKMCs, cells that had undergone 3 passages were detached 
from the flasks and centrifuged (220g, 5 minutes). Cell pellets (approximately 4 x 106 cells) 
were resuspended in Cell Freezing Medium (Cell Applications, 040-50). Each flask provided 
sufficient cells for two vials. Cells were stored at -80 ºC overnight, and then in liquid nitrogen 
for long-term freezing. 
 
2.1.3 Conjugation of palmitate to BSA 
The conjugation of palmitate to bovine serum albumin (BSA) was based on previous 
literature and optimized for palmitate-induced ER stress in skeletal myocytes 240. Fatty-acid 
free BSA (12 g; Sigma Aldrich, A3803) was dissolved in 120 mL of Milli-Q water at 37ºC, 
forming a 10% solution. Separately, 0.125g of sodium palmitate (Sigma Aldrich, P9767) was 
dissolved in 3 mL of 50% ethanol at 70 ºC, forming a 150 mM solution. The 120 mL BSA 
solution was then split in two. The 3 mL palmitate solution was added to one aliquot in 1 mL 
intervals, with the palmitate:BSA solution continually stirred at 37 ºC throughout. 3 mL of 
50% ethanol was added to the second aliquot of BSA solution, forming the vehicle control. 
The final palmitate concentration of the stock palmitate:BSA solution was 7.143 mM.   
 
2.1.4 Cell harvesting 
C2C12 cells were detached from wells using 0.5 mL of a trypsin-EDTA solution, and then 
resuspended in 1 mL of serum-free media (DMEM; D6429, Sigma Aldrich) and transferred 
to Eppendorf tubes. Primary HSkMCs were detached from wells using 0.4 mL of a trypsin-
EDTA solution, and then resuspended in 1 mL of Skeletal Muscle Cell Basal Medium (Cell 
Applications, 150-500). A small aliquot (100 µL) was diluted in 500 µL of phosphate 
buffered saline (PBS, Sigma Aldrich, D8662) for cell count, which was performed using an 
automated cell counter (Scepter: Merck). Cells were pelleted with a microcentrifuge (4,600g, 
7 minutes), and the supernatant removed, prior to storage at -80°C. 
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2.2 Animal studies 
Below are brief outlines of three mouse studies that provided skeletal muscle (gastrocnemius) 
and, in some cases, plasma for this PhD. The studies were carried out as part of other 
projects, but full permission was provided for the use of the tissue in this context. Nutrient 
information for each diet is summarised in Table 2.1. All procedures were carried out in 
accordance with U.K. Home Office protocols by a personal license holder. 
 
2.2.1 Western diet mouse model 
Five-week-old mice (wild-type, strain C57Bl/6J) were purchased from Harlan Laboratory 
Ltd. Four animals were housed per cage and had an acclimitisation period of 7 days. The 
temperature was maintained at 20 ± 4 ºC with a 12 hour light/dark cycle. Mice were fed 
either a western diet (WD, TD88137) or a low-fat control (LFC, TD08485) diet, for 12 weeks 
(n=8 per group), with diets supplied by Teklad Custom Research Diets (Envigo).  Following 
the conclusion of the study, mice were sacrificed by cervical dislocation, and subsequently 
dissected. Tissue was flash frozen in liquid nitrogen and stored at -80 ºC. The study was 
carried out under a project license held by Professor Toni Vidal-Puig (PPL number: 80/2584) 
and personal license of Dr Michele Vacca (PIL number: I8C7616E4). 
 
2.2.2 High-fat diet mouse model 
C57Bl/6J mice were purchased from the Jackson laboratory and housed at 24ºC. Mice were 
fed either RM3 breeders chow (n=10; Special Diet Services, 801066) or 60% calories-from-
fat high-fat diet (n=13; Research Diets, D12492). Mice were culled at 14 weeks of age. They 
were fasted overnight (4 pm till 10 am) prior to cervical dislocation. Tissues were collected, 
weighed, immediately frozen on dry ice and stored at -80oC until further processing. This 
study was carried out under a project license held by Professor Toni Vidal-Puig (PPL 
number: 80/2584) and personal license of Dr Sam Virtue (PIL number: 80/9004).  
 
 
 
  Chapter 2 
 
40 
 
2.2.3 Long-term high-fat diet mouse model 
Male C57Bl/6J mice (6 weeks old; n = 10) (Charles River Laboratories) were weight 
matched and received either standard chow (n = 5; F4031, Bio Serv) or a 60% fat diet (n = 5; 
F3282, Bio Serv) ad libitum for 17 weeks, with food and water intake monitored. Animals 
were housed in conventional cages at room temperature with a 12 hour light/dark cycle. On 
completion of the study mice were culled by cervical dislocation, plasma was collected by 
left ventricular puncture, and tissues were removed and snap frozen in liquid nitrogen, prior 
to storage at -80 ºC. This study was carried out under a project license held by Dr Lee 
Roberts (PPL number: P606320FB) and a personal license held by Dr Lee Roberts (PIL 
number: I2CD54CD0).  
 
 
2.3 Human skeletal muscle biopsies 
75 eligible and consecutive patients (Table 2.2) undergoing routine pacemaker therapy in Dr 
Klaus Witte’s clinic at Leeds General Infirmary volunteered to participate in the study. 
Eligible patients were grouped into two cohorts based on the presence or absence of T2DM. 
The T2DM cohort had a previous diagnosis of T2DM (>3 months) and/or was receiving 
treatment for diabetes. In such cases, T2DM was defined as a documented history of diabetes, 
fasting plasma glucose ≥ 7.0 mmol/L, plasma glucose ≥ 11.1 mmol/L two hours after the 
OGTT or a glycated haemoglobin (HbA1c) ≥ 6.5% (≥ 48 mmol/L).  
Human skeletal muscle (pectoralis major) biopsies were obtained from eligible participants 
during their pacemaker operation. Pacemaker procedures were otherwise entirely routinely 
carried out: lidocaine was initially injected to anaesthetize the area and a small incision was 
made under the left clavicle. During creation of the pre-pectoral pocket for the generator 
%kcal from TD08485 TD88137 RM3 D12492 F4031 F3282  
Protein 19.1 15.2 27.28 20.0 20.9 14.9  
Carbohydrate 67.9 42.7 61.24 20.0 62.6 26.0  
Fat 13.0 42.0 11.48 60.0 16.3 59.0  
Table 2.1: Nutrient information for the diets used in the animal studies. 
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above the pectoralis major a portion of the muscle (approximately 100mg) was sampled. This 
sample was immediately placed into a 1.5 mL Eppendorf tube and snap frozen in liquid 
nitrogen. The study is approved by the Leeds West Research Ethics Committee 
(11/YH/0291) and Leeds Teaching Hospitals R&D committee (CD11/10015) and conforms 
to the Declaration of Helsinki. 
 
 
 
 
2.4 RNA handling and reverse transcription quantitative 
polymerase chain reaction  
 
2.4.1 RNA isolation and purification 
RNA was extracted and purified in situ, using the RNeasy mini kit (Qiagen, 74104), 
following the manufacturer’s instructions. Briefly, 350 µL of lysis buffer was added to the 
cells in situ. Following lysis, 350 µL of 70% ethanol was added, and the sample was well 
mixed by pipetting up and down, before transfer to a spin column. Ethanol aids RNA binding 
to the silica membrane in the spin column. Samples were centrifuged (9391g, 30s), and the 
eluent was discarded. A series of washes with the provided buffers removes contaminants. 
First, 700 μL of buffer RW1 was added to the column to remove biomolecules such as 
carbohydrates and fatty acids that non-specifically bind to the membrane. The samples were 
centrifuged at 9391g for 30s and the eluent discarded. Two 500 μL washes with buffer RPE 
 Number of 
patients 
Number 
of males 
Number 
of females 
Age 
(years) 
BMI 
(kg/m2) 
Weight 
(kg) 
Control 
patients 
53 43 10 72.05 ± 
11.54 
27.43 ± 
4.829 
80.6 ± 
13.83 
T2DM 
patients 
22 19 3 73.04 ± 
10.01 
30.94 ± 
7.129 
93.64 ± 
22.50 
P    0.7305 0.0157 0.0025 
Table 2.2: Data from patients who provided skeletal muscle biopsies during routine 
pacemaker therapy. 
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followed to remove traces of salts from previous buffers. After the first addition, samples 
were centrifuged at 9391g for 30s and the eluent discarded. After the second addition samples 
were centrifuged at 9391g for 2 minutes and the eluent discarded. Spin columns were 
transferred to a fresh collection tube and centrifuged at full speed for 1 minute to dry the 
membrane. RNase free water (40 μL) was then added to the spin column and samples 
centrifuged at 9391g for 1 minute to elute the RNA. Samples were stored at -80 ºC.   
 
2.4.2 cDNA synthesis 
The concentration (determined by A260, requirement of > 50 ng/mL RNA) and quality (a 
requirement of absorbance ratios to be: A260:A230 > 1.7; 1.8 < A260:A280 < 2) of RNA was 
determined using the NanoDrop-1000 spectrophotometer (NanoDrop Technologies) and then 
standardized to 50 ng/mL in a volume of 8 μL for all samples. cDNA was synthesized by a 
two-step process with the RT2 First Strand Kit (Qiagen, 330404). Genomic DNA was 
removed by the addition of 2 μL of genomic elimination buffer followed by incubation at 42 
ºC for 5 minutes in a PrimeG thermal cycler (Techne). Ten μL of a reverse transcriptase mix 
(containing the reverse transcription buffer BC3, RNase free water, the reverse transcriptase 
enzyme mix RE3, and the primer and external control mix P2 in a ratio of 4:3:2:1) was then 
added to each sample, mixed well and incubated at 42 ºC for 15 minutes in the thermal 
cycler. The reaction was ended by increasing the temperature to 95 ºC for 5 minutes. Samples 
were cooled to 4 ºC. Subsequently samples were diluted with RNase free water to a total 
volume of 100 µL. 
 
2.4.3 Reverse transcription quantitative polymerase chain reaction 
cDNA (5 µL) was mixed with 10 µL of a SYBR Green PCR mastermix containing ROX 
(Qiagen, 330523), 4.4 µL of RNase-free water and 0.6 µL of a primer mix (Qiagen) for one 
of the genes in question in each well of a 96-well plate (Applied Biosystems, 4346906). 
Samples were then analysed using a Step One Plus Real Time Cycler (Applied Biosystems), 
quantified using the ΔΔ-CT method with expression normalized to the housekeeping gene. 
This method begins with a 10 minute incubation at 95 ºC, which activates the HotStart DNA 
Taq polymerase. There are then 40 cycles consisting of a 15 second period at 95 ºC to 
denature the cDNA, followed by 1 minute at 60 ºC, in which primers anneal to the template 
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and are elongated by the polymerase. Fluorescence is measured as a consequence of the 
SYBR Green dye binding to the double stranded DNA (excitation and emission maxima are 
at 494 and 521 nm, respectively), and is collected at the end of each of these 40 cycles. Δ-CT 
values are calculated by first subtracting the CT-value for the housekeeping gene from the 
CT-value of the gene of interest for each sample. The ΔCT-value from a treated sample is 
then subtracted from the ΔCT-value from a control sample giving the ΔΔ-CT value for that 
sample. The fold-change for each gene is calculated using the equation: fold change = 2(-ΔΔCt).  
For murine samples, Rn18s (PPM72041A) was used as the housekeeping gene, while ACTB 
(PPH00073G) was used for analysis of primary HSKMCs. The induction of ER stress was 
assessed throughout this thesis using primers for Atf3 (PPM04669C), Atf4 (PPM04670E), 
Hspa5 (PPM03586B) and Edem1 (PPM26189B) for murine samples, and ATF3 
(PPH00408C), ATF4 (PPH02016A), HSPA5 (PPH00158E) and EDEM1 (PPH12935B) for 
human samples.  
 
2.5 Metabolite extractions 
 
2.5.1 Cell metabolite and lipid extraction for mass spectrometry 
Metabolites were extracted using a modified Bligh and Dyer method 241. The cells were 
treated with 600 µl methanol/chloroform (2:1) and sonicated until the cell pellet broke up. 
Then, 200 µl chloroform and 200 µl water were added, and the samples vortexed and 
sonicated for 15 minutes. Subsequently, the samples were centrifuged (16,100g, 20 minutes), 
giving an aqueous layer and an organic layer containing the lipid fraction. The two layers 
were separated and the relevant internal standard mixture was added to the organic fraction. 
The fractions were dried under nitrogen gas flow and then stored at -80°C. 
 
2.5.2 Human and mouse skeletal muscle tissue extraction 
Approximately 30 mg of tissue was weighed for extraction. 600 µL of methanol/chloroform 
(2:1) was added to each sample, and they were lysed in a TissueLyser (Qiagen) in 5 minute 
intervals for a total of 20 minutes, at 20 Hz. Once the samples were homogenous, 200 µL of 
water and 200 µL of chloroform were added, and samples were then well vortexed and 
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centrifuged (16,100g, 20 minutes). Aqueous and organic layers were separated and dried as 
before, prior to storage at -80 ºC. 
 
2.5.3 Plasma extraction 
For plasma, 600 µL of methanol/chloroform (2:1) was added to 20 µL of plasma, and 
vortexed thoroughly. Samples were then centrifuged (16,100g, 20 minutes), and the two 
phases were separated, dried and stored as described previously.  
 
2.5.4 Cell media extraction 
One mL of cell media was mixed with 800 µL of methanol/chloroform (1:1) and vortexed 
well. Samples were then centrifuged (16,100g, 20 minutes), and the two phases separated, 
dried and stored as outlined above.  
 
2.5.5 Internal standard mixture for lipidomics 
The internal standard mix was composed of deuterated standards sourced from Avanti Polar 
Lipids (C16-d31 Ceramide, 16:0-d31-18:1 phosphatidic acid, 16:0-d31-18:1 
phosphatidylcholine, 16:0-d31-18:1 phosphatidylethanolamine, 16:0-d31-18:1 
phosphatidylglycerol, 16:0-d31-18:1 phosphatidylinositol, 14:0 phosphatidylserine-d54, and 
16:0-d31 sphingomyelin) and CDN Isotopes/QMX Laboratories (18:0-d6 cholesteryl ester, 
15:0-d29 fatty acid, 17:0-d33 fatty acid, 20:0-d39 fatty acid, 14:0-d29 
lysophosphatidylcholine-d13, 45:0-d87 triacylglyceride, 48:0-d83 triacylglyceride, and 54:0-
d105 triacylglyceride). The internal standards were dissolved in methanol/chloroform (1:1) to 
form stock solutions at a concentration of 0.5 mg/mL. One mL of each stock solution was 
then mixed together with a further 184 mL of methanol/chloroform (1:1), with each internal 
standard at a final concentration of 2.5 µg/mL.  
This internal standard mixture was used for peak normalisation in LC-MS open profiling of 
lipids and GC-MS analysis of fatty acid methyl esters (FAMEs) to adjust for non-biological 
sample-to-sample variation. For each sample, 250 µL was added to the organic phase prior to 
evaporation under nitrogen. For LC-MS profiling, internal standards were annotated based on 
accurate mass. For GC-MS analysis, the internal standard mixture underwent FAME 
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derivatisation along with the sample. Identification of internal standard peaks was achieved 
by comparison of fragmentation patterns to a derivatised blank sample containing only the 
internal standard mixture.  
 
2.6 Liquid chromatography-mass spectrometry open profiling of 
lipids 
 
2.6.1 Sample preparation 
Metabolites from the organic phase were reconstituted in 50 μL of methanol/chloroform (1:1) 
and vortexed thoroughly. Ten μL of the sample was then diluted into 190 μL of propan-2-
ol/acetonitrile/water (IPA:ACN:H2O; 2:1:1). Samples were briefly vortexed to ensure they 
were well mixed.  
 
2.6.2 Chromatography parameters 
For both positive and negative ionisation modes, 5 µL of sample was injected onto a C18 
CSH column, 2.1 x 100 mm (1.7 µm pore size; Waters, 186005297), which was held at 55oC 
using an Ultimate 3000 UHPLC system (Thermo Fisher Scientific). The mobile phase 
comprised solvents A (ACN/H2O; 60:40) and B (ACN/IPA; 10:90), run through the column 
in a gradient (40% B, increased to 43% B after 2 minutes, 50% B at 2.1 minutes, 54% B at 12 
minutes, 70% B at 12.1 minutes, raised to 99% B at 18 minutes before returning to 40% for 2 
minutes). Total run time was 20 minutes, with a flow rate of 0.400 µL/min. In positive mode, 
10 mM ammonium formate (Fisher Scientific, A/3440/53) was added to solvents A and B. In 
negative mode, 10 mM ammonium acetate (Sigma Aldrich, 516961) was the solvent additive. 
Solvent additives were chosen based on current literature 242. 
 
2.6.3 Mass spectrometry parameters 
Mass spectrometry was then carried out using the LTQ Orbitrap Elite Mass Spectrometer 
(Thermo Fisher Scientific) in positive and negative mode. Metabolites were ionised by heated 
electrospray before entering the spectrometer. The source temperature was set to 420 ºC, and 
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the capillary temperature to 380 ºC. In positive mode, the spray voltage was set to 3.5 kV, 
while in negative it was 2.5 kV. Data was collected using the Fourier transform mass 
spectrometer (FTMS) analyser. The resolution was set to 60,000 and the data was obtained in 
profile mode. The full scan was performed across an m/z range of 110-2000.  
2.6.4 Fragmentation analysis 
To overcome limitations in LC-MS annotation of lipid species arising from the isobaric 
nature of many lipid species, and to facilitate the identification of the fatty acyl chains 
esterified to complex lipids, a tandem mass spectrometry (LC-MS/MS) fragmentation method 
was used. The subsequent fragmentation spectra were then used to conclusively identify the 
fatty acid composition of each PC that contained 4 or more double bonds.  
The method described in Section 2.6.3 Mass spectrometry parameters was adapted to include 
a second scan event. Ions were fragmented using collision induced dissociation (CID) at a 
normalised collision energy of 35. Precursor ions were selected from a mass list, with the 
most intense ion on the list fragmented in each scan. The minimum signal required was set to 
5000 counts and the isolation width was set to 1. The activation time was 10 ms and the 
activation Q was set to 0.25. Fragmentation spectra were acquired in centroid mode at a 
resolution of 15,000 using the FTMS analyser. The interpretation of fragmentation spectra 
was aided by online resources, with common fragmentation patterns summarised in Table 2.3 
243. 
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2.6.5 Data processing using R 
For data processing, spectra were converted from Xcalibur .raw files into .mzML files using 
MS Convert (Proteowizard) for analysis by XCMS within R studio. XCMS software was 
used to process data and identify peaks. Peaks were identified based on an approximate 
FWHM of 5 seconds and a signal to noise threshold of 5. To improve peak identification, 
peaks had to be present in a minimum of 25% of the samples. Peaks were annotated by 
accurate mass, using an automated R script and comparison to the LipidMaps database 232. 
Intensity was normalised to internal standards, and cell number (or dry protein pellet weight 
for animal tissue).  
 
Phosphatidylcholine 
(PC) species 
Precursor 
ion (m/z) 
Fragment 
ion 1 (m/z) 
Fragment 
ion 2 (m/z) 
Fragment 
ion 3 (m/z) 
Fragment 
ion 4 (m/z) 
PC 16:0/18:3 756.55 478.35 500.33 496.36 518.34 
PC 16:0/20:4 782.57 478.35 526.35 496.36 544.36 
PC 16:0/20:5 780.55 478.35 524.33 496.36 542.34 
PC 16:0/22:6 806.57 478.35 550.35 496.36 568.36 
PC 16:1/18:3 754.54 476.33 500.33 494.34 518.34 
PC 16:1/20:4 780.55 476.33 526.35 494.34 544.36 
PC 16:1/20:5 778.54 476.33 524.33 494.34 542.34 
PC 16:1/22:6 804.55 476.33 550.35 494.34 568.36 
PC 18:0/18:3 784.59 506.38 500.33 524.39 518.34 
PC 18:0/20:4 810.60 506.38 526.35 524.39 544.36 
PC 18:0/20:5 808.59 506.38 524.33 524.39 542.34 
PC 18:0/22:6 834.60 506.38 550.35 524.39 568.36 
PC 18:1/18:3 782.57 504.36 500.33 522.37 518.34 
PC 18:1/20:4 808.59 504.36 526.35 522.37 544.36 
PC 18:1/20:5 806.57 504.36 524.33 522.37 542.34 
PC 18:1/22:6 832.59 504.36 550.35 522.37 568.36 
Table 2.3: Fragment m/z values for common polyunsaturated fatty acid-containing 
phosphatidylcholines 
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2.7 Statistics 
Univariate statistics was used to assess the significance of changes in individual metabolites. 
Statistical significance was assessed using either a one-way ANOVA with a Tukey’s multiple 
comparisons test, two-way ANOVA with Sidak’s multiple comparisons test or Student’s t-
test, as detailed in each figure. Linear regression was used to analyse human skeletal muscle 
biopsies for correlations between lipid species and BMI. In each case, n ≥ 3 and the 
significance level was set to p ≤ 0.05. All univariate analysis was conducted using GraphPad 
Prism (version 6) software. 
  
 
Chapter 3 
 
Chronic palmitate treatment induces ER Stress and 
stimulates phospholipid remodelling in skeletal muscle  
 
3.1 Introduction 
T2DM is estimated to affect over 370 million people worldwide aged between 20 and 79 
years old, with obesity as the leading risk factor 244–246. Obese individuals have increased 
concentrations of plasma free fatty acids resulting from, in part, increased lipolysis in 
dysfunctional white adipose tissue 247. The association between these fatty acids in plasma 
and impaired insulin action is well established in the context of obesity and T2DM 42,248. 
However, research has since suggested that it is not solely total fatty acid concentration, but 
also the specific fatty acid species, which contributes to metabolic perturbation in T2DM 249. 
Current thought emphasises the importance of saturated fatty acids, in particular palmitate, in 
the development of insulin resistance. Putative mechanisms suggested to underpin the 
relationship between saturated fatty acids and insulin resistance include lipotoxicity and 
inflammation 78,248,250.  
Lipotoxicity stems from the perturbation of lipid storage resulting in elevated concentrations 
of lipid species within plasma and ectopic lipid storage in non-adipose tissues, such as 
skeletal muscle and liver 251. As the concentration of these ectopic lipids increase they disrupt 
cellular processes, including insulin signalling. Ceramides and DGs have been suggested as 
the primary mediators of saturated fatty acid-induced insulin resistance in skeletal muscle, 
adipose and the liver 52,57,58,252.   
Lipotoxicity is closely integrated with inflammatory signalling in metabolic disease 78. 
Palmitate increases the levels of pro-inflammatory cytokines such as Tnfα, Ccl2 and Il6 82–
84,253. Circulating macrophages respond to these inflammatory signalling cues, infiltrating 
peripheral tissues and switching from an M2 alternative activation state to a more classical, 
pro-inflammatory M1 polarisation 88–91. This phenotypic switch has been causally linked to 
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increases in insulin resistance 254. Palmitate can also directly activate immune cells, further 
enhancing lipid-induced inflammation 99,100.  
ER stress, and the subsequent activation of the UPR, may represent a unifying mechanism 
underpinning palmitate-induced insulin resistance. ER stress was initially linked to metabolic 
disease following analysis of UPR markers in the tissues of dietary and genetic mouse models 
of obesity, with ER stress identified in liver and adipose tissue of obese mice 103. Markers of 
UPR activation and inflammation were attenuated in obese individuals following gastric 
bypass-induced weight loss, concomitant with improvements in insulin sensitivity in adipose 
tissue and the liver 163. Similarly, treatment of obese individuals with tauroursodeoxycholic 
acid (TUDCA), a chemical chaperone that improves protein folding and reduces ER stress, 
increased insulin sensitivity in the liver and skeletal muscle 255.  
Saturated fatty acids may provide a mechanistic link between lipotoxicity, inflammation and 
ER stress as part of metabolic diseases. Palmitate has been shown to induce ER stress in key 
insulin-sensitive tissues, including adipose, liver and skeletal muscle 171,172,179,256. 
Mechanisms linking palmitate with ER stress are under-investigated, but alterations of 
phospholipid bilayer composition may represent one potential mechanism. Forced expression 
of Lpcat3, the gene encoding lysophosphatidylserine acyltransferase 3, increased the 
incorporation of PUFAs into phospholipids and ameliorated palmitate-induced ER stress in 
hepatocytes 175. Furthermore, an increase in the PC/PE ratio, found in the livers of obese 
mice, increases ER stress, while correcting this ratio reduced ER stress and improved glucose 
homeostasis 176. 
While there has been significant study of ER stress and lipotoxicity in the liver and adipose 
tissue, the link between lipotoxicity and ER stress in skeletal muscle remains poorly defined. 
Treatment of human myotubes with palmitate increased expression of UPR markers, which 
was prevented with forced expression of SCD1 179, also highlighting the potential benefits of 
fatty acid desaturation in palmitate-induced ER stress and lipotoxicity. Oleate treatment and 
AMPK/PPARδ activation attenuated palmitate-induced ER stress, and ameliorated insulin 
signalling and inflammation, further implying ER stress as a connecting mechanism between 
palmitate and insulin resistance 54,180. However, this work is contradicted by research 
demonstrating that chemical chaperones do not improve palmitate-induced insulin resistance 
in myotubes 181. Further work is required to delineate the importance of ER stress as a 
mechanism mediating the effects of lipotoxicity in skeletal muscle during metabolic disease.  
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3.2 Aims and objectives 
This chapter aims to better understand the link between chronic lipotoxicity, the induction of 
ER stress and lipid metabolism in skeletal myocytes using a multi-modal mass spectrometry 
approach. This work focuses on the analysis of skeletal muscle, a tissue critical to whole-
body glucose homeostasis in which the importance of ER stress in the development of insulin 
resistance is poorly understood. Previous research in this area has investigated the effects of 
saturated fatty acids at high doses, in an acute setting, typically no longer than 24 hours 
54,103,257–260. However, obesity and T2DM are chronic disorders, with chronically increased 
levels of plasma fatty acids. Therefore, this study aims to develop a more physiological 
approach and utilises an in vitro model of chronic lipotoxicity to understand the effects of 
prolonged palmitate exposure on lipid metabolism in skeletal myocytes.  
This investigation is supported with the following objectives: 
1) The establishment of a model of chronic, lipid-induced ER stress in C2C12 myotubes, 
an immortalised skeletal muscle cell line.  
2) GC-MS analysis of total fatty acids in C2C12 myotubes following chronic palmitate 
exposure. 
3) Investigation of the effects of chronic palmitate treatment on the intact lipid profile of 
C2C12 myotubes using LC-MS. 
4) Analysis of primary human skeletal muscle cells and in vivo models of metabolic 
disease to increase the relevance of results to the clinical setting.  
5) Assessment of ER stress as an underpinning mechanism of palmitate-induced lipid 
changes, using both pharmacological inhibition of the Perk and Ire1 signalling arms, 
and tunicamycin as a chemical inducer of ER stress.  
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3.3 Materials and Methods 
3.3.1 C2C12 culture 
C2C12 cells were grown and differentiated as described in Chapter 2 Materials and 
Methods (section 2.1.1 C2C12 myoblast culture and differentiation). Cells were 
differentiated and treated in 12-well plates. Cells were treated with inhibitors (detailed in 
section 3.3.4 Pharmacological inhibitors) for the final 24 hours of experiments. 
 
3.3.2 Primary human skeletal muscle cell culture 
Primary human skeletal muscle cells (HSkMCs) were cultured as described in Chapter 2 
Materials and Methods (section 2.1.2 Primary human skeletal muscle cell culture and 
differentiation). Cells were treated with inhibitors (detailed in section 3.3.4 Pharmacological 
inhibitors) for the final 24 hours of experiments. All cells were treated in 12-well plates.  
 
3.3.3 Conjugation of palmitate to BSA 
Palmitate was conjugated to BSA as described in Chapter 2 Materials and Methods 
(section 2.1.3 Conjugation of palmitate to BSA).  
 
3.3.4 Pharmacological inhibitors 
AMG PERK 44 and 4µ8c were purchased from Tocris Bioscience, and dissolved in DMSO 
to a concentration of 20 mM. The inhibitors were diluted into culture media to a final 
concentration of 10 µM. Tunicamycin from Streptomyces (Sigma Aldrich, T7765) was 
dissolved in DMSO to a concentration of 100 µg/mL. The inhibitor was then diluted into 
culture media to a final concentration of either 10 ng/mL or 50 ng/mL. 
 
3.3.5 Cell harvesting 
Cells were harvested and pelleted as described in Chapter 2 Materials and Methods 
(section 2.1.4 Cell harvesting). Cell counts were performed using a Scepter automated cell 
counter (Millipore). 
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3.3.6 Animal studies 
The detail of three mouse studies analysed in this chapter are summarised in Chapter 2 
Materials and Methods (section 2.2 Animal studies). 
 
3.3.7 Human skeletal muscle biopsies 
Biopsies of pectoralis major were taken from volunteers undergoing pacemaker therapy, as 
described in Chapter 2 Materials and Methods (section 2.3 Human skeletal muscle 
biopsies).  
 
3.3.8 RNA isolation and purification 
RNA was harvested and purified from cells in situ using the Qiagen RNeasy Mini kit, 
following manufacturer’s instructions, as described in Chapter 2 Materials and Methods 
(section 2.4.1 RNA isolation and purification).  
 
3.3.9 cDNA synthesis 
cDNA was synthesised using the Qiagen RT2 First Strand kit, following the manufacturer’s 
instructions, as summarised in Chapter 2 Materials and Methods (section 2.4.2 cDNA 
synthesis).  
 
3.3.10 Reverse transcription quantitative polymerase chain reaction 
Samples were than analysed using the Applied Biosystems StepOnePlus Real-Time PCR 
system, as described in Chapter 2 Materials and Methods (Section 2.4.3 Reverse 
transcription quantitative polymerase chain reaction). Expression of Atf3, Atf4, Hspa5 and 
Edem1, normalised to Rn18s, was used to assess ER stress activation in C2C12 myotubes. 
Expression of ATF3, ATF4, HSPA5 and EDEM1, normalised to Actb, was used to assess ER 
stress induction in primary human skeletal muscle cells.  
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3.3.11 Metabolite extraction from cells 
Metabolites were extracted from cells using a modified Bligh and Dyer method, as described 
in Chapter 2 Materials and Methods (section 2.5.2 Cell metabolite and lipid extraction for 
mass spectrometry). 
 
3.3.12 Metabolite extraction from skeletal muscle tissue 
Approximately 30 mg of tissue was first homogenised using a TissueLyser (Qiagen), and 
metabolites were then extracted using a Bligh and Dyer extraction, outlined in Chapter 2 
Materials and Methods (section 2.5.2 Human and mouse skeletal muscle tissue extraction).  
 
3.3.13 FAME derivatisation 
Dried organic samples were made up in 750 µl methanol/chloroform (1:1). Samples were 
then derivatised using 125 µl 10% BF3 in methanol, and incubated at 80°C for 90 minutes. 
500 µl MilliQ water and 1 ml hexane were added, and the samples vortexed, forming two 
layers. The organic phase was extracted and dried down, before reconstitution in 100 µl 
hexane.  
 
3.3.14 Gas chromatography-mass spectrometry analysis of FAMEs 
All samples were run on a Trace GC Ultra paired to a DSQ II single-quadrupole mass 
spectrometer 261. For organic samples, a 30 m x 0.25 mm 70% cyanopropyl polysilphenylene-
siloxane column (0.25 µm TR-FAME stationary phase; Thermo Scientific) was used. 4 µl of 
the sample was injected, with a split ratio of 8. The injector temperature was set to 230 °C, 
the transfer line to 240 °C, the ion source to 250 °C and the helium carrier gas was used at a 
constant flow rate of 1.2 ml/min. The initial column temperature of 60 °C was held for 2 
minutes and then increased by 15 °C/min to 150 °C and then by 4 °C/min to 230 °C. The run 
time for each sample was 28 minutes.  
The subsequent chromatograms were analysed using Xcalibur software (version 2.2; Thermo 
Scientific). Each peak was integrated and normalized to an internal standard peak. Peak 
assignment was based on mass fragmentation patterns matched to the NIST/ EPA/NIH mass 
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spectral library. Identification was supported by comparison with a FAME standard mix 
(Supelco 37 Component FAME Mix; Sigma Aldrich). 
 
3.3.15 Liquid chromatography-mass spectrometry analysis of lipids  
Samples were dissolved in 50 µl methanol/chloroform (1:1) and 10 µl of this was added to 
190 µl IPA/ACN/H2O (2:1:1). They were then analysed using an Orbitrap Elite mass 
spectrometer (Thermo Fisher), as described in Chapter 2 Materials and Methods (section 
2.6 Liquid chromatography-mass spectrometry open profiling of lipids). Chromatogram files 
were converted using MSConvert (Proteowizard), and processed using XCMS within an R 
script. Peaks were normalised to a relevant internal standard and then either cell number, for 
in vitro experiments, or dry protein pellet weight, for the analysis of skeletal muscle tissue. 
 
3.3.16 Statistics 
Statistical significance was assessed using either one-way ANOVA, with Tukey’s multiple 
comparison test, or Student’s t-tests, as detailed in each figure. In each case, n ≥ 3 and the 
significance level was set to P ≤ 0.05. The GraphPad Prism (version 6) software was used for 
all univariate analysis. 
  
  Chapter 3 
 
56 
 
3.4 Results 
3.4.1 The induction of ER stress in C2C12 myotubes under differing culture media 
serum conditions 
C2C12 cells, isolated from mice recessive for the dystrophic dy gene, are capable of 
undergoing differentiation from myoblasts to myotubes 262–264. They have been reported as 
cultured to confluence as myoblasts in media containing 10% foetal bovine serum (FBS) and 
1% penicillin-streptomycin 83,265. The myoblasts are then differentiated into myotubes with 
the addition of differentiation media. The composition of this differentiation media varies, 
with media containing 2% horse serum (HS) reported 83,265, while American Type Culture 
Collection (ATCC) instruct use of a media containing 10% horse serum 266.  
To determine the optimal serum conditions for palmitate-induced ER stress, C2C12 
myoblasts were cultured to confluence and then differentiated in media containing either 2% 
or 10% HS, as well as 1% penicillin-streptomycin and 750 nM insulin. Insulin is widely-
accepted to not only enhance differentiation but also increase fatty acid, and therefore 
palmitate, uptake 267–269. Cells were then differentiated for 6 days, during which they were 
treated with either 100 µM or 200 µM palmitate conjugated BSA, or the BSA vehicle. 
Concentrations of palmitate were based on measured plasma concentrations in the literature 
(122 µM free palmitate, measured by GC-MS) 270.  
RT-qPCR of a panel of four UPR-related genes – Atf3, Atf4, Hspa5 and Edem1 - was used to 
determine the induction of ER stress. Atf4 is downstream of Perk signalling 271, while Atf6 
and Atf4 increase the expression of Hspa5 and Atf3 272,273. Ire1 activation triggers elevated 
transcription of Edem1, via spliced Xbp1 274. Transcriptional analysis of these four genes 
provides an assessment of induction of the three arms of the UPR.  
In 10% HS conditions, 100 µM palmitate did not induce expression of the ER stress gene 
panel, but 200 µM palmitate significantly increased the expression of all four genes (1.8-fold 
increase in Atf3, 2.3-fold increase in Atf4, 1.7-fold increases in Hspa5 and Edem1) (Figure 
3.1B). Conversely, 200 µM palmitate had no effect on the expression of the gene-panel when 
myotubes were grown in 2% HS (Figure 3.1A). The lower concentration of palmitate was 
able to increase transcription of Atf3 (1.5-fold) and Hspa5 (1.3-fold), but this was not to the 
same extent as with 200 µM palmitate in 10% HS conditions. Therefore, 10% HS 
differentiation media was utilised to assess palmitate-induced ER stress in C2C12 cells.  
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Figure 3.1: Chronic palmitate treatment increases expression of unfolded protein 
response genes in C2C12 cells differentiated in 10% serum-containing media  
C2C12 cells were differentiated for 6 days in media containing either 2% (A) or 10% (B) 
horse serum. During this period, myotubes were exposed to either 100 or 200 µM 
palmitate, or the vehicle control. RT-qPCR was used to analyse the expression of key 
unfolded protein response genes (Atf3, Atf4, Hspa5 and Edem1). Each gene was analysed 
using a one-way ANOVA test with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n=4).  
 
A 
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3.4.2 Acute exposure to palmitate induces ER stress in C2C12 myotubes 
Canonically, palmitate-induced ER stress has been investigated using acute treatment with 
the fatty acid, typically for 18-24 hours 54,103,257–260. To compare the C2C12 model used in 
this thesis with the acute investigations of the effects of high-concentration palmitate in other 
in vitro cell culture systems reported in the literature, cells were grown to confluence, and 
then differentiated for 5 days in 10% HS. Following this, myotubes were treated with 750 µM 
palmitate for 24 hours, or the vehicle control. RNA was extracted from the cells and the 
expression of UPR gene-panel was analysed using RT-qPCR. Palmitate significantly 
increased the expression of Atf3 (13.5-fold), Atf4 (4-fold), Hspa5 (2-fold) and Edem1 (12-
fold), indicating activation of ER stress (Figure 3.2). The increase in expression of UPR 
markers is much greater following an acute treatment, but the gene expression changes 
observed in the chronic model are much more in keeping with alterations seen in vivo in 
murine skeletal muscle, following high-fat feeding 275. This suggests that a chronic model of 
palmitate-induced ER stress is more physiologically relevant to understanding the link 
between lipotoxicity and ER-stress in metabolic disease. The acute treatment regime does not 
reflect the physiological scenario in obesity, where saturated plasma fatty acid concentrations 
are chronically elevated 166,276. To replicate the pathophysiological environment, experiments 
within this thesis will use C2C12 cells treated with a lower, more physiological dose of 
palmitate (200 µM), for a prolonged period of time (6 days).  
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3.4.3 Chronic palmitate treatment alters fatty acid metabolism in C2C12 myotubes 
To investigate potential metabolic alterations that may derive from palmitate-driven 
lipotoxicity and ER stress in skeletal myocytes, GC-MS was used to interrogate the fatty acid 
profile of C2C12 cells treated for 6 days with either 100 or 200 µM palmitate, or a BSA 
vehicle control. Lipids were extracted from the cells and derivatised to yield FAMEs prior to 
analysis with GC-MS. The use of this derivatisation hydrolyses fatty acids from complex 
lipid species, and so this GC-MS analysis is of the total intracellular fatty acid profile.  
Exposing C2C12 myotubes to palmitate greatly increased the intracellular concentration of 
palmitate in a dose responsive manner, which may reflect uptake from the media (Figure 
3.3A). Concentrations of palmitoleate, the desaturation product of palmitate, were also 
increased analogously (Figure 3.3B).  
 
 
Figure 3.2: Acute palmitate treatment induces endoplasmic reticulum stress 
Differentiated C2C12 myotubes were treated with 750 µM palmitate, or the BSA vehicle 
control, for 24 hours. The transcription of unfolded protein response genes (Atf3, Atf4, 
Hspa5 and Edem1) was analysed using RT-qPCR. Each gene was analysed using a 
Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (n=4).  
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Chronic palmitate treatment also induced changes in both n-6 and n-3 PUFAs. In the n-6 
pathway, γ-linolenic acid (GLA, 18:3) concentration is dose-responsively increased, while 
the concentration of downstream metabolites - dihomo-γ-linolenic acid  (DGLA, 20:3), 
arachidonic acid (AA, 20:4) and docosatetraenoic acid (22:4) – are all decreased (Figure 
3.4A).In the n-3 pathway palmitate treatment results in a dose-dependent increase in α-
linolenic acid (ALA, 18:3) and eicosatetraenoic acid (20:4) concentration, and a decrease in 
docosapentaenoic acid (22:5). Eicosapentaenoic acid (EPA, 20:5), however, was unchanged 
(Figure 3.4B).  
B A 
Figure 3.3: Chronic palmitate treatment increases total intracellular palmitate and 
palmitoleate concentrations 
C2C12 myotubes were treated with either 100 or 200 µM palmitate for 6 days. Fatty acid 
methyl ester (FAME) analysis by gas chromatography-mass spectrometry demonstrates 
increases in palmitate (A) and palmitoleate (B). FAMEs were analysed using a one-way 
ANOVA test with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 
0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n=4).  
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Figure 3.4: Chronic palmitate alters the levels of polyunsaturated fatty acid methyl 
esters 
C2C12 myotubes were treated with either 100 or 200 µM palmitate for 6 days. Fatty acid 
methyl ester (FAME) analysis by gas chromatography-mass spectrometry highlights 
alterations in both the n-6 (A) and the n-3 (B) polyunsaturated fatty acid pathways. 
FAMEs were analysed using a one-way ANOVA test with Tukey’s multiple comparison 
test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean 
± SEM (n=4). 
B 
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3.4.4 Acute palmitate treatment of C2C12 myotubes induces less pronounced 
perturbation of fatty acid metabolism 
To investigate the effect of acute palmitate-induced ER stress on fatty acid metabolism, 
differentiated C2C12 myotubes were treated with 750 µM palmitate for 24 hours. Lipids 
were isolated and derivatised to yield FAMEs and analysed using GC-MS. Acute palmitate 
treatment increased intracellular palmitate concentrations to a much greater extent than 
chronic palmitate treatment, reflecting the higher concentration in the media. Palmitoleate 
was also increased, but to a lesser extent than in the chronic scenario (Figure 3.5).  
In comparison to the chronic model, however, acute palmitate treatment had a reduced effect 
on PUFA metabolism. Within the n-6 pathway, there was an increase in linoleic acid (18:2), 
while concentrations of DGLA and AA decreased. The direction of changes were in keeping 
with the chronic model, but differences between control and treatment groups were much 
smaller (Figure 3.6A). Similarly, in the n-3 pathway acute palmitate treatment increases 
ALA concentrations, with concomitant decreases in EPA and docosapentaenoic acid (Figure 
3.6B). 
Figure 3.5: Acute palmitate treatment increases total palmitate and palmitoleate 
concentrations 
Differentiated C2C12 myotubes were treated with 750 µM palmitate, or the vehicle 
control, for 24 hours. Gas chromatography-mass spectrometry analysis of fatty acid 
methyl esters (FAMEs) shows increases in palmitate (A) and palmitoleate (B) following 
acute exposure to palmitate. FAMEs were analysed using a Student’s t-test. * P ≤ 0.05, ** 
P < 0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n=4). 
 
B A 
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The analysis of total fatty acid metabolism highlights that, while acute palmitate induces 
greater expression of UPR genes, a lower, chronic dose of palmitate has far greater effects on 
intracellular fatty acid concentrations, against a background of ER stress, more in keeping 
with the in vivo situation in obese murine skeletal muscle. In particular, chronic palmitate 
treatment increases the concentration of early members of the n-6 and n-3 PUFA pathways, 
including GLA, ALA and eicosatetraenoic acid, while downstream fatty acids – DGLA, AA, 
docosatetraenoic acid, and docosapentaenoic acid – were all decreased.  
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Figure 3.6: Acute palmitate treatment alters the concentrations of intracellular 
polyunsaturated fatty acids in C2C12 myotubes 
C2C12 myotubes were treated with 750 µM palmitate, or the vehicle control, for 24 
hours. Fatty acid methyl ester (FAME) analysis by gas chromatography-mass 
spectrometry highlights alterations in both the n-6 (A) and the n-3 (B) polyunsaturated 
fatty acid pathways. FAMEs were analysed using a Student’s t-test. * P ≤ 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n=4).  
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3.4.5 Chronic palmitate treatment induces breakdown of PUFA-containing 
phosphatidylcholines in C2C12 myotubes 
GC-MS analysis of FAMEs provides information on the total fatty acid profile, but does not 
give information on the intact lipid the fatty acid may be derived from. An untargeted LC-MS 
method was employed to investigate the effects of chronic palmitate treatment on intact 
complex lipids. Cells were treated with either 100 or 200 µM palmitate, or the BSA vehicle 
for 6 days during differentiation. Metabolites were extracted from the cells as before and the 
organic phase was analysed using LC-MS. In positive mode, diacyl- and triacylglycerols, as 
well as phosphatidylcholines, lysophosphatidylcholines and sphingomyelins were all 
detected. In negative mode, free fatty acids, ceramides and other phospholipid species such as 
phosphatidylethanolamines, phosphatidylglycerols and phosphatidylinositols were analysed. 
Approximately 500 annotated lipid species were detected in positive ionisation mode and a 
further 150 in negative ionisation mode.  As well as increases in saturated glycerolipids, 
chronic palmitate treatment decreased levels of PUFA-containing PCs, in keeping with 
alterations observed in FAME profiles. Fragmentation spectra were then used to conclusively 
identify fatty acid composition of each PC that contained 4 or more double bonds. In 
particular, intracellular PC 16:0/20:4 and 18:0/20:4 were significantly decreased in C2C12 
cells with palmitate treatment (Figure 3.7A). Similar changes were also seen in PCs 
containing EPA, with PC 16:0/20:5, 16:1/20:5 and 18:1/20:5 all decreased following 
exposure to palmitate (Figure 3.7B). This suggests that the decreases in total PUFAs within 
the cells detected via GC-MS analysis correspond to a reduction in PUFA- containing PCs. 
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Figure 3.7: Chronic palmitate treatment induces breakdown of polyunsaturated 
fatty acid-containing phosphatidylcholines 
C2C12 myotubes were treated with either 100 or 200 µM palmitate for 6 days, or the 
vehicle control. Liquid chromatography-mass spectrometry analysis shows palmitate-
induced breakdown of phosphatidylcholine (PC) species containing arachidonic acid (A) 
and eicosapentaenoic acid (B). (C) shows a typical LC-MS chromatogram, while (D) is a 
typical fragmentation spectrum of m/z 782.57. Peaks at m/z of 478 and 496 are typical of 
a PC containing palmitate, while peaks at 526 and 544 indicate the presence of 
arachidonic acid. PCs were analysed using a one-way ANOVA test with Tukey’s 
multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data 
are expressed as mean ± SEM (n=4).  
A 
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3.4.6 Chronic palmitate treatment increases expression of ER stress genes and induces 
breakdown of PUFA-containing phosphatidylcholines in primary human skeletal 
muscle cells 
To determine whether palmitate increases ER stress and phospholipid remodelling in human 
skeletal muscle, experiments were also conducted using primary human skeletal muscle cells 
(HSkMCs). HSkMCs represent a model more applicable to investigations of lipotoxicity-
induced ER stress in human disease when compared with the C2C12 myoblast immortalised 
mouse cell line.  HSkMCs were grown to confluence in growth media and then differentiated 
for 6 days in differentiation media. During differentiation, cells were treated with either 50 or 
100 µM palmitate, or the BSA vehicle. Reduced palmitate concentrations were used 
compared to C2C12 myotube culture due to high levels of cell death at 200 µM. RNA was 
extracted and analysed using RT-qPCR to assess induction of the UPR. Metabolites were 
extracted using a modified Bligh and Dyer method, and the lipid-containing organic phase 
was analysed using an open-profiling LC-MS/MS lipidomics method.  
Palmitate increased the expression of the UPR gene panel in a dose-responsive manner 
(control vs. 100 µM palmitate: ATF3 2.6-fold, ATF4 1.3-fold, HSPA5 1.6-fold, EDEM1 1.2-
fold), indicating the induction of ER stress (Figure 3.8A). Five phosphatidylcholine species 
were conclusively annotated. Palmitate dose-responsively decreased the levels of the AA-
containing PCs (PC 16:0/20:4, PC 18:0/20:4, and PC 18:1/20:4) (Figure 3.8B), consistent 
with observations made in C2C12 myotubes. However, PC 16:0/20:5 was increased with 
palmitate exposure, in contrast to results seen in the C2C12 model. It’s important to note, 
however, that this data is reported as fold-change. The concentration of PC 18:0/20:4 is much 
higher than PC 16:0/20:5, and so the impact of this palmitate-stimulated increase may be 
reduced in this model. These data indicate that chronic palmitate treatment stimulates 
phospholipid remodelling in HSkMCs, particularly in relation to the concentrations of AA-
containing species.  
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Figure 3.8: Chronic palmitate treatment stimulates phospholipid remodelling in 
primary human skeletal muscle cells, concomitant with an increase in ER stress  
Primary human skeletal muscle cells were treated with 50 or 100 µM palmitate, or the 
vehicle for 6 days. (A) RT-qPCR was used to analyse transcription of unfolded protein 
response markers. (B) Phospholipid species were measured using liquid chromatography-
mass spectrometry. Each species was analysed using a one-way ANOVA test with 
Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 
0.0001. Data are expressed as mean ± SEM (n = 4).  
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3.4.7 Phospholipid remodelling in high-fat diet mouse models 
Sustained feeding of mice with a high fat diet (HFD) increases body weight and reduces 
insulin sensitivity, providing a model for obesity and T2DM 277. This project makes use of 
two separate studies in which mice were fed either a regular chow diet or a high-fat diet to 
investigate phospholipid remodelling in the skeletal muscle of an in vivo model of obesity.  
In the first study, 10 male C57Bl6 mice were fed a regular chow diet and 13 were fed a high-
fat diet for 14 weeks. Metabolites from the gastrocnemius muscle of these mice were 
extracted from the tissue, and the lipid fraction was analysed by LC-MS. Ten PUFA-
containing PC species were definitively annotated in positive mode, using fragmentation 
analysis. Intensities were normalised to an internal standard, and dried protein pellet weight. 
Lipidomic analysis identified a phospholipid profile inconsistent with in vitro studies. PC 
14:0/20:4, 16:0/20:4 and 18:0/20:4 were all increased in the muscle of mice fed a high-fat 
diet. PC 16:1/20:4 was the only AA-containing PC concentration decreased in the muscle of 
HFD fed mice (Figure 3.9A). However, the behaviour of EPA and DHA-containing PCs was 
consistent with the results observed in palmitate-treated myotubes, with PC 16:0/20:5, 
16:1/20:5, 16:0/22:6 and 18:1/22:6 decreased in the muscle of mice fed a high-fat diet 
(Figure 3.9B). 
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Figure 3.9: High fat diet-fed mice have alterations in polyunsaturated fatty acid-
containing phosphatidylcholines in skeletal muscle  
Mice were fed either a chow or high-fat diet (HFD) for 14 weeks. Liquid 
chromatography-mass spectrometry analysis of phospholipids extracted from 
gastrocnemius tissue show alteration in (A) arachidonic acid-, (B) eicosapentaenoic acid- 
and docosahexaenoic acid-containing phosphatidylcholines. Each species was analysed 
using a Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (chow: n = 10, HFD: n = 13).  
 
B 
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In the second study, male C57Bl6 mice were fed either a regular chow (n = 5) or a high fat 
diet (n = 5) for 17 weeks. The gastrocnemius muscle lipid profile was then analysed using 
LC-MS, with CID fragmentation to confirm lipid annotations. Intensities were normalised to 
an internal standard, and dried protein pellet weight. Unlike the first study, and the in vitro 
studies, the majority of detected PUFA-containing PCs were unaffected by high fat diet 
feeding. However, PC 16:1/20:4, 18:2/20:5 and 16:0/22:6 concentrations were decreased by a 
high fat diet (Figure 3.10). These murine studies suggest that while increased lipid exposure 
does increase breakdown of some PUFA-containing PCs, the effect is blunted when 
compared to the remodelling observed when exposing myotubes to palmitate in vitro.  
 
 
 
 
Figure 3.10: Changes in polyunsaturated fatty acid-containing phosphatidylcholines 
are less pronounced in a second mouse study  
Mice were fed either a chow or high-fat diet for 17 weeks. Liquid chromatography-mass 
spectrometry analysis of phospholipids extracted from gastrocnemius tissue show 
polyunsaturated fatty acid-containing phosphatidylcholines are partially affected by high-
fat diet. Each species was analysed using a Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P 
< 0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n = 5).  
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3.4.8 Mice fed a “western-style” diet have reduced concentrations of skeletal muscle 
PUFA-containing phosphatidylcholines compared with mice fed a low-fat control diet 
A recent study highlighted the importance of diet composition in the induction of obesity and 
insulin resistance 278. The authors demonstrated that a diet closely related to the human 
Western diet (WD), enriched in fat and carbohydrate, provided a robust obesogenic model. 
Therefore, phospholipid remodelling was analysed in a WD-fed mouse model. Eight male 
C57Bl6 mice were fed either a low-fat control diet or a western diet for 12 weeks.  
Metabolites were extracted from the gastrocnemius skeletal muscle using a Bligh and Dyer 
extraction, and the organic fraction was dried and analysed by LC-MS/MS. Eleven PUFA-
containing PCs were annotated using fragmentation analysis. The intensity of each lipid 
species was normalised to the relevant internal standard and dried protein pellet weight. Mice 
fed a western diet had decreased levels of PUFA-containing phosphatidylcholines suggesting 
an induction of phospholipid breakdown similar to that detected in vitro (Figure 3.11). 
Unlike mice fed a high fat diet, decreases in phospholipids were not fatty acid-specific, with 
decreases observed in AA-, EPA-, and DHA-containing PCs. 
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Figure 3.11: Mice fed a western diet have reduced concentrations of polyunsaturated 
fatty acid-containing phosphatidylcholines   
Mice were fed either a “western-style” diet or a low fat control diet for 12 weeks. Liquid 
chromatography-mass spectrometry analysis of gastrocnemius muscle shows mice fed a 
western diet had reduced levels of phosphatidylcholines containing (A) arachidonic acid 
(B) eicosapentaenoic acid and docosahexaenoic acid. Each species was analysed using a 
Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (n = 8).  
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3.4.9 Concentrations of PUFA-containing phosphatidylcholines are reduced in skeletal 
muscle biopsies of type 2 diabetic patients 
With free fatty acid-induced phospholipid remodelling observed in murine and human 
skeletal muscle cells, as well as dietary mouse models of obesity, it was hypothesised that 
phosphatidylcholine catabolism may be perturbed in the skeletal muscle of clinical patients 
with T2DM. To test this, biopsies were taken from the pectoralis major muscle of 75 patients 
during fitting of a pacemaker, and lipids were extracted using a modified Bligh and Dyer 
extraction. Phospholipid species were analysed using LC-MS/MS, with peaks normalised to 
an internal standard and dry protein pellet weight. Five PUFA-containing PCs – PC 
16:0/20:4, 18:0/20:4, 18:1/20:4, 16:0/20:5 and 16:0/22:6 - were definitively identified using 
LC-MS/MS, and correlation of each species with BMI was assessed using linear regression 
(Figure 3.12). While the slope of each regression line was negative, correlations between 
intensity and BMI were not significant. Furthermore, low R2 values indicate that the 
regression models failed to explain the majority of the variation in the dataset. It’s important 
to note that adiposity data was not available, which may be a better measure of obesity than 
BMI. The concentrations of each phospholipid, when compared between patients suffering 
from T2DM (n = 22) and non-diabetics (n = 53) demonstrated phospholipid remodelling in 
T2DM, with concentrations of PC 16:0/20:4, 16:0/20:5 and 16:0/22:6 significantly decreased 
in the skeletal muscle of T2DM patients (Figure 3.12F).   
This data highlights that phospholipid remodelling in skeletal muscle is not simply an artefact 
of in vitro cell culture, but translates to both in vivo models of metabolic disease and patients 
with T2DM. Analysis of patients here also serves to highlight that phospholipid remodelling 
is not only associated with lipid accumulation, but also defects in insulin sensitivity.  
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Figure 3.12: Concentrations of polyunsaturated fatty acid-containing 
phosphatidylcholines are reduced in skeletal muscle biopsies from patients with type 2 
diabetes   
Liquid chromatography-mass spectrometry analysis of skeletal muscle biopsies collected 
from patients during pacemaker fitting. Normalised concentration of phosphatidylcholines  
(PCs) (A) 16:0/20:4, (B) 18:0/20:4, (C) 18:1/20:4, (D) 16:0/20:5, and (E) 16:0/22:6 from 
skeletal muscle biopsies plotted against patient BMI, with correlations analysed by linear 
regression. (F) Concentration of polyunsaturated fatty acid-containing phosphatidylcholines 
in non-diabetic controls and patients with type 2 diabetes. Each species was analysed using 
a Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean (10-90th percentile) (non-diabetic: n = 43, diabetic: n = 19).  
 
A B 
C D 
F 
E 
  Chapter 3 
 
76 
 
3.4.10 Chronic tunicamycin treatment increases ER stress but not phospholipid 
remodelling in skeletal myocytes 
The reduction in PUFA-containing phospholipids correlates with the induction of ER stress, 
but to understand if the lipid changes are due to activation of the UPR, the ER stress effects 
of palmitate need to be separated from the lipotoxic effects. Therefore, C2C12 cells were 
treated with tunicamycin, which inhibits n-linked glycosylation, leading to a build-up of 
unfolded proteins and ER stress. Cells were treated with 10 or 50 ng/ml tunicamycin, or the 
appropriate volume of DMSO as a vehicle control, for the 6 days of differentiation, with 
concentrations chosen based on the literature 279,280. RNA was extracted and analysed by RT-
qPCR. Metabolites were extracted from cells and the organic fraction was analysed by LC-
MS as described previously.  
The 50 ng/ml dose of tunicamycin increased the expression of Atf3 (1.5-fold), Atf4 (1.9-fold), 
Hspa5 (1.4-fold) and Edem1 (1.7-fold), indicating the induction of ER stress (Figure 3.13). 
The lower 10 ng/ml dose of tunicamycin also significantly increased the expression of Atf4.  
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However, despite the induction of ER stress, LC-MS analysis showed that tunicamycin 
treatment did not affect concentrations of PCs containing arachidonic acid (Figure 3.14A). 
Furthermore, EPA-containing PCs were predominantly unchanged following tunicamycin 
exposure, with the exception of PC-18:1/20:5, which was increased (Figure 3.14B). These 
data do not follow the pattern of palmitate treatment, suggesting that the palmitate-induced 
alterations in PC and PUFA metabolism are not due to ER stress, but rather an independent 
effect of the lipotoxic insult.  
  
Figure 3.13: Chronic tunicamycin treatment increases expression of unfolded 
protein response genes  
C2C12 cells were treated for 6 days with either 10 or 50 ng/ml tunicamycin, or the vehicle 
control. RT-qPCR analysis highlights tunicamycin-induced increases in the transcription 
of unfolded protein response genes (Atf3, Atf4, Hspa5 and Edem1). Each gene was 
analysed using a one-way ANOVA test with Tukey’s multiple comparison test. * P ≤ 
0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean ± SEM 
(n=4).  
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Figure 3.14: Chronic tunicamycin treatment does not affect the concentration of 
polyunsaturated fatty acid-containing phosphatidylcholines  
C2C12 cells were treated for 6 days with either 10 or 50 ng/ml tunicamycin, or the vehicle 
control. Liquid chromatography-mass spectrometry analysis demonstrates the negligible 
effects of tunicamycin on (A) arachidonic acid- and (B) eicosapentaenoic acid-containing 
phosphatidylcholines (PCs). PCs were individually analysed using a one-way ANOVA 
test with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** 
P < 0.0001. Data are expressed as mean ± SEM (n=4).  
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To confirm these results, HSkMCs were also treated with 10 or 50 ng/ml of tunicamycin, or 
the DMSO vehicle. RNA was extracted, and activation of ER stress was analysed using RT-
qPCR analysis of the expression of a panel of UPR genes. A modified Bligh and Dyer 
extraction was used to purify lipids for LC/MS analysis. Phospholipid intensities were 
normalised to an internal standard and cell number.  
Increases in the expression of Atf3 (2.3-fold), Atf4 (1.6-fold), Hspa5 (1.7-fold) and Edem1 
(1.9-fold) demonstrate that tunicamycin induced ER stress in a dose-responsive manner 
(Figure 3.15A). However, LC-MS analysis showed that tunicamycin had no effect on the 
concentration of PC-containing PUFAs (Figure 3.15B). These results, in conjunction with 
analogous experiments in C2C12 cells, suggest that palmitate-induced phospholipid 
remodelling is independent of the activation of UPR signalling.  
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A 
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Figure 3.15: Tunicamycin induces endoplasmic reticulum stress in primary human 
skeletal muscle cells but has no effect on the concentration of polyunsaturated fatty 
acid-containing PCs 
Primary human skeletal muscle cells were treated with 50 or 100 ng/mL tunicamycin, or the 
DMSO vehicle control for 6 days. (A) Induction of expression of endoplasmic reticulum 
stress-associated genes (Atf3, Atf4, Hspa5 and Edem1) were assessed using RT-qPCR. (B) 
Polyunsaturated fatty acid-containing phosphatidylcholines were measured using liquid 
chromatography-mass spectrometry. Each species was analysed using a one-way ANOVA 
test with Tukey’s multiple comparison test.* P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 
0.0001. Data are expressed as mean ± SEM (n = 4).  
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3.4.11 Inhibition of Perk and Ire1 suggests phosphatidylcholine remodelling is 
independent of the UPR 
Although models of chemical-induced ER stress did not induce PC catabolism, a role for 
UPR induction in PC remodelling cannot be ruled out. Therefore, a pharmacological inhibitor 
approach was used to probe the relationship between phospholipid remodelling and ER 
stress. C2C12 myoblasts were grown to confluence and then treated with either 200 µM 
palmitate or the BSA vehicle for 6 days during differentiation. During these 6 days, cells 
were also co-cultured with either 10 µM AMG PERK 44, which selectively binds to the 
kinase domain of Perk to inhibit its activity 281, or 10 µM 4µ8C, an inhibitor of Ire1 
ribonuclease activity 282. Inhibitor concentrations were chosen based on the literature 283,284. 
Metabolites were then extracted using a modified Bligh and Dyer extraction, and the organic 
fraction was analysed by LC-MS. Phospholipid species were annotated using fragmentation 
analysis, and normalised to an internal standard and cell number.  
Treatment with the inhibitor of Perk signalling showed no significant effect on the six PUFA-
containing PCs definitively annotated, irrespective of the fatty acid composition (Figure 
3.16A). Similarly, inhibition of Ire1, did not reverse palmitate-induced breakdown of PUFA-
containing PCs, although treatment with 4µ8C did reduce levels of PC 16:0/20:5, while 
increasing PC 16:1/22:6 (Figure 3.16B). As previously observed palmitate significantly 
decreases the concentrations of PC 16:0/20:4 and 18:0/20:4, while the other lipid species, 
although not significantly decreased, trend towards lower concentrations. This is a likely 
product of a lower replicate number (3), and an increase in variation within the drug-
treatment groups. These results suggest neither Perk nor the Ire1 UPR signalling arms 
mediate palmitate-induced phospholipid remodelling, consistent with the inference from the 
tunicamycin treatment studies which suggested that phospholipid catabolism is independent 
of the induction of ER stress.  
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Figure 3.16: Phospholipid remodelling is not dependent on the Perk and Ire1 arms of 
the unfolded protein response   
C2C12 myotubes were treated with 200 µM palmitate, or the vehicle for 6 days. For the 
final 24 hours, cells were also co-incubated with either (A) 10 µM AMG PERK 44 (B) 10 
µM 4µ8c, or the relevant vehicle. Polyunsaturated fatty acid-containing 
phosphatidylcholines were profiled using liquid chromatography-mass spectrometry. Each 
species was analysed using a one-way ANOVA test with Tukey’s multiple comparison 
test.* P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. Data are expressed as mean ± SEM 
(n = 3).  
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3.5 Discussion 
Palmitate-induced lipotoxicity and ER stress are proposed mechanisms behind the aetiology 
of T2DM and obesity 103,104,248,285. This chapter aimed to define the effects of palmitate-
induced lipotoxicity on lipid metabolism, in the context of ER stress. 
Previous studies performed to address the contribution of ER stress to insulin resistance and 
metabolic pathology have focussed on the effects of acute stresses 54,103,181,257–260,286. 
However, in a clinical setting in humans with obesity or T2DM, the phenotype is of chronic 
stress resulting from raised blood FFA concentrations 166,276. Therefore, the analyses carried 
out in this chapter aimed to define the metabolic differences between acute and chronic FFA-
induced lipotoxicity and ER stress within skeletal muscle cells.  
While acute palmitate treatment increased transcript levels of ER stress-mediated UPR genes 
to a greater extent than chronic exposure, UPR gene expression was still activated by the 
lower, chronic dose of palmitate and the transcriptional changes were more consistent with in 
vivo data in murine skeletal muscle 275. Therefore, chronic treatment of cells with palmitate 
may represent a more accurate representation of the physiological obese state in vivo. Chronic 
palmitate exposure induced UPR gene expression in cells cultured in differentiation medium 
containing 10% horse serum, an effect not observed with 2% horse serum. The reasons for 
this, however, are unclear, but are likely a result of increased lipid load on myotubes. 
Fatty acid analysis by GC-MS demonstrated that while the effect of chronic palmitate on 
UPR induction was less than that of acute palmitate, the impact on fatty acid metabolism was 
far greater. Increases in cellular palmitate and palmitoleate suggest that exogenous palmitate 
is entering the cell. The increase in palmitoleate is a well described mechanism to detoxify 
palmitate through the generation of monounsaturated fatty acids, including palmitoleate, in 
the context of lipotoxicity 53,287–289. Perhaps most interesting was the effect of chronic 
palmitate exposure on PUFA metabolism. PUFAs can be separated into the n-6 and n-3 
pathways. While GLA was elevated following chronic palmitate treatment, the subsequent 
PUFAs in the n-6 pathway were all decreased. A similar pattern was observed in the n-3 
pathway, with ALA and eicosatetraenoic acid increased, but docosapentaenoic acid 
decreased. One possible explanation is an enzymatic block or inhibition in the pathway, 
increasing the concentration of metabolites prior to the block and subsequently decreasing 
proceeding species. However, the block is situated in different reactions of the n-3 and n-6 
pathway despite a shared enzymatic set. The block for the n-6 pathway would occur between 
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GLA and DGLA, catalysed by Elovl5 290. However, this elongase also catalyses the 
conversion of octadecatetraenoic acid to eicosatetraenoic acid, the latter of which is increased 
with palmitate treatment.  
Instead, LC-MS profiling of intact lipids from C2C12 myotubes and primary HSkMCs 
showed chronic palmitate treatment stimulated catabolism of PUFA-containing PCs, 
suggesting that reductions in total PUFAs are a result of phospholipid remodelling. These 
results also translated to both murine and human in vivo models of metabolic disease. It is 
important to note that results from mice fed a western diet, comprising 42.7% carbohydrate 
and 42.0% fat (%kcal), were more consistent with in vitro models than mice fed a high-fat 
diet, which contained approximately 20% carbohydrate and 60% fat. Previous work has 
demonstrated that mice fed a western diet have increased de novo lipogenesis, a product of 
which is palmitate, and so may explain the differences between the in vivo models 291.  
The phospholipid changes are consistent with previous work showing concentrations of 
PUFA-containing PCs correlate with insulin sensitivity 292. Similarly, skeletal muscle from 
individuals treated with nicotinic acid, which induces insulin resistance, had reduced 
concentrations of PUFA-containing PCs 293. While there is evidence for phospholipid 
remodelling in the literature, the results of this chapter highlight the importance of palmitate 
in driving phospholipid remodelling. Further work will seek to understand the functional 
consequences of these changes.  
Hydrolysis of phospholipids by cytoplasmic phospholipase A2 (cPLA2) releases free PUFAs 
for the synthesis of eicosanoids, a class of bioactive lipids with an important role in 
inflammatory signalling 294. Decreases in PUFA-containing PCs following chronic exposure 
to palmitate may be a result of increased cPLA2 activity and eicosanoid synthesis. 
Eicosanoids have been implicated in metabolic disease previously, with mice lacking both 5- 
and 12/15-lipoxygenase, enzymes important in the generation of a subset of eicosanoid 
species, protecting against diet-induced insulin resistance 295,296. Furthermore, work has 
shown that eicosanoids may function in the control of ER stress, with inhibition of 5-
lipoxygenase ameliorating palmitate-induced ER stress in C2C12 myotubes 297. This suggests 
that while phospholipid remodelling is not dependent on ER stress, the consequences of PC 
catabolism could influence the induction of UPR signalling.  
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Conclusion 
Chronic palmitate induces ER stress in C2C12 myotubes and primary human skeletal 
myocytes, concomitant with decreases in PUFA-containing PCs. This phospholipid 
remodelling in skeletal muscle translates to mouse and human models of metabolic disease 
and will be investigated further in subsequent chapters. 
  
 
Chapter 4 
 
Phospholipid remodelling and eicosanoid generation 
regulates ER stress and inflammatory signalling 
 
4.1 Introduction 
The processes linking obesity to the aetiology of T2DM remain to be fully described. A role 
for inflammation in the development of insulin resistance in a number of insulin-sensitive 
tissues, including skeletal muscle, has long been postulated 104. The inflammatory response in 
these tissues observed during obesity is distinct from that of infection or autoimmunity. 
Instead, it has been referred to as “low-grade” inflammation 298, or “metaflammation” 299. 
Circulating inflammatory markers, such as C-reactive protein (CRP), and the chemokines 
chemokine (C-C motif) ligand 2 (CCL2) and interleukin-6 (IL-6), predict T2DM onset in 
large population studies 300–302. Increases in inflammatory cytokines, such as TNFα (Tumour 
Necrosis Factor α), IL-6 and CCL2, in peripheral tissues, including skeletal muscle, adipose 
and the liver, of obese individuals, reinforce the observed associations seen in plasma from 
patients 303–307. An increased inflammatory environment in peripheral tissues is then 
infiltrated by immune cells, with increased immune cell infiltration in the skeletal muscle of 
both mice fed a high-fat diet and obese humans having been reported 91.  
The in vivo associations between obesity, insulin resistance and inflammation are mimicked 
by exposing cultured myocytes to saturated fatty acids. Treating C2C12 cells with palmitate 
increases Tnf expression, concomitant with decreases in Glut4 transcription and glucose 
uptake 83. Similarly, palmitate has been shown to increase concentrations of other 
proinflammatory cytokines, including IL-6 and CCL2, in human primary and C2C12 
myotubes, respectively 89,308.  
However, inflammatory signalling can also be controlled by lipid signalling, as well as by 
protein cytokines. Eicosanoids are bioactive lipids produced by the oxidation of free PUFAs, 
following their hydrolysis from phospholipids by cPLA2 (Figure 4.1) 50. They represent a 
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group of autocrine and paracrine signalling molecules, diffusing from their site of synthesis to 
bring about receptor-mediated effects on inflammation in nearby cells 309,310. As shown in 
Chapter 3, chronic palmitate treatment increases breakdown of PUFA-containing PCs. GC-
MS analysis of total fatty acids also showed decreases in a number of PUFAs, such as 
arachidonic acid. One explanation for these results is an increase in substrate usage. 
Experiments in this chapter, therefore, investigate the hypothesis that the palmitate-induced 
breakdown of PUFA-containing PCs was to provide increased substrate for eicosanoid 
synthesis.  
 
 
Figure 1: Eicosanoid synthesis pathway 
Diagram depicting the key enzymatic pathways in the synthesis of eicosanoids. Free 
polyunsaturated fatty acids (PUFAs) are released from the phospholipid bilayer by 
cytoplasmic phospholipase A2 (cPLA2). Cyclooxygenase (COX), lipoxygenase (LOX) 
and cytochrome P450 (CYP450) enzymes convert PUFAs to varying eicosanoid species. 
Prostaglandins (PGs) and thromboxane (TXA2) are produced by COX. 
Hydroxyeicosatetraenoic acids (HETEs), hydroxyeicosapentaenoic acids (HEPEs), 
hydroxyoctadecaenoic acids (HODEs), leukotrienes (LTs) and hydroxydocosahexaenoic 
acids (HDoHEs) are produced by LOX enzymes. Epoxyeicosatrienoic acids (EETs), 
epoxyoctadecenoic acids (EpOMEs) and HETEs are produced by CYP450 enzymes 405.  
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Previous work has shown the potential importance of eicosanoids in metabolic disease. Mice 
lacking 5-LOX show reduced immune cell infiltration in adipose tissue and partial protection 
from HFD-induced insulin resistance 295. Leukotriene B4 (LTB4), a 5-LOX product, is 
increased in the adipose, skeletal muscle and liver tissue of obese mice 311. In the same study, 
LTB4 was then also shown to increase inflammation and insulin resistance in cultured 
myotubes, macrophages and hepatocytes, while inhibition of the LTB4 receptor improved 
insulin sensitivity and protected against hepatic steatosis. Similarly, 12/15-LOX-KO mice are 
also protected against diet-induced insulin resistance and adipose tissue inflammation, 
highlighting roles for a number of different lipoxygenase enzymes in the development of the 
chronic inflammation observed during obesity and T2DM 296.  
The palmitate-induced breakdown of PUFA-containing PCs in C2C12 myotubes was 
accompanied by increases in the activation of ER stress. While tunicamycin treatment 
suggested that phospholipid remodelling was not ER stress-dependent, it remains unclear 
whether eicosanoid generation impacts on UPR activation. There is evidence supporting a 
role for eicosanoids in the regulation of ER stress. Inhibition of 5-lipoxygenase with zileuton 
in C2C12 myotubes reduced markers of ER stress, confirming a potential link between 
eicosanoids and ER stress 297. Furthermore, 15-HETE has been shown to increase ER stress 
markers in in human retinal endothelial cells, while Alox15-KO mice had reduced diabetes-
induced ER stress in the retina 312. 
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4.2 Aims and Objectives 
The aim of this chapter was to define the functional consequences of the palmitate-induced 
phospholipid remodelling identified in Chapter 3. A key set of objectives were designed to 
investigate this process: 
1) Pharmacological inhibition of phospholipase enzymes to determine the important isoform 
in membrane remodelling.  
2) LC-MS/MS profiling of eicosanoids in response to palmitate treatment. 
3) Pharmacological inhibition of key eicosanoid synthesis enzymes to probe the roles of 
distinct classes of eicosanoids lipids and their signalling pathways in the induction of ER 
stress and inflammatory signalling in myotubes.  
4) Co-culturing of myotubes and macrophages to investigate the role of eicosanoids in 
immune cell activation.   
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4.3 Materials and Methods 
4.3.1 C2C12 culture 
C2C12 cells were cultured as described in Chapter 2 Materials and Methods (Section 2.1.1 
C2C12 myoblast culture and differentiation). Pharmacological inhibitors (detailed in section 
4.3.5 Pharmacological inhibitors) were used for the final 24 hours of experiments. Cells for 
analysis by RT-qPCR, ELISA or LC-MS analysis of phospholipids were treated in collagen I-
coated 12-well plates. Cells for eicosanoid analysis were treated in collage I-coated T75 
flasks.  
  
4.3.2 Primary human skeletal muscle cell culture 
Primary human skeletal muscle cells (HSkMCs) were cultured as described in Chapter 2 
Materials and Methods (section 2.1.2 Primary human skeletal muscle cell culture and 
differentiation). Cells were treated with inhibitors (detailed in section 4.3.5 Pharmacological 
inhibitors) for the final 24 hours of experiments. All cells were treated in 12-well plates.  
 
4.3.3 Raw 264.7 macrophage culture and co-culturing assays 
Raw 264.7 cells (ATCC) were grown to confluence in DMEM supplemented with 10% FBS 
(Sigma Aldrich) and 1% P/S (Sigma Aldrich). For co-culture assays, C2C12 cells were 
grown to confluence in 12-well plates, and then differentiated for 6 days. During this 6 day 
period, C2C12 cells were cultured with their respective agonists. Separately, Raw 264.7 
macrophages were grown to confluence in a T75 flask. Transwell inserts (Corning) were 
initially submerged in 1.5 mL of serum-free media for 24 hours to improve cell adherence. 
Macrophages were lifted from the flask using trypsin, and pelleted in a centrifuge. 
Subsequently, they were resuspended in growth media (10% FBS, 1% P/S) and transferred to 
the inserts for 24 hours to adhere to the membrane, corresponding to the final 24 hours of 
C2C12 treatment. Culture media was then switched to serum-free, agonist-free media on both 
sets of cells. Finally, the inserts were combined with the plate of C2C12 cells and co-culture 
assays lasted for 24 hours. 
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4.3.4 Conjugation of palmitate to BSA 
Palmitate was bound to BSA following the protocol summarised in Chapter 2 Materials 
and Methods (section 2.1.3 Conjugation of palmitate to BSA).  
 
4.3.5 Pharmacological inhibitors 
PD146176 and NCTT-956 were purchased from Sigma Aldrich (Gillingham, UK), and 
dissolved in DMSO to a concentration of 20 mM. The inhibitors were diluted into culture 
media to achieve a final concentration of 10 µM. AACOCF3 was purchased from Abcam 
(Cambridge, UK) and dissolved in DMSO to a concentration of 100 mM. The inhibitor was 
diluted in culture media to a final concentration of 100 µM.  
 
4.3.6 Cell harvesting 
Cells were harvested and pelleted as described in Chapter 2 Materials and Methods 
(section 2.1.4 Cell harvesting). Cell counts were performed using a Scepter automated cell 
counter (Millipore). 
 
4.3.7 RNA isolation and purification 
RNA was extracted and purified from cells using an RNeasy mini kit (Qiagen), according to 
the manufacturer’s instructions and as outlined in Chapter 2 Materials and Methods 
(section 2.4.1 RNA isolation and purification).   
 
4.3.8 cDNA synthesis  
RNA concentrations were standardised and cDNA then synthesised using an RT2 First Strand 
kit (Qiagen), following manufacturer’s instructions as set out in Chapter 2 Materials and 
Methods (section 2.4.2 cDNA synthesis).  
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4.3.9 Reverse transcription quantitative polymerase chain reaction 
Transcript levels were analysed using the StepOnePlus Real-Time PCR system (Applied 
Biosystems), as described in Chapter 2 Materials and Methods (section 2.4.3 Reverse 
transcription quantitative polymerase chain reaction). Transcription of Atf3, Atf4, Hspa5 and 
Edem1, normalised to Rn18s, was used to assess the induction of ER stress in C2C12 
myotubes. Expression of ATF3, ATF4, HSPA5 and EDEM1, normalised to ACTB, was used 
to assess the induction of ER stress in primary HSkMCs. Other murine primers used in this 
chapter are Ccl2 (PPM03151G), Il6 (PPM03015A), Alox5 (PPM28755C), Alox12 
(PPM25685A), Tnf (PPM03113G), Arg1 (PPM31770C), Nos2 (PPM02928B) and Egr2 
(PPM04478F), with all expression normalised to Rn18s. Other human primers used in this 
chapter are CCL2 (PPH00192F) and IL6 (PPH00560C), with all expression normalised to 
ACTB. All primers are purchased from Qiagen.   
 
4.3.10 Metabolite extraction from cells 
Metabolites were extracted from cells using a modified Bligh and Dyer method, described in 
Chapter 2 Materials and Methods (section 2.5.1 Cell metabolite and lipid extraction for 
mass spectrometry).   
 
4.3.11 Liquid chromatography-mass spectrometry of lipids 
The dried-down organic fraction was dissolved in 50 µl methanol/chloroform (1:1), and 
diluted into 190 µl IPA/ACN/H2O (2:1:1). Samples were then analysed using an Orbitrap 
Elite mass spectrometer, using a method with two scan events as described in Chapter 2 
Materials and Methods (section 2.6 Liquid chromatography-mass spectrometry open 
profiling of lipids). Chromatogram files were converted using MSConvert (Proteowizard), 
and processed using XCMS within an R script. Peaks were normalised to a relevant internal 
standard and then either cell number, for in vitro experiments, or dry protein pellet weight, 
for the analysis of skeletal muscle tissue.  
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4.3.12 Eicosanoid extraction from cells and media 
Cell pellets were resuspended in 1mL water and mixed with 2.5 mL IPA/hexane/1M acetic 
acid (20:30:2). 5 mL of conditioned cell culture media was dried down under nitrogen to a 
total volume of 1 mL, and mixed with 2.5 mL IPA/hexane/1M acetic acid (20:30:2). 10 µL of 
a 1 ng/µL internal standard mix (12-HETE-d8, PGE2-d4, and 8-iso-PGF2a-d4) was added 
and each sample was vortexed for 30 seconds. 2.5 mL hexane was then added and samples 
vortexed for another 30 seconds before centrifugation (5 minutes, 1500rpm, 4ºC). The upper 
layer was transferred to a glass vial and dried down under nitrogen gas for storage at -80ºC.  
 
4.3.13 Liquid chromatography-mass spectrometry/mass spectrometry of eicosanoids 
Dried samples were reconstituted in 50 µL of methanol and analysed using a TSQ Quantiva 
Triple Quadrupole mass spectrometer (Thermo Fisher), coupled to a Vanquish UHPLC 
system (Thermo Fisher). Five µL of sample was injected and separated using a C18 CSH 
column (1.7 µM, 2.1x100 mm, Waters). The flow rate was set at 0.5 mL/min. Solvent A was 
composed of H2O/solvent B (95/5, 0.1% glacial acetic acid) and solvent B was 
acetonitrile/methanol (80:20, 0.1% glacial acetic acid). Solvent B begins at 30% until the first 
minute, when it is increased to 35% by 4 minutes, 67.5% by 8 minutes, and 100% at 13 
minutes. It is held in this condition for 3 minutes, before returning to initial conditions for 2 
minutes. Eicosanoids were detected in negative ionisation mode, with an electrospray voltage 
of 2.5 kV. The source temperature was set to 420 ºC, and nitrogen was used as the drying gas 
for solvent evaporation. Eicosanoid species were detected using a targeted MS/MS analysis, 
with precursor and fragment ions detailed in Table 4.1. 
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Compound  Precursor 
ion (m/z) 
Fragment ions 
(m/z) 
Retention time 
(minutes) 
5-HEPE 317.2 255,299,115 11.62 
12-HEPE 317.2 179,255,299 11.35 
15-HEPE 317.21 219,255,299 11.12 
5-HETE 319 301,257,115 12.78 
12-HETE 319 179 12.71 
15-HETE 319 301,257,219 13.57 
9-HODE 295.25 277,171,123 11.76 
13-HODE 295.2 277,195,179 11.8 
8,9-EET 319 301,257,275 13.76 
11,12-EET 319 167,301,179 13.64 
7-HDOHE  343 325,281,201 12.59 
13-HDOHE 343.2 193,281,325 12.35 
17-HDOHE 343.2 193,281,326 12.26 
9,10-EPOME 295.2 277,170,183 13.41 
 
 
4.3.14 Statistics 
Statistical significance was assessed using either a one-way ANOVA, with Tukey’s multiple 
comparison test, or Student’s t-test, as detailed in each figure. In each case, n ≥ 3 and the 
significance level was set to p ≤ 0.05. All univariate analysis was conducted using GraphPad 
software (version 6, Prism).  
Table 4.1: Fragment m/z values for eicosanoids 
 
  Chapter 4 
 
95 
 
4.4 Results 
4.4.1 Cytosolic phospholipase A2 inhibition reverses palmitate-induced catabolism of 
PUFA-containing phosphatidylcholines  
Phospholipid breakdown is catalysed by hydrolytic phospholipase enzymes 313. This enzyme 
class comprises a number of sub-families and isoforms with differing preferences of substrate 
and hydrolytic site. PLA2 enzymes hydrolyse the phospholipid sn-2 fatty acyl chain and have 
a preference for PUFAs 314. There are a number of PLA2 classes, but it is cPLA2 that is best 
documented for its roles in intracellular arachidonic acid metabolism, as well as 
inflammatory signalling 315. 
To determine if cPLA2 has a role in palmitate-driven phospholipid remodelling, C2C12 
myotubes were grown to confluence and treated with 200 µM palmitate, or the BSA vehicle, 
for 6 days. For the final 24 hours, cells were also co-treated with 100 µM AACOCF3, a 
cPLA2 inhibitor, or the DMSO vehicle. The concentration of AACOCF3 used was based on 
treatment of C2C12 myotubes in previous papers 316,317. Metabolites were extracted and the 
lipid phase was analysed by LC-MS/MS. AACOCF3 greatly increased the concentrations of 
PUFA-containing PCs with and without palmitate treatment, highlighting a pronounced role 
for cPLA2 in palmitate-driven PC remodelling (Figure 4.2A and 4.2B).  
AACOCF3 does have off-target effects, including a potency for calcium-independent 
phospholipase A2 (iPLA2). Therefore, separately cells were also co-treated with 10 µM R-
bromoenollactone (R-BEL), an iPLA2 inhibitor, for the final 24 hours of a 6-day palmitate 
treatment (Figure 4.2C). The concentration of R-BEL was based on the literature 318. PUFA-
containing phospholipid levels were unaffected by R-BEL treatment, demonstrating that 
palmitate-driven phospholipid remodelling is cPLA2-specific. 
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Figure 4.2: Palmitate-induced phosphatidylcholine breakdown is dependent on 
cytosolic phospholipase A2 
C2C12 myotubes were treated with 200 µM palmitate for 6 days, or the vehicle control. 
Liquid chromatography-mass spectrometry (LC-MS) analysis of (A) arachidonic acid- and 
(B) eicosapentaenoic acid-containing phosphatidylcholines (PCs) from cells following co-
treatment with 100 µM AACOCF3, or the vehicle control. (C) LC-MS analysis after co-
treatment with 10 µM R-BEL, or the vehicle control. PCs were analysed using a one-way 
ANOVA test with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 
0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n=3).  
A 
B 
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4.4.2 Chronic palmitate treatment induces changes in eicosanoid synthesis and secretion 
Phospholipid remodelling catalysed by cPLA2 provides a source of free cytosolic PUFAs, in 
particular AA and EPA, which are precursors for the synthesis of eicosanoids. This class of 
bioactive lipids have key roles in inflammatory signalling. Palmitate-driven breakdown of 
PUFA-containing PCs may be a result of increased eicosanoid synthesis, and so a targeted 
LC-MS/MS method was used to investigate the eicosanoid concentrations.  
C2C12 cells were grown to confluence, and differentiated for 5 days. During this period cells 
were treated with 200 µM palmitate, or the BSA-vehicle. Eicosanoids are typically unstable, 
transient mediators, and so a time-course was carried out to understand the dynamics of 
eicosanoid synthesis during chronic palmitate treatment. Cells were harvested every 24 hours 
for the 5 days, and eicosanoids were analysed using LC-MS/MS. Analysis identified 
palmitate-induced changes in the concentrations of eicosanoid species generated by 
lipoxygenase (LOX) enzymes, including hydroxyeicosatetraenoic (HETE), 
hydroxyeicosapentaenoic (HEPE) and hydroxyoctadecadienoic (HODE) acids. After 24 
hours of treatment, palmitate increased the concentrations of arachidonic acid-derived 5-, 12- 
and 15-HETE (Figure 4.3A). 5- and 12-HEPE, produced from EPA by the same LOX 
isoforms, were also increased at the 24 hour time point (Figure 4.3B). Levels of these 
eicosanoids fell during the subsequent 4 days, with 15-HETE significantly decreased for the 
final 3 days of palmitate treatment. Similarly, 13-HODE and 9-HODE, produced from 
linoleic acid, were increased in response to palmitate treatment after 24 hours, before falling 
back to control levels for the subsequent 4 days (Figure 4.3C). On the other hand, 
epoxyeicosatrienoic (EET) acids are produced by cytochrome P450 epoxygenase enzymes. 
8,9-, 11,12-, and 14,15-EET were found to decrease in palmitate-treated cells from 3 days 
onwards (Figure 4.3D).  
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Eicosanoids function as local signalling molecules. They are released from the cell and bind 
to receptors on nearby cells. Therefore, to better understand the potential effect of palmitate 
exposure on eicosanoid-driven signalling, the concentrations of eicosanoids within 
conditioned cell culture media were analysed. C2C12 cells were grown and treated as before, 
across a 5-day timecourse. For the final 24 hours, media was changed to serum-free media. 
Therefore, eicosanoids were only present in the media as a result of secretion from the cells, 
rather than as a constituent part of the media serum. Media was extracted and analysed in an 
analogous manner to the cells.  
Similar to the intracellular eicosanoid species detected, the predominant eicosanoids observed 
in the media were LOX-derived. However, the secretory time-course profile differed from the 
intracellular pattern. As before, the HETE and HEPE species detected were increased after 
the first 24 hours of palmitate treatment, but this increase prolonged to 48 hours before falling 
D C 
B A 
Figure 4.3: Intracellular eicosanoid concentrations in response to palmitate treatment 
over a 5-day timecourse 
C2C12 myotubes were treated with 200 µM palmitate for 6 days, or the vehicle control. 
Samples were harvested every 24 hours, and eicosanoid levels were analysed by liquid 
chromatography-mass spectrometry, identifying changes in (A) hydroxyeicosatetraenoic 
acids, (B) hydroxyeicosapentaenoic acids, (C) hydroxyoctadecadienoic acids, and (D) 
epoxyeicosatrienoic acids. Eicosanoids were analysed using a Student’s t-test * P ≤ 0.05, ** P 
< 0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n=4).  
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over days three and four (Figure 4.4A and B). Following 5 days of palmitate-treatment, the 
release of 5- and 12-HETE and 5-, 12-, and 15-HEPE into the media was significantly 
increased. Similarly, 9- and 13-HODE were increased at the 24 hour mark, but, while 9-
HODE levels continued to follow the profile seen intracellularly, 13-HODE concentration in 
the media was increased across the time course by palmitate treatment (Figure 4.4C).  
EET species were not detected in the media, but two other classes of eicosanoids were found 
to change in response to palmitate exposure. Hydroxydocosahexaenoic (HDoHE) acids are 
produced from DHA. The secretion of 5-LOX-generated 7-HDoHE and 15-LOX-generated 
17-HDoHE were increased on days 1, 2 (only 17-HDoHE), and 5 of palmitate treatment 
(Figure 4.4D). A similar pattern was also observed for the COX2-derived 13-HDoHE. 
Finally, two cytochrome P450 products of linoleic acid were also increased in the media in 
response to palmitate. 9(10)-EpOME (leukotoxin) was increased after 1, 2 and 5 days of 
palmitate treatment, while 12(13)-EpOME (isoleukotoxin) was elevated at day 1 and 5 
(Figure 4.4E). These data highlight that palmitate-induced PC remodelling leads to 
alterations in eicosanoid synthesis and secretion.  
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Figure 4.4: Secretion of eicosanoids in response to palmitate treatment over a 5-day 
timecourse 
C2C12 myotubes were treated with 200 µM palmitate for 6 days, or the vehicle control. 
Media samples were taken every 24 hours, and eicosanoid levels were analysed by liquid 
chromatography-mass spectrometry, identifying changes in (A) hydroxyeicosatetraenoic 
acids, (B) hydroxyeicosapentaenoic acids, (C) hydroxyoctadecadienoic acids, (D) 
hydroxydocosahexaenoic and (E) epoxyoctadecenoic acids. Eicosanoids were analysed using 
a Student’s t-test * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are expressed 
as mean ± SEM (n=4).  
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4.4.3 Chronic palmitate treatment alters expression of key inflammatory cytokines 
Increases in eicosanoid secretion may influence the control of inflammatory signalling. 
Previous literature has shown palmitate treatment increases the expression of inflammatory 
cytokines, including Tnf, Il6, and Ccl2 in skeletal muscle 83,89,253. However, in keeping with 
investigations into ER stress, the majority of experiments have focused on acute palmitate 
exposures. Therefore, the effect of chronic palmitate on the expression of key inflammatory 
cytokines in myotubes was assessed by RT-qPCR. C2C12 cells were grown to confluence, 
and differentiated for 6 days, during which myotubes were treated with either 200 µM 
palmitate or the BSA vehicle. RNA was extracted and purified at the end of 6 days, and 
cDNA was synthesised. RT-qPCR analysis shows chronic palmitate exposure increases 
expression of Ccl2, while expression of Il6 decreased (Figure 4.5). These results confirm that 
chronic palmitate treatment impacts not only UPR induction but also the expression of 
inflammatory cytokines. A decrease in Il6 expression contradicts previous work in which 
acute palmitate increases expression of Il6, suggesting differences between acute and chronic 
models of FFA-induced lipotoxicity.  
To confirm the effects of chronic palmitate treatment on inflammatory cytokine expression 
translate in human-derived cells, experiments were repeated in primary HSkMCs. HSkMCs 
were grown to confluence and then treated with 100 µM palmitate or the BSA vehicle 
Figure 4.5: Chronic palmitate treatment increases expression of Ccl2 but decreases 
transcription of Il6 in C2C12 myotubes 
C2C12 myotubes were treated with 200 µM palmitate, or the vehicle for 6 days. 
Transcription of inflammatory markers (Ccl2 and Il6) were assessed using RT-qPCR. Each 
species was analysed using a Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P 
< 0.0001. Data are expressed as mean ± SEM (n = 4).  
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throughout 6 days of differentiation. RNA was subsequently extracted, and RT-qPCR was 
used to analyse mRNA expression. Chronic palmitate significantly elevated expression of 
Ccl2, similar to results seen in C2C12 cells (Figure 4.6). Il6 expression, however, was not 
consistent with that in C2C12 myotubes, with palmitate exposure here increasing expression 
of Il6. While expression patterns are slightly inconsistent between the two cell types, the 
results still highlight a role for palmitate in the alteration of inflammatory cytokine 
expression.  
4.4.4 Expression of lipoxygenase isoforms are increased with palmitate exposure in 
myocytes 
Induction of ER stress and alterations in expression of inflammatory cytokines were 
concomitant with changes in lipoxygenase-derived eicosanoid secretion and synthesis. To 
further understand the mechanism behind these changes, C2C12 cells were grown to 
confluence and treated with either 200 µM palmitate, or the BSA vehicle, during a 6-day 
differentiation period. RNA was extracted and purified, prior to analysis of the expression of 
the lipoxygenase isoforms arachidonate 5-lipoxygenase (Alox5), arachidonate 12-
lipoxygenase (Alox12) and arachidonate 15-lipoxygenase (Alox15) by RT-qPCR. Chronic 
palmitate exposure increased the expression of Alox5 and Alox12 compared to BSA vehicle 
Figure 4.6: Chronic palmitate treatment increases expression of CCL2 and IL6 in 
primary human skeletal muscle cells 
Primary human skeletal myocytes were treated with 100 µM palmitate, or the vehicle for 6 
days. Transcription of inflammatory cytokines (CCL2 and IL6) were assessed using RT-
qPCR. Each species was analysed using a Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 
0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n = 4).  
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control-treated myotubes (Figure 4.7). Expression of Alox15, however, was below the limit 
of detection in the myocytes. These results highlight that increases in eicosanoid secretion are 
concomitant with increased gene expression of key synthetic enzymes.  
 
4.4.5 Inhibition of eicosanoid synthesis exacerbates palmitate-induced ER stress and 
inflammation in C2C12 myotubes 
With chemical inhibition highlighting little role for ER stress in phospholipid remodelling, 
and therefore eicosanoid generation, the question remained of whether eicosanoid synthesis 
may lie upstream in signalling leading to the activation of the UPR following palmitate 
treatment. Previous research has highlighted a potential role for 5-LOX, via LTB4, in 
palmitate-induced ER stress 297, but little other work has addressed this question. Here, 
pharmacological inhibitors of cPLA2 (AACOCF3), 12-LOX (NCTT-956), and 15-LOX 
(PD146176) have been used to assess the role that other lipoxygenase isoforms may have in 
the activation of inflammatory and stress signalling pathways.  
RT-qPCR was used to profile the effects of phospholipase and lipoxygenase inhibition on ER 
stress signalling and inflammatory cytokines. C2C12 cells were grown to confluence and 
Figure 4.7: Chronic palmitate treatment increases expression of 5-lipoxygenase and 
12-lipoxygenase isoforms. 
C2C12 myotubes were treated with 200 µM palmitate, or the BSA vehicle for 6 days. 
Transcription of lipoxygenase enzymes, 5-lipoxygenase (Alox5) and 12-lipoxygenase 
(Alox12) was measured using RT-qPCR. Each species was analysed using a Student’s t-test. 
* P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. Data are expressed as mean ± SEM.  
  Chapter 4 
 
104 
 
treated for 6 days through differentiation with 200 µM palmitate or the BSA vehicle. For the 
final 24 hours, cells were co-treated with either 100 µM of the PLA2 inhibitor AACOCF3, 10 
µM of the 15-LOX inhibitor PD146176 or 10 µM of the 12-LOX inhibitor NCTT-956, or the 
relevant volume of the DMSO vehicle control 319,320. RNA was then extracted and the 
expression of UPR and inflammatory markers were analysed using RT-qPCR.  
Inhibition of cPLA2 had a profound effect on the activation of ER stress. Treatment with 
AACOCF3 increased the expression of all four UPR markers (Atf3 increased 12.7-fold, Atf4 
increased 7.5-fold, Hspa5 increased 5.7-fold, Edem1 1.8-fold), and exacerbated palmitate-
induced ER stress relative to control-treated cells (Atf3 increased 6.6-fold, Atf4 increased 6.7-
fold, Hspa5 increased 3-fold, Edem1 increased 2-fold) (Figure 4.8A). However, a 
combination of palmitate and the cPLA2 inhibitor reduced expression of Atf3 and Hspa5 
when compared to cells treated with the inhibitor alone, suggesting the two treatments are not 
additive. While cPLA2 inhibition had a profound effect on UPR gene expression, the 
consequences of inhibition on inflammatory cytokines were less clear (Figure 4.8B). There 
were no significant effects on Ccl2 expression with AACOCF3 treatment, although inhibition 
did increase levels of Il6 (4-fold). These results suggest that palmitate-induced eicosanoid 
secretion may have an important role in controlling the induction of ER stress. Since cPLA2 
inhibition increased expression of UPR markers, eicosanoid signalling may function to 
oppose the induction of ER stress following palmitate treatment.  
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However, cPLA2 inhibition also greatly increased concentrations of PUFA-containing PCs, 
potentially through inhibition of PUFA release from PCs within the plasma membrane, which 
is likely to affect membrane shape and fluidity. Previous work has highlighted the importance 
of membrane composition in the induction of ER stress, and so the exacerbation of palmitate-
induced ER stress by cPLA2 inhibition may not be a result of disrupted eicosanoid synthesis 
Figure 4.8: Inhibition of cytosolic phospholipase A2 exacerbates palmitate-induced 
endoplasmic reticulum stress 
C2C12 myotubes were treated with 200 µM palmitate, or the vehicle for 6 days during 
differentiation. For the final 24 hours, myotubes were also co-incubated with either 100 µM 
AACOCF3, or the vehicle. Transcription of (A) unfolded protein response markers (Atf3, 
Atf4, Hspa5 and Edem1) and (B) inflammatory cytokines (Ccl2 and Il6) were measured 
using RT-qPCR. Each species was analysed using a one-way ANOVA with Tukey’s 
multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (n = 3).  
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175,176. Chemical inhibition of LOX isoforms circumvents the issues related to membrane 
structure by inhibiting eicosanoid synthesis further down the pathway. Furthermore, it 
provides a more detailed analysis of eicosanoid function, focusing on specific branch points 
of the pathway and a subset of the eicosanoid species (Figure 4.1).  
Inhibition of 15-LOX with PD146176 had little effect on the induction of UPR genes in the 
Ire1 mediated pathways, but the palmitate-induced increase in Atf3 expression was 
exacerbated 1.5-fold when combined with the inhibition (Figure 4.9A). 15-LOX abrogation 
did, however, have a more pronounced effect on inflammatory markers. PD146176 treatment 
of cells exposed to palmitate significantly increased the expression of Ccl2 1.6-fold compared 
to those cells treated with only palmitate, while 15-LOX inhibition also increased the mRNA 
levels of Il6 (1.8-fold) (Figure 4.9B). 
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In contrast, 12-LOX inhibition, using NCTT-956, was associated with increases in the 
expression of Atf3 (1.9-fold), Atf4 (2.5-fold), and Edem1 (1.3-fold) (Figure 4.10A). 
Furthermore, cells co-treated with palmitate and the inhibitor exhibited additive expression of 
Atf3 (1.9-fold), Atf4 (1.4-fold), and Edem1 (1.3-fold) when compared to those exposed only 
to palmitate. The effect of 12-LOX inhibition on Ccl2 and Il6 was less pronounced when 
Figure 4.9: Inhibition of 15-lipoxygenase increases expression of inflammatory 
cytokines in C2C12 myotubes. 
C2C12 myotubes were treated with 200 µM palmitate, or the vehicle for 6 days during 
differentiation. For the final 24 hours, myotubes were also co-incubated with either 10 µM 
PD146176, or the vehicle. Transcription of (A) unfolded protein response markers (Atf3, 
Atf4, Hspa5 and Edem1) and (B) inflammatory cytokines (Ccl2 and Il6) were measured 
using RT-qPCR. Each species was analysed using a one-way ANOVA with Tukey’s 
multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (n = 3).  
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compared with 15-LOX inhibition, although co-treatment of palmitate with NCTT-956 
significantly increased the expression of Ccl2 (2.4-fold) and reduced expression of Il6 (by 
60%) compared to cells treated with the vehicle control (Figure 4.10B).  
These data highlight a role for 12-LOX-derived eicosanoids in the regulation of UPR gene 
expression, and suggests that eicosanoids generated via 12-LOX oppose palmitate-mediated 
activation of the UPR.  
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Figure 4.10: Inhibition of 12-lipoxygenase amplifies palmitate-induced unfolded 
protein response gene expression in C2C12 myotubes 
C2C12 myotubes were treated with 200 µM palmitate, or the vehicle for 6 days during 
differentiation. For the final 24 hours, myotubes were also co-incubated with either 10 µM 
NCTT-956, or the vehicle. Transcription of (A) unfolded protein response genes (Atf3, Atf4, 
Hspa5 and Edem1) and (B) inflammatory cytokines (Ccl2 and Il6) were measured using 
RT-qPCR. Each species was analysed using a one-way ANOVA with Tukey’s multiple 
comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (n = 3).  
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4.4.6 Inhibition of 12- and 15-lipoxygenase increases unfolded protein response 
induction in primary human skeletal muscle cells 
To investigate whether the observations made in mouse C2C12 cells translate to a human 
model of skeletal myocytes, experiments were repeated in primary HSkMCs. Cells were 
cultured to confluence and treated with 100 µM palmitate, or the BSA vehicle, throughout a 6 
day differentiation period. For the final 24 hours, cells were also co-cultured with either 10 
µM PD146176 (15-LOX inhibitor), 10 µM NCTT-956 (12-LOX inhibitor), or the DMSO 
vehicle control. RNA was isolated and the mRNA levels of UPR genes (ATF3, ATF4, HSPA5 
and EDEM1) and inflammatory cytokines (CCL2 and IL6) were measured using RT-qPCR.  
Inhibition of 15-LOX with PD146176 exacerbated palmitate-induced ER stress, with 
expression of ATF4 (2.1-fold), HSPA5 (1.3-fold), and EDEM1 (2-fold) significantly higher in 
myocytes treated with both palmitate and the inhibitor compared with palmitate alone 
(Figure 4.11A). The expression of CCL2 (5-fold, compared to the control) and IL6 (11.1-
fold, compared to the control) were also increased following co-treatment of myocytes with 
both the 15-LOX inhibitor and palmitate (Figure 4.11B). These results suggest a more 
prominent role for 15-LOX derived metabolites in human myocytes than the immortalised 
C2C12 mouse cell line. 
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Inhibition of 12-LOX, via NCTT-956 treatment, also increased palmitate-induced 
transcription of UPR genes including ATF3 (1.7-fold compared to palmitate treated), HSPA5 
(1.5-fold compared to palmitate treated) and EDEM1 (1.7-fold compared to control), similar 
to results detected in C2C12 cells (Figure 4.12A). The effect of 12-LOX inhibition on 
inflammatory cytokine expression was negligible, however (Figure 4.12B). These data are, at 
Figure 4.11: Inhibition of 15-lipoxygenase exacerbates palmitate-induced endoplasmic 
reticulum stress in primary human skeletal muscle cells 
Primary human skeletal muscle cells were treated with 100 µM palmitate, or the vehicle for 
6 days during differentiation. For the final 24 hours, myotubes were also co-incubated with 
either 10 µM PD146176, or the vehicle. Transcription of (A) unfolded protein response 
markers (Atf3, Atf4, Hspa5 and Edem1) and (B) inflammatory cytokines (Ccl2 and Il6) were 
measured using RT-qPCR. Each species was analysed using a one-way ANOVA with 
Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. 
Data are expressed as mean ± SEM (n = 3).  
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least partially, in agreement with experiments conducted in C2C12 cells, and reinforce a 
potential role for LOX-derived eicosanoids in the control of ER stress and the expression of 
inflammatory cytokines.  
 
Figure 4.12: Inhibition of 12-lipoxygenase increases palmitate-induced endoplasmic 
reticulum stress in primary human skeletal muscle cells 
Primary HSkMCs were treated with 100 µM palmitate, or the vehicle for 6 days during 
differentiation. For the final 24 hours, myotubes were also co-incubated with either 10 µM 
NCTT-956, or the vehicle. Transcription of (A) unfolded protein response markers (Atf3, 
Atf4, Hspa5 and Edem1) and (B) inflammatory cytokines (Ccl2 and Il6) were measured 
using RT-qPCR. Each species was analysed using a one-way ANOVA with Tukey’s 
multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (n = 3).  
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4.4.7 Co-culturing palmitate-conditioned C2C12 myotubes with untreated Raw 264.7 
macrophages increases transcription of genes associated with macrophage activation 
Palmitate-induced eicosanoid secretion increases local concentrations of the oxidised lipids 
for cells in close proximity. Thus far, the effects of these eicosanoids have been considered 
on myocytes, but they may also provide a means of communication between myocytes and 
cells of the immune system. Immune cell infiltration is associated with obesity in skeletal 
muscle, while in vitro experiments have suggested the potential for cross-talk between 
myocytes and macrophages 91,100,321. To investigate a role for myocyte-derived eicosanoids in 
paracrine and endocrine signalling to immune cells, C2C12 myotubes were co-cultured with 
Raw 264.7 cells, an immortalised macrophage cell line. C2C12 cells were grown to 
confluence and differentiated for 6 days, during which they were treated with either 200 µM 
palmitate or the BSA vehicle. For the final 24 hours, myotubes were also co-treated with 100 
µM AACOCF3 to inhibit cPLA2, and therefore eicosanoid production, or the DMSO vehicle. 
Separately, Raw 264.7 cells were grown to confluence and then plated in Transwell inserts 
for 24 hours. Following the end of the C2C12 treatment regime, culture media was switched 
to serum-free media on both myocytes and macrophages, and the inserts were then added to 
the wells of C2C12 cells. The two cell lines were co-cultured for 24 hours, and RNA was 
harvested from both cell types at the end of this time period. Expression of both ER stress 
associated genes and macrophage polarisation markers were measured by RT-qPCR.  
Macrophage activation states exist between the pro-inflammatory M1 and the anti-
inflammatory M2 phenotypes 322. Here, expression of two M1 markers – tumour necrosis 
factor (Tnf) and nitric oxide synthase 2 (Nos2) – and two M2 markers – early growth 
response 2 (Egr2) and arginase 1 (Arg1) – were measured to understand if cross-talk with 
myocytes influences macrophage activation. Expression of Arg1 (3-fold), Tnf (2.6-fold) and 
Nos2 (2-fold) were all significantly elevated in macrophages co-cultured with palmitate-
treated myocytes (Figure 4.13A). This suggests an increase in macrophage polarisation and 
activation, but with higher levels of both M1 and M2 markers, it is unclear whether these 
macrophages display both M1 and M2 phenotypes or if there are a mixed population of cells 
responding to different pro- and anti-inflammatory cues. Inhibition of cPLA2 had only a 
limited effect on the activation markers. AACOCF3 treatment increased Arg1 expression 
(2.9-fold), suggesting a potential role for eicosanoids in suppressing M2 activation, but 
combining palmitate treatment with cPLA2 inhibition did not exacerbate the phenotype. 
Furthermore, inactivation of cPLA2 also impacted on the transcription of Nos2, with co-
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treatment of myocytes with palmitate and AACOCF3 insignificant compared with vehicle 
control treated cells.  
Macrophages co-cultured with palmitate-treated C2C12 cells also exhibited increased 
expression of Atf4 (2.9-fold) and Hspa5 (1.8-fold), indicating the induction of ER stress 
(Figure 4.13B). Inhibiting cPLA2 in palmitate-treated C2C12 myotubes reduced 
transcription of these UPR markers, suggesting that myocyte-derived eicosanoids are 
important in the induction of macrophage ER stress.  
  Chapter 4 
 
115 
 
 
 
 
 
A 
Figure 4.13: Co-culture of Raw 264.7 macrophages with palmitate-treated C2C12 
myotubes increases macrophage polarisation and endoplasmic reticulum stress  
C2C12 myotubes were treated with 200 µM palmitate, or the vehicle for 6 days during 
differentiation. For the final 24 hours, myotubes were also co-incubated with either 100 µM 
AACOCF3, or the vehicle. Subsequently, media was switched to serum-free media and 
myotubes were co-cultured with Raw 264.7 macrophages grown on Transwell inserts. 
Transcription of (A) macrophage activation markers (Arg1, Egr2, Nos2 and Tnf) and (B) 
UPR genes (Atf3, Atf4, Hspa5 and Edem1) in Raw 264.7 macrophages were measured using 
RT-qPCR. Each species was analysed using a one-way ANOVA with Tukey’s multiple 
comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (n = 3).  
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RT-qPCR analysis of C2C12 myotubes co-cultured with the macrophages demonstrated that 
the effects of cPLA2 inhibition were consistent with previous experiments, as expression of 
Atf3, Atf4, Hspa5 and Edem1 were increased independent of palmitate exposure (Figure 
4.14A). However, expression of ER stress genes were unchanged between control and 
palmitate treatment groups, which suggests that macrophages confer a degree of protection 
against palmitate-induced ER stress in myotubes. The effects of cPLA2 inhibition on 
inflammatory markers were also consistent with previous experiments not involving co-
culture (Figure 4.14B).  
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Figure 4.14: Co-culturing C2C12 myotubes with Raw 264.7 macrophages reduces 
palmitate-induced endoplasmic reticulum stress in myotubes 
C2C12 myotubes were treated with 200 µM palmitate, or the vehicle for 6 days during 
differentiation. For the final 24 hours, myotubes were also co-incubated with either 100 µM 
AACOCF3, or the vehicle. Subsequently, media was switched to serum-free media and 
myotubes were co-cultured with Raw 264.7 macrophages grown on Transwell inserts. 
Transcription of (A) endoplasmic reticulum stress markers (Atf3, Atf4, Hspa5 and Edem1) 
and (B) inflammatory cytokines (Ccl2 and Il6) in C2C12 myotubes were measured using 
RT-qPCR. Each species was analysed using a one-way ANOVA with Tukey’s multiple 
comparison test.* P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (n = 3).  
A 
B 
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4.4.8 Inhibition of lipoxygenase isoforms in C2C12 myotubes reduces macrophage 
activation in co-cultured Raw 264.7 macrophages  
Inhibition of cPLA2 in myotubes partially impacted upon co-cultured macrophage expression 
of Arg1 and Nos2, suggesting a potential role for eicosanoids in macrophage polarisation. To 
investigate the effects of the downstream 12-LOX and 15-LOX branches of eicosanoid 
metabolism, C2C12 cells were cultured to confluence and treated for 6 days during 
differentiation with 200 µM palmitate or the BSA vehicle. For the final 24 hours, cells were 
co-treated with either 10 µM of the 15-LOX inhibitor PD146176, 10 µM of the 12-LOX 
inhibitor NCTT-946, or the DMSO vehicle. Following the end of the treatment regime, cell 
culture media was switched to serum-free media, and myotubes were co-cultured with 
macrophages grown on Transwell inserts. After 24 hours, RNA was extracted from 
macrophages and transcription of ER stress and macrophage polarisation markers were 
analysed using RT-qPCR.  
Treatment of C2C12 cells with the 15-LOX inhibitor PD146176 and palmitate reduced 
macrophage expression of Arg1 and Tnf so that it was unchanged relative to the cells treated 
with the vehicle control, suggesting a role for 15-LOX-derived eicosanoids in the control of 
macrophage activation (Figure 4.15A). Macrophage transcription of ER stress markers, on 
the other hand, were unaffected by exposure to PD146176 (Figure 4.15B).  
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Inhibition of 12-LOX in myotubes treated with palmitate reduced expression of Tnf in co-
cultured macrophages to a level that was the same as vehicle-treated control cells. However, 
NCTT-946 treatment exacerbated palmitate-induced expression of Egr2 (1.8-fold compared 
to the control), with the increase reaching significance compared to cells treated with the 
vehicle controls, suggesting that eicosanoids synthesised by 12-LOX may have opposing 
A 
B 
Figure 15: Inhibition of 15-lipoxygenase in C2C12 myotubes partially reduces 
activation of Raw 264.7 macrophages  
C2C12 myotubes were treated with 200 µM palmitate, or the vehicle for 6 days during 
differentiation. For the final 24 hours, myotubes were also co-incubated with either 10 µM 
PD146176, or the vehicle. Subsequently, media was switched to serum-free media and 
myotubes were co-cultured with Raw 264.7 macrophages grown on Transwell inserts. 
Transcription of (A) macrophage activation markers (Arg1, Egr2, Nos2 and Tnf) and (B) 
unfolded protein response genes (Atf3, Atf4, Hspa5 and Edem1) in Raw 264.7 macrophages 
were measured using RT-qPCR. Each species was analysed using a one-way ANOVA with 
Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. 
Data are expressed as mean ± SEM (n = 3).  
 
  Chapter 4 
 
120 
 
effects on some M1 and M2 markers (Figure 4.16A). Similar to 15-LOX inhibition, 
treatment with NCTT-946 had little effect on macrophage expression of ER stress markers 
(Figure 4.16B).  
A 
B 
Figure 4.16: 12-lipoxygenase-derived eicosanoids secreted from C2C12 myotubes may 
push Raw 264.7 macrophages towards an M1 phenotype 
C2C12 myotubes were treated with 200 µM palmitate, or the vehicle for 6 days during 
differentiation. For the final 24 hours, myotubes were also co-incubated with either 10 µM 
NCTT-956, or the vehicle. Subsequently, media was switched to serum-free media and 
myotubes were co-cultured with Raw 264.7 macrophages grown on Transwell inserts. 
Transcription of (A) macrophage activation markers (Arg1, Egr2, Nos2 and Tnf) and (B) 
UPR genes (Atf3, Atf4, Hspa5 and Edem1) in Raw 264.7 macrophages were measured using 
RT-qPCR. Each species was analysed using a one-way ANOVA with Tukey’s multiple 
comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (n = 3).  
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The effects of LOX inhibition on C2C12 expression of UPR markers were minimal, although 
15-LOX and 12-LOX inhibition reduced palmitate-induced expression of Atf4 and Atf3, 
respectively, to a level that’s insignificant from vehicle-treated cells (Figure 4.17). However, 
it is important to note that ER stress levels do appear to be lower than previously observed in 
experiments without macrophages, suggesting a potential role for macrophages in 
suppressing palmitate-induced ER stress.  
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Figure 4.17: Lipoxygenase inhibition has little effect on endoplasmic reticulum stress 
in C2C12 myotubes following co-culture with Raw 264.7 macrophages  
C2C12 myotubes were treated with 200 µM palmitate, or the vehicle for 6 days during 
differentiation. For the final 24 hours, myotubes were also co-incubated with either 10 µM 
PD146176, 10 µM NCTT-956, or the vehicle. Subsequently, media was switched to 
serum-free media and myotubes were co-cultured with Raw 264.7 macrophages grown on 
Transwell inserts. Transcription of endoplasmic reticulum stress markers (Atf3, Atf4, 
Hspa5 and Edem1) in C2C12 myotubes following treatment with (A) PD1467176 and (B) 
NCTT-956) were measured using RT-qPCR. Each species was analysed using a one-way 
ANOVA with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001. Data are expressed as mean ± SEM (n = 3).  
B 
A 
  Chapter 4 
 
123 
 
Cell Type Inhibitor Phenotype 
Raw 264.7 AACOCF3 (cPLA2) Palmitate stimulated an increase in macrophage 
activation and ER stress markers. Inhibition of 
cPLA2 reduced induction of ER stress, 
suggesting a role for eicosanoid signalling in the 
propagation of UPR activation, but had limited 
effect on activation markers. 
C2C12 
  
AACOCF3 (cPLA2) Induction of palmitate-stimulated ER stress was 
abrogated by co-culture with macrophages. 
Inhibition of cPLA2 increased ER stress 
markers and Il6 expression. 
Raw 264.7 PD146176 (15-LOX) Inhibition of 15-LOX slightly reduced 
palmitate-induced increases in expression of 
Nos2 and Tnf to a level insignificant to the 
vehicle control. ER stress markers were 
unaffected.  
C2C12 PD146176 (15-LOX) 15-LOX inhibition had limited effect on ER 
stress genes. 
Raw 264.7 NCTT-956 (12-LOX) Inhibition of 12-LOX partially reduced 
expression of Tnf and increased expression of 
Egr2. Furthermore, there were increases in Atf3 
expression and palmitate-induced transcription 
of Edem1.  
C2C12 NCTT-956 (12-LOX) 12-LOX inhibition had limited effect on ER 
stress genes.  
  
Table 4.1: Summary table of results from co-culture experiments 
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4.5 Discussion 
This chapter sought to understand the functional consequences of palmitate-induced 
phospholipid remodelling. LC-MS/MS analysis of C2C12 myotube culture media showed an 
increase in eicosanoid secretion in response to both acute and chronic palmitate treatment, 
with lipoxygenase-derived species particularly affected. Signalling dynamics between 
skeletal muscle and the immune system have previously been considered at the protein level, 
centring on a role for cytokines in transmitting inflammation between cells 323,324. However, 
the palmitate-induced increases in eicosanoid secretion discussed here represent an 
alternative route for myocyte-myocyte and myocyte-macrophage cross-talk.  
Inhibiting cPLA2 activity greatly increased expression of ER stress markers in myocytes, 
suggesting a role for eicosanoids in the control of lipotoxic ER stress in muscle. Previous 
work has implicated LOX-derived eicosanoids in the induction of UPR signalling, with 
zileuton, a pharmacological inhibitor of 5-LOX, reducing lipid induced ER stress in C2C12 
myotubes and mouse models of obesity 297. Similarly, human retinal endothelial cells treated 
with 15-HETE exhibited increased ER stress, while diabetes-induced ER stress was reduced 
in the retina of Alox15-KO mice 312. Further evidence for an association between ER stress 
and eicosanoids stems from research on the role of Lpcat3 in liver 175. Elevated Lpcat3 
activity, which increases incorporation of PUFAs into the phospholipid membrane, thereby 
reducing eicosanoid generation, decreased markers of lipid-induced ER stress, in both in vitro 
and in vivo models. It’s important to note, however, that the effect of elevated LPCAT3 
activity in the previous study, as well as AACOCF3 treatment in this chapter, will also affect 
membrane composition and fluidity, potentially impacting on UPR induction. This is 
highlighted by decreases in expression of Atf3 and Hspa5 in palmitate and AACOCF3 co-
treatment groups compared to myotubes treated with only AACOCF3, suggesting a 
normalised membrane composition reduces ER stress. It’s likely, therefore, that the effects of 
AACOCF3 on UPR induction may result from both membrane composition and eicosanoid 
signalling.  
The role of 12- and 15-LOX derived eicosanoids in myocyte ER stress and inflammatory 
signalling has not been investigated.  In C2C12 myotubes 12-LOX-derived eicosanoids 
appear important in suppressing ER stress induction, while 15-LOX inhibition increased 
expression of inflammatory markers. Differences between murine and human LOX isoforms 
likely explain the differing results in primary HSkMCs, with chemical inhibition indicating 
  Chapter 4 
 
125 
 
an important role for 15-LOX in both ER stress induction and inflammation. Notably, mouse 
isoforms of Alox12 and Alox15 are both capable of producing 12- and 15-HETE, for 
example, while the human isoforms are much more stringent in their products, with ALOX12 
and ALOX15 forming only 12-HETE and 15-HETE, respectively  325.  
The results suggest that these bioactive lipids finely regulate protein-induced signalling 
responses and that the manipulation of specific eicosanoid pathways and species could 
alleviate ER stress and inflammatory signalling. The experiments presented here have 
focused on loss-of-function. Future work should look at increasing activity of LOX isoforms 
and exogenously exposing cells to different eicosanoids species. It will then be possible to 
isolate specific eicosanoid species important in the control of these signalling cascades. 
Importantly, very little research, if any, has focused on the eicosanoid species detected here 
by LC-MS/MS. Investigating the roles species such as HETEs, HEPEs and HODEs may play 
in metabolic disease represents an interesting and under-investigated field of research.  
In contrast with the results of this chapter, inhibition of 12/15-LOX (Alox15) has previously 
been identified to ameliorate tunicamycin-induced ER stress in cultured adipocytes, while 
exogenously exposing these cells to 12-HETE increased induction of the UPR 326. However, 
this work looked only at ER stress induced by tunicamycin, rather than palmitate, and used 
only acute treatments, never exceeding longer than 24 hours. Furthermore, Cole and 
colleagues also showed that 12/15-LOX knockout mice had increased expression of Hspa5 
and Atf4. While exposing cultured adipocytes extracted from these mice to tunicamycin for 4 
hours highlighted a potential protective role for 12/15-LOX, this effect largely diminished 
after 24 hours of tunicamycin treatment. The results of experiments in this chapter differ from 
the work of Cole et al. on differences in both substrate and treatment time, as well as cell 
tissue type.  
The role for eicosanoid signalling between C2C12 myotubes and Raw 264.7 macrophages 
was assessed in this chapter, using Transwell inserts for co-culturing of the two cell lines. 
Analysis of M1 and M2 marker expression showed increases in macrophage activation 
following co-culture with C2C12 cells treated with palmitate. Interestingly, however, 
expression of both M1 and M2 markers were increased. This may be explained by a mixed 
population of macrophages – exhibiting a distinct preference for either a M1-like or M2-like 
phenotype. These cells may be responding to variable local concentrations of inflammatory 
mediators, a theory supported by the eicosanoid profiling results, which demonstrated 
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increases in species that are both pro- and anti-inflammatory. However, a general increase in 
the M1 and M2 markers may also simply represent an alternative activation state, separate 
from the rigid and increasingly debated M1/M2 polarisation states 95. Single-cell flow 
cytometry analysis of macrophage activation markers would provide greater insight into this 
scenario. 
In this chapter inhibition of both 15- and 12-LOX in myotubes appeared to weakly impact on 
both M1 and M2 marker expression in co-cultured macrophages. Increasing replicate number 
in these experiments (from n = 3) may reduce some of the variation in the data, giving greater 
statistical power to make inference. Furthermore, using lentiviral-mediated knockdown of 
LOX isoforms may provide a more specific and targeted ablation of function, and provide 
greater insight into the roles LOX-derived eicosanoids originating from myocytes play in the 
regulation of macrophage polarisation.  
The assessment of macrophage polarisation in this chapter is preliminary. Analysis of protein 
levels of important polarisation markers, while also investigating any switch in oxidative 
metabolism using respirometry techniques would strengthen the phenotyping 327,328. Using 
flow cytometry cell sorting to assess populations of M1 and M2 macrophages would also be 
important. To improve the relevance to human disease, these experiments could also be 
repeated using primary HSkMCs and human macrophages.    
With experiments investigating the roles of eicosanoids in macrophage polarisation 
inconclusive, it is likely that protein signals and cytokines may also play a major role in this 
process. Chronic palmitate treatment increased the expression of Ccl2 in C2C12 cells and 
previous work has highlighted the importance of Ccl2 in macrophage infiltration and 
polarisation 91. Il-6 has also been shown to increase macrophage infiltration during muscle 
regeneration 329. However, expression of Il-6 was reduced in C2C12 myotubes in response to 
palmitate treatment and so is unlikely to be important in this model.  
The data for Il-6 in metabolic disease is conflicting, with roles in both insulin sensitivity and 
resistance reported 330. Previous work has shown an increase in Il6 expression in response to 
acute palmitate treatment, but experiments in this chapter demonstrate that chronic palmitate 
decreased transcription of Il6 in C2C12 myotubes 253. Chronic exposure to Il6 increased 
insulin resistance in cultured myocytes, but acute treatment was associated with increases in 
glucose uptake, indicating a dual role for Il-6 in glucose homeostasis 331. Furthermore, 
exercise increases both insulin sensitivity and circulating levels of Il-6, creating the paradox 
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of Il-6 in mediating insulin sensitivity and resistance 332–334. The differences observed here 
between acute and chronic palmitate treatment in C2C12 cells, as well as between C2C12 and 
primary human myotubes highlights the complexity of Il-6 signalling in metabolic disease. 
Much work is required to disentangle the role that Il-6 may play during palmitate-induced 
lipotoxicity and inflammation.  
The interaction between C2C12 myocytes and Raw 264.7 macrophages highlights an 
interaction between skeletal muscle and the immune system following palmitate exposure. 
Macrophage polarisation in adipose tissue from obese individuals is also dependent on the 
activation of a population of natural killer (NK) cells, demonstrating a role for other immune 
cell classes in insulin resistance 335. Furthermore, neutrophils are one of the first immune cell 
types recruited to sites of inflammation, and this infiltration in adipose and liver tissue 
promotes insulin resistance in mice fed a high fat diet 336. Future work, could extend studies 
into the interaction of skeletal muscle with different immune cell populations and the role this 
interaction may play in the diet-induced inflammation and insulin resistance.  
Analysis of ER stress markers in C2C12 myocytes following co-culture with macrophages 
demonstrated potential bi-directional signalling between the two cell types. Co-culture with 
macrophages reduced transcription of UPR markers compared to previous experiments, 
suggesting a role for macrophages in resolving ER stress. This suggests previous experiments 
focusing on ER stress in myocyte monoculture do not provide a complex enough model for 
the in vivo scenario. These findings also open a therapeutic avenue, with potential treatments 
harnessing the immune system to relieve stress signalling in peripheral tissues. Further 
questions may focus on the active macrophage phenotype required to alleviate stress, whether 
there are any consequences for insulin signalling and glucose uptake, and whether these 
results translate to other insulin-sensitive tissues such as adipose and the liver.  
 
Conclusion 
Here, chronic palmitate increased secretion of lipoxygenase-derived eicosanoid species, a set 
of bioactive lipids under-investigated in metabolic disease. Pharmacological inhibition 
suggests a role for lipoxygenase-derived eicosanoids in the control of ER stress and 
inflammatory signalling in myocytes and co-cultured macrophages. 
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Ceramides are cell non-autonomous secreted signals 
propagating ER stress between myocytes  
 
5.1 Introduction 
While a role for palmitate in activating ER stress is well documented, the underlying 
mechanisms remain poorly understood. A number of putative mechanisms have been 
suggested, with phospholipid composition thought to play an important role. Knock down of 
SCD1 in HeLa cells increased the SFA/MUFA ratio in phospholipids, and induced ER stress, 
while combining palmitate treatment with SCD1-knockdown exacerbated UPR induction 289. 
Construction of mutant UPR kinases highlighted that Ire1 and Perk sense alterations in ER 
membrane composition through their transmembrane domains, which enhance dimerisation 
and activation of the proteins 337. Phospholipid composition of the ER in the liver of obese 
mice was shown to inhibit the sarco/endoplasmic reticulum calcium ATPase (SERCA) pump 
and induce ER stress 176. In particular, an increase in the PC/PE ratio in the ER of obese mice 
impaired calcium homeostasis, and correcting this ratio with shRNA-mediated knockdown of 
Pemt, the enzyme responsible for converting PE to PC, improved calcium handling and 
ameliorated lipid-induced ER stress.  
However, induction of ER stress in the context of metabolic disease is complex, and there is 
evidence for alternative mechanisms linking saturated fatty acid exposure with the activation 
of the UPR. Increases in bioactive lipid species, including eicosanoids and ceramides are 
important for the activation of ER stress. Inhibition of 5-LOX ameliorates palmitate-induced 
ER stress in C2C12 myotubes, via downregulation of LTB4 levels and AMPK activation 297. 
In pancreatic β-cells, palmitate increased synthesis of ceramides, concomitant with the 
induction of ER stress, while inhibition of ceramide synthesis attenuated palmitate-induced 
ER stress. 338. Moreover, siRNA-mediated knockdown of ceramide synthases 5 and 6 
suppressed myristate-induced Xbp1 splicing in intestinal epithelial cells 339. While it is worth 
noting that an earlier paper demonstrated that increased ceramide production did not mediate 
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palmitate-induced ER stress in the liver 172, a number of papers have highlighted a causative 
role for ceramides in insulin resistance, which is integrated strongly with the induction of ER 
stress 58,74,340–343. Furthermore, infusing rats with C6-ceramide, a cell-permeable ceramide 
that is then converted to longer chain ceramides intracellularly, increased ER stress in the 
hypothalamus 344. C2-ceramide also increased ER stress in human adenoid cystic carcinoma 
cells, via the inhibition of the SERCA pump 345.  
The mechanisms linking palmitate with the induction of ER stress have focused on the 
generation of palmitate-derived mediators that function in a cell autonomous manner. 
However, recent evidence suggests the presence of a non-autonomous secreted signal that can 
propagate ER stress 146. Macrophages exposed to conditioned medium from murine prostate 
tumour cells, chemically-treated with thapsigargin to induce ER stress, increased levels of 
UPR markers, demonstrating the ability for tumour-derived signals to propagate ER stress 
signalling to separate cell types 147. Indeed, a similar response is seen in the Raw 264.7 
macrophages co-cultured with C2C12 cells in Chapter 4.  
This phenomenon has also been reported in vivo, with constitutive activation of spliced Xbp1 
in pro-opiomelanocortin (Pomc) neurons reducing diet-induced adiposity and insulin 
resistance, concomitant with induction of ER stress in the liver 150. This work demonstrated 
that cell non-autonomous propagation of ER stress can have profound effects on metabolic 
phenotypes and glucose homeostasis. However, the identity of the cell non-autonomous ER 
stress propagating signals remain unknown. The discovery of ER stress propagating signals 
could have a large impact on our understanding of the fundamental biological process of ER 
stress and further elucidate its role in metabolic disease.   
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5.2 Aims and Objectives 
The aim of this chapter was to assess the role cell non-autonomous signalling may play in ER 
stress propagation following palmitate exposure. The following set of objectives were 
designed to achieve this:  
1) Identify the presence and nature of a paracrine ER stress signal, aided by LC-MS 
profiling of culture media to produce a list of candidate signals. 
2) Assay candidate signals with RT-qPCR of a UPR gene panel. 
3) Recapitulate the results in primary HSkMCs and in vivo models of metabolic disease.  
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5.3 Materials and Methods 
5.3.1 C2C12 culture 
C2C12 cells were cultured as described in Chapter 2 Materials and Methods (Section 2.1.1 
C2C12 myoblast culture and differentiation). Cells were differentiated and treated in collagen 
I-coated 12-well plates.  
 
5.3.2 Primary human skeletal muscle cell culture 
Primary human skeletal muscle cells (HSkMCs) were cultured as described in Chapter 2 
Materials and Methods (Section 2.1.2 Primary human skeletal muscle cell culture and 
differentiation). Cells were treated in collagen I-coated 12-well plates.  
 
5.3.3 Production of conditioned media and conditioned media transfer experimentation 
Myocytes were treated with 200 µM palmitate or the BSA vehicle during 6 days of 
differentiation. At the end of this period culture media was switched to serum-free media, 
free from any agonists, for 24 hours, allowing for the accumulation of secreted factors from 
the myocytes. This conditioned media was then transferred on to untreated myocytes for 10 
hours. 
 
5.3.4 Boiling protocol 
Conditioned media was submerged in a water bath set to 100 ºC for 5 minutes. Media was 
then allowed to cool, before transfer on to untreated myocytes.  
 
5.3.5 Conjugation of palmitate to BSA 
Palmitate was bound to BSA following the protocol summarised in Chapter 2 Materials 
and Methods (2.1.3 Conjugation of palmitate to BSA).  
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5.3.6 Cell harvesting 
Cells were harvested and pelleted as described in Chapter 2 Materials and Methods 
(section 2.1.4 Cell harvesting). Cell counts were performed using a Scepter automated cell 
counter (Millipore). 
 
5.3.7 Animal studies 
The detail of three mouse studies analysed in this chapter are summarised in Chapter 2 
Materials and Methods (Section 2.2 Animal studies).  
 
5.3.8 Human skeletal muscle biopsies 
Biopsies of pectoralis major were taken from volunteers undergoing pacemaker therapy, as 
described in Chapter 2 Materials and Methods (Section 2.3 Human skeletal muscle 
biopsies).  
 
5.3.9 RNA isolation and purification 
RNA was extracted and purified from cells using an RNeasy Mini kit (Qiagen), as outlined in 
Chapter 2 Materials and Methods (Section 2.4.1 RNA isolation and purification). 
 
5.3.10 cDNA synthesis  
RNA concentrations were standardised and cDNA then synthesised using a RT2 First Strand 
kit (Qiagen), following manufacturer’s instructions as set out in Chapter 2 Materials and 
Methods (Section 2.4.2 cDNA synthesis). 
 
5.3.11 Reverse transcription quantitative polymerase chain reaction 
Transcript levels were analysed using the StepOnePlus Real-Time PCR system, as described 
in Chapter 2 Materials and Methods (Section 2.4.3 Reverse transcription quantitative 
polymerase chain reaction).  
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5.3.12 Metabolite extraction from cells 
Metabolites were extracted from cells using a modified Bligh and Dyer method, described in 
Chapter 2 Materials and Methods (Section 2.5.1 Cell metabolite extraction for mass 
spectrometry).  
 
5.3.13 Metabolite extraction from skeletal muscle tissue 
Tissue was first homogenised using a TissueLyser (Qiagen), and metabolites were then 
extracted using a Bligh and Dyer extraction, outlined in Chapter 2 Materials and Methods 
(Section 2.5.2 Human and mouse skeletal muscle tissue extraction). 
 
5.3.14 Metabolite extraction from plasma 
600 µL of methanol/chloroform (2:1) was added to 20 µL of plasma, followed by 200 µL of 
water and 200 µL of chloroform. Samples were vortexed and centrifuged (16,100g, 20 
minutes). The organic layer was separated and dried under nitrogen gas prior to storage at -80 
ºC. 
 
5.3.15 Metabolite extraction from media 
One mL of serum-free cell culture media was collected. 800 µL of methanol/chloroform (1:1) 
was added to each sample and mixed well by vortexing. Samples were centrifuged (16,100g, 
20 minutes), and the organic layer subsequently separated and dried down under nitrogen gas. 
Dried samples were stored at -80 ºC. 
 
5.3.16 Liquid chromatography-mass spectrometry analysis of lipids 
The dried-down organic fraction was dissolved in 50 µl methanol/chloroform (1:1), and 
diluted into 190 µl IPA/ACN/H2O (2:1:1). Samples were then analysed using an Orbitrap 
Elite mass spectrometer, as described in Chapter 2 Materials and Methods (Section 2.6 
Liquid chromatography-mass spectrometry open profiling of lipids). Chromatogram files 
were converted using MSConvert (Proteowizard), and processed using XCMS within an R 
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script. Peaks were normalised to a relevant internal standard and then either cell number, for 
in vitro experiments, or dry protein pellet weight, for the analysis of skeletal muscle tissue.  
 
5.3.17 Statistics 
Statistical significance was assessed using either a one-way ANOVA with Tukey’s multiple 
comparisons test, a two-way ANOVA with Sidak’s multiple comparisons test or Student’s t-
test, as detailed in each figure. Linear regression was used to analyse human skeletal muscle 
biopsies for correlations between phospholipids and BMI. In each case, n ≥ 3 and the 
significance level was set to P ≤ 0.05. All univariate analysis was conducted using GraphPad 
(version 6) software. 
  
  Chapter 5 
 
135 
 
5.4 Results 
5.4.1 Conditioned media transfer induces ER stress in C2C12 cells 
Recent work has highlighted a role for paracrine and endocrine signalling in the propagation 
of ER stress 146. Manipulating the paracrine and endocrine intercellular communication of ER 
stress could represent a novel therapeutic approach. However, the identity of these signals 
and the mechanisms through which they operate are not known. To investigate the potential 
of paracrine signalling in palmitate-induced ER stress, C2C12 myotubes were treated with 
200 µM palmitate or the BSA vehicle for 6 days during differentiation. The media was then 
changed to serum-free and palmitate-free media for 24 hours, allowing any secreted signals to 
accumulate in the media. This conditioned media was then collected and transferred to naïve 
C2C12 myotubes for 10 hours. RNA was then extracted and analysed by RT-qPCR to assess 
UPR induction. Conditioned media from palmitate treated cells significantly increased the 
expression of Atf4 (3.4-fold), Edem1 (2-fold) and Hspa5 (1.3-fold), indicating activation of 
the UPR, although expression of Atf3 was unaffected (Figure 5.1). This data suggests the 
presence of a paracrine signal released from myocytes capable of transmitting ER stress.  
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To define the nature of this signal, conditioned media from palmitate- or vehicle-treated 
C2C12 myotubes was boiled for 5 minutes to denature proteins in the media prior to transfer 
to untreated cells. RT-qPCR analysis of UPR gene expression showed that conditioned media 
from cells treated with 200 μM palmitate increased expression of Atf4 (3-fold) and Edem1 
(2.5-fold) as before (Figure 5.2). Similarly, conditioned media from palmitate treated cells 
that was subjected to boiling also increased expression of Atf4 (2.9-fold) and Edem1 (2.4-
fold) compared to cells treated with boiled conditioned media from control treated cells. As 
boiling of conditioned media did not ablate the induction of ER stress, the paracrine signal is 
likely a small molecule and non-protein.  
Figure 5.1: Conditioned media from palmitate-treated C2C12 myotubes induces ER 
stress in untreated myotubes  
C2C12 cells were treated with 200 µM palmitate or the BSA vehicle control during a 6-
day differentiation period. Subsequently, media was switched to serum-free media for 24 
hours, allowing for the accumulation of secreted factors. This conditioned media was then 
transferred to untreated myotubes for 10 hours and RT-qPCR was used to analyse the 
expression of key unfolded protein response genes (Atf3, Atf4, Hspa5 and Edem1). Each 
gene was analysed using a Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P 
< 0.0001. Data are expressed as mean ± SEM (n = 4).  
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5.4.2 Liquid chromatography-mass spectrometry profiling of conditioned media 
Previous literature has demonstrated palmitate-induced secretion of a number of lipid species, 
including triacylglycerols, ceramides and sphingosine-1-phosphate, which may represent 
potential signals 346–348. To identify putative signals in the organic fraction, C2C12 myotubes 
were treated with either 100 or 200 µM palmitate, or the BSA vehicle, for 6 days during 
differentiation. Culture medium was then switched to serum-free media, free from palmitate 
and BSA, for 24 hours. Conditioned media was harvested and extracted using a modified 
Bligh and Dyer method, and the organic fraction was analysed using LC-MS. Approximately 
300 lipid species, including lysophosphatidylcholines, ceramides, phosphatidylcholines, 
diacylglycerides and triacylglycerides, were detected in positive and negative ion mode. Peak 
intensities were normalised to an internal standard of relevant lipid class.  
Figure 5.2: Boiling of conditioned media does not ablate the induction of 
endoplasmic reticulum stress  
C2C12 cells were treated with 200 µM palmitate or the BSA vehicle control during a 6-
day differentiation period. Subsequently, media was switched to serum-free media for 24 
hours, allowing for the accumulation of secreted factors. Conditioned media was 
harvested and left either at room temperature or boiled for five minutes. This conditioned 
media was then transferred to untreated myotubes for 10 hours and RT-qPCR was used to 
analyse the expression of key unfolded protein response genes (Atf4 and Edem1). Each 
gene was analysed using a one-way ANOVA test with Tukey’s multiple comparison test. 
* P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean ± 
SEM (n = 3).  
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Analysis of free fatty acids showed concentrations of palmitate in conditioned media were 
unchanged across the three treatment groups (Figure 5.3). This indicates that the increase in 
transcription of ER stress markers following conditioned media transfer from palmitate-
treated cells is independent of the fatty acid.  
 
However, concentrations of a number of other lipid species were increased in conditioned 
media collected from myotubes treated with palmitate, representing potential ER stress 
propagating signals. The list of potential signals was narrowed based on the literature; lipids 
with documented bioactivity in cell signalling were investigated further to assess any 
potential in activating ER stress. Lysophosphatidylcholines (LPCs) are produced from 
phospholipids following hydrolysis of the sn2 fatty acid by phospholipase enzymes. Previous 
literature has suggested a potential bioactive role for these metabolites 349,350. Here, treatment 
of C2C12 myotubes with 200 µM of palmitate increased the secretion of LPC 16:0, 16:1 and 
18:0 (Figurer 5.4A). 
Palmitate treatment also increased the secretion of diacylglycerol (DG) and ceramide species. 
Both classes of lipid are important in mediating saturated fatty acid-induced insulin resistance 
Figure 5.3: Palmitate concentrations are unchanged in conditioned media  
Conditioned media was collected from C2C12 myotubes treated with either 100 or 200 
µM palmitate, or the BSA vehicle control.  Metabolites were extracted from the media 
and analysis of the organic phase by LC-MS shows free palmitate concentrations were 
unchanged between the three treatment groups. Palmitate was analysed using a one-way 
ANOVA test with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 
0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n = 4).  
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in peripheral tissues including skeletal muscle, adipose and the liver 40. Saturated and 
monounsaturated DG species were all increased following exposure to 200 µM palmitate, 
with DG 32:0, 34:1, and 36:1 approximately 5-fold higher in the treatment group (Figure 
5.4B).  
Ceramides have previously been shown to mediate palmitate-induced insulin resistance 40. 
Ceramide 34:1, 40:1 and 42:1 all accumulated in the media of palmitate-treated myotubes, 
with the increase in ceramide 40:1 dose-dependent (Figure 5.4C).  
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 A 
Figure 5.4: Chronic palmitate treatment of myotubes increases concentrations of 
lysophosphatidylcholines, diacylglycerides and ceramides in conditioned media 
Conditioned media was collected from C2C12 myotubes treated with either 100 or 200 
µM palmitate, or the BSA vehicle control.  Metabolites were extracted from the media 
and analysis of the organic phase by LC-MS shows increases in (A) 
lysophosphatidylcholines, (B) diacylglycerides and (C) ceramides following chronic 
palmitate treatment. Species were analysed using a one-way ANOVA test with Tukey’s 
multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data 
are expressed as mean ± SEM (n = 4).  
B 
C 
  Chapter 5 
 
141 
 
5.4.3 Exogenous ceramides induce ER stress 
To identify potential signals from the candidate lipid species, the ability of ceramides 40:1 
(C22) and 42:1 (C24), DG 16:0/16:0, and LPCs 16:0 and 18:0 to induce ER stress in C2C12 
myotubes was investigated. Myotubes were grown to confluence and differentiated for 6 
days. For the final 10 hours, cells were exposed to two concentrations of each candidate, or 
the vehicle control. RNA was harvested and the transcription of Atf4 and Edem1 were 
analysed by RT-qPCR. A reduced panel of genes was used to assay the effects of potential 
signalling candidates to increase throughput for each test. Treatment of cells with DG 32:0 
had no effect on the expression of UPR markers compared to myotubes treated with the 
ethanol vehicle control (Figure 5.5A). Similarly, LPC 16:0 did not induce ER stress, 
compared to cells cultured with the saline vehicle control (Figure 5.5B). However, both 5 
and 50 µM of LPC 18:0 did increase the expression of Edem1 (1.4-fold and 1.3-fold, 
respectively), suggesting that LPC 18:0 may be a potential ER stress propagating signal 
(Figure 5.5C). However, the expression of Atf4 was unchanged despite conditioned media 
increasing transcript levels of Atf4 3.4-fold. Furthermore, the increase in expression of Edem1 
following treatment with LPC 18:0 was much smaller than that induced by conditioned media 
transfer. Together, this suggests the presence of other signals.  
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Figure 5.5: Lysophosphatidylcholine 18:0 increases the expression of Edem1 
C2C12 myotubes were differentiated for six days and then treated for 10 hours with either 
(A) diacylglyceride (DG) 16:0/16:0, (B) lysophosphatidylcholine (LPC) 16:0, or (C) LPC 
18:0.  Induction of ER stress was assessed by RT-qPCR of a reduced panel of unfolded 
protein response genes (Atf4 and Edem1). Species were analysed using a one-way 
ANOVA test with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 
0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n = 4).  
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Treatment with C22 ceramide increased transcription of Atf4 in a dose-dependent manner, 
compared to myotubes treated with the ethanol vehicle control (Figure 5.6A). Both 5 and 10 
μM C24 ceramide also increased expression of Atf4, although transcription of Edem1 was 
unaffected with both ceramide treatments (Figure 5.6B). These data suggest exogenous 
treatment of myotubes with ceramides C22 and C24 may increase the induction of ER stress. 
However, while some chemical distributors suggest solubility of ceramide in ethanol, some 
publications have opted for a ethanol/dodecane (98:2) vehicle, which may improve the 
solubility of ceramides 351.  
Figure 5.6: Long chain ceramides increase the expression of Atf4 
C2C12 myotubes were differentiated for six days and then treated for 10 hours with either 
(A) C22 ceramide (ceramide 40:1) or (B) C24 ceramide (ceramide 42:1).  Induction of ER 
stress was assessed by RT-qPCR of a reduced panel of unfolded protein response genes 
(Atf4 and Edem1). Species were analysed using a one-way ANOVA test with Tukey’s 
multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data 
are expressed as mean ± SEM (n=4).  
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To test if an ethanol/dodecane vehicle improved sensitivity to ceramide induced ER stress, 
C2C12 myoblasts were differentiated for 6 days with either 10 μM C22 ceramide, 10 μM 
C24 ceramide, or the ethanol/dodecane (98:2) vehicle control treatment for the final 10 hours. 
RNA was harvested and the induction of UPR target genes was assessed using RT-qPCR. 
C24 ceramide increased the expression of Atf4 (2.9-fold) and Hspa5 (1.5-fold), while C22 
ceramide also increased expression of Hspa5 (1.6-fold) (Figure 5.7). Expression of Atf3 and 
Edem1 were unaffected with ceramide treatment. These data suggest that treatment with 
individual ceramides increase the expression of key markers of ER stress.  
However, LC-MS analysis of cell culture media demonstrated concomitant increases in a 
number of ceramides.  Thus, multiple ceramide species may act in an additive or synergistic 
manner to increase the expression of UPR genes. Therefore, the effect of combined ceramide 
treatment on the induction of ER stress was investigated. C2C12 myotubes were 
differentiated for 6 days, as before. For the final 10 hours, myotubes were treated with a 
combination of 10 μM C22 ceramide and 10 μM C24 ceramide, or the ethanol/dodecane 
(98:2) vehicle control. RNA was harvested and the induction of ER stress was assessed using 
RT-qPCR. Ceramide treatment increased the expression of Atf4 (3.2-fold) and Hspa5 (1.4-
Figure 5.7: An ethanol/dodecane vehicle enhances sensitivity to ceramide-induced 
increases in Atf4 expression 
C2C12 myotubes were differentiated for six days and then treated for 10 hours with either 
10 μM C22 ceramide (ceramide 40:1) or 10 μM C24 ceramide (ceramide 42:1), dissolved 
in ethanol/dodecane (98:2).  Induction of ER stress was assessed by RT-qPCR of a panel 
of unfolded protein response genes (Atf3, Atf4, Hspa5 and Edem1). Species were analysed 
using a one-way ANOVA test with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n = 3).  
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fold) and Edem1, while Atf3 narrowly missed out on significance (p=0.06) (Figure 5.8). This 
suggests that combined treatment with ceramides 22 and 24 can increase the expression of 
UPR target genes.  
Whether the induction of ER stress was dependent on the acyl chain-length of the ceramide 
species was investigated. Differentiated C2C12 myotubes were treated with medium chain 
length ceramide species 10 µM C16 (ceramide 34:1) or 10 µM C18 (ceramide 36:1), or the 
ethanol:dodecane (98:2) vehicle control. RNA was harvested and the expression of UPR 
target genes was assessed using RT-qPCR. While C16 ceramide only increased the 
expression of Atf4 (1.6-fold), C18 ceramide elevated transcription of Atf4 (2.1-fold), Hspa5 
(1.7-fold) and Edem1 (1.6-fold) (Figure 5.9). Therefore, ceramide-induced ER stress is not 
restricted to signalling from individual species but is conserved across long and medium 
chain acyl chain-containing species.  
Figure 5.8: Combined long chain ceramide treatment induces endoplasmic reticulum 
stress 
C2C12 myotubes were differentiated for six days and then treated for 10 hours with a 
combination of 10 μM C22 ceramide (ceramide 40:1) and 10 μM C24 ceramide (ceramide 
42:1), dissolved in ethanol/dodecane (98:2).  Induction of ER stress was assessed by RT-
qPCR of a panel of unfolded protein response genes (Atf3, Atf4, Hspa5 and Edem1). 
Species were analysed using a Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001. Data are expressed as mean ± SEM (n = 3).  
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5.4.4 Long chain ceramide induced ER stress is conserved in primary human skeletal 
muscle cells 
To understand if the effects of long chain ceramides on ER stress translate to human disease, 
experiments were repeated in primary HSkMCs. HSkMCs were grown to confluence and 
treated with 100 µM palmitate, or the BSA vehicle control, during a 6-day differentiation 
period. Culture media was then switched to basal media for 24 hours to allow for the 
accumulation of secreted factors. Subsequently, conditioned media was transferred on to 
untreated primary HSkMCs for 10 hours. RNA was then harvested and the induction of ER 
stress assessed using RT-qPCR. Conditioned media from palmitate treated-HSkMCs 
increased expression of Atf3 (1.8-fold), Atf4 (1.7-fold) and Hspa5 (1.7-fold), compared to 
cells exposed to conditioned media from vehicle-treated control cells, although Edem1 
expression was unchanged (Figure 5.10). These results show that primary HSkMCs also 
secrete an ER stress propagating signal or signals.  
Figure 5.9: Exogenous treatment with medium length acyl chain-containing 
ceramides induces endoplasmic reticulum stress 
C2C12 myotubes were differentiated for six days and then treated for 10 hours with either 
10 μM C16 ceramide (ceramide 34:1) or 10 μM C18 ceramide (ceramide 36:1), dissolved 
in ethanol/dodecane (98:2).  Induction of ER stress was assessed by RT-qPCR of a panel 
of unfolded protein response genes (Atf3, Atf4, Hspa5 and Edem1). Species were analysed 
using a one-way ANOVA test with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n = 4).  
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To investigate the role long-chain ceramides may play in paracrine stress signalling in 
primary HSkMCs, conditioned media from HSkMCs treated for 6 days with either 50 or 100 
µM palmitate, or the BSA vehicle control, were analysed by LC-MS. The palmitate-induced 
secretion of ceramides 34:1, 40:1 and 42:1 in a dose-dependent manner, observed in C2C12 
myotubes, was conserved in HSkMCs. Therefore, the ceramides may act as paracrine signals 
in primary HSkMCs (Figure 5.11A).  
To confirm that exogenous treatment of primary HSkMCs with long-chain ceramides can 
induce ER stress, HSkMCs were grown to confluence and differentiated for 6 days. Myocytes 
were then treated with either 10 µM C22 ceramide (40:1), 10 µM C24 ceramide, a 
combination of the both, or the ethanol/dodecane (98:2) vehicle control, for 10 hours. RNA 
was harvested and the transcription of UPR markers analysed by RT-qPCR. Combined 
treatment with C22 and C24 ceramide increased expression of ATF3 (2.5-fold), ATF4 (1.7-
fold) and EDEM1 (2-fold), relative to cells exposed to the vehicle control, although HSPA5 
expression was only increased with C22 ceramide treatment (2.6-fold) (Figure 5.11B). These 
results highlight that long chain ceramides are potential cell non-autonomous ER stress 
propagating signals. 
Figure 5.10: Conditioned media from palmitate-treated primary human myocytes 
increases endoplasmic reticulum stress in untreated myocytes 
Primary human skeletal muscle cells (HSkMCs) were treated with 200 µM palmitate or 
the BSA vehicle during a 6-day differentiation period. Media was switched to basal media 
for 24 hours and this conditioned media was then transferred on to untreated HSkMCs for 
10 hours. Induction of ER stress was assessed by RT-qPCR of a panel of unfolded protein 
response genes (ATF3, ATF4, HSPA5 and EDEM1). Species were analysed using a 
Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (n = 4).  
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Figure 5.11: Long chain ceramides increase endoplasmic reticulum stress in primary 
human skeletal muscle cells 
(A) Primary human skeletal muscle cells (HSkMCs) were treated with 200 µM palmitate 
or the BSA vehicle during a 6-day differentiation period. Media was switched to basal 
media for 24 hours and metabolites were subsequently extracted from conditioned media. 
Liquid chromatography-mass spectrometry analysis of the organic phase shows chronic 
palmitate treatment increases media ceramide concentrations. (B) Treatment of 
differentiated HSkMCs with either 10 µM C22:0 ceramide, 10 µM C24:0 ceramide, a 
combination of both, or the vehicle control. Induction of ER stress was assessed by RT-
qPCR of a panel of unfolded protein response genes (ATF3, ATF4, HSPA5 and EDEM1). 
Species were analysed using a one-way ANOVA test with Tukey’s multiple comparison 
test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean 
± SEM ((A) n = 4, (B) n = 3).  
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5.4.5 Palmitate increases intracellular concentrations of ceramides 
With the identification of ceramides as potential paracrine signals, subsequent experiments 
sought to investigate if the palmitate-stimulated secretion of ceramides was a result of 
increased intracellular synthesis. C2C12 myotubes were grown to confluence and 
differentiated for 6 days. During this period, cells were treated with either 100 or 200 µM 
palmitate, or the BSA vehicle control. Cells were then harvested and metabolites extracted 
using a modified Bligh and Dyer method. The organic phase was analysed using LC-MS. 
Peaks were annotated based on accurate mass and intensities were normalised to a relevant 
internal standard and cell number. Myotubes treated with 200 µM palmitate had increased 
concentrations of ceramides 34:1, 40:1 and 42:1, while 100 µM palmitate also increased 
concentrations of ceramide 34:1 relative to control treated cells (Figure 5.12A). 
These results were also confirmed in primary HSkMCs. Human myocytes were grown to 
confluence and differentiated for 6 days. During this period, cells were exposed to either 50 
or 100 µM palmitate, or the BSA vehicle control. Metabolites were extracted from cell pellets 
using a modified Bligh and Dyer extraction, and the organic phase was analysed by LC-MS. 
Annotated peaks were normalised to a relevant internal standard and cell number. Ceramides 
34:1 and 42:1 were increased with 100 µM palmitate treatment, while ceramide 40:1 was 
increased in a dose-dependent manner (Figure 5.12B). Together, these results show that 
treating myocytes chronically with palmitate increases ceramide synthesis as well as 
secretion.   
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Figure 5.12: Chronic palmitate treatment increases intracellular ceramide 
concentrations in skeletal myocytes 
(A) C2C12 myotubes were treated with either 100 or 200 µM palmitate, or the vehicle 
control during a 6-day differentiation period. Metabolites were extracted from cells and 
ceramides were analysed by liquid chromatography-mass spectrometry (LC-MS). (B) LC-
MS analysis of primary human skeletal muscle cells following treatment with either 50 or 
100 µM palmitate, or the vehicle control, during 6 days of differentiation. Species were 
analysed using a one-way ANOVA test with Tukey’s multiple comparison test. * P ≤ 
0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean ± SEM 
(n=4).  
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5.4.6 Ceramide concentrations in the plasma and skeletal muscle of mice fed a high fat 
diet  
Following the demonstration that secreted ceramides can propagate intercellular palmitate-
induced ER stress signalling in vitro, experiments sought to understand the regulation of 
ceramides in mouse models of dyslipidaemia and obesity. Gastrocnemius skeletal muscle was 
analysed from mice across three dietary studies. In the first study, 5 C57Bl6 mice were fed a 
regular chow diet and 5 mice were fed a high-fat diet for 17 weeks. Metabolites were 
extracted from approximately 25 mg of gastrocnemius skeletal muscle using a modified Bligh 
and Dyer extraction, and the organic phase was analysed by LC-MS. Peaks were annotated 
using accurate mass, and intensities normalised to a relevant internal standard and dry protein 
pellet weight. Analysis of the lipidome highlighted that ceramides 40:1 and 42:1 were 
unchanged with high fat diet (Figure 5.13A). However, other long chain ceramides were 
altered with a high fat diet, with increases observed in ceramides 36:1, 38:1 and 42:3, 
demonstrating that high fat diet can increase concentrations of some longer chain ceramides 
(Figure 5.13B).  
Since in vitro experiments highlighted an important role for secreted ceramides in the 
propagation of ER stress signalling, the concentrations of ceramides in plasma are also of 
interest. Metabolites from 20 µL of plasma were extracted using a modified Bligh and Dyer 
extraction, and the organic phase was analysed using LC-MS. Peaks were annotated using 
accurate mass, and normalised to a relevant internal standard. High fat diet significantly 
increased ceramide 40:1 in the plasma of these mice (Figure 5.13C).  
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Figure 5.13: Long chain ceramides are increased in skeletal muscle of mice fed a 
high-fat diet 
Mice were fed either a chow or high-fat diet for 17 weeks. (A) and (B) Liquid 
chromatography-mass spectrometry analysis of ceramides extracted from gastrocnemius 
tissue. (C) LC-MS analysis of ceramides extracted from plasma. Species were analysed 
using a Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (n=5).  
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In a second dietary mouse study, 10 mice were given a regular chow diet and 13 mice were 
fed a high fat diet for 14 weeks. Approximately 25 mg of gastrocnemius skeletal muscle was 
extracted using a modified Bligh and Dyer extraction, and the organic phase was analysed 
using LC-MS. Peaks were annotated using accurate mass and peak intensities were 
normalised to a relevant internal standard and dry protein pellet weight. Ceramide 40:1 was 
significantly increased in the muscle of high fat diet fed mice (Figure 5.14A). Plasma was 
also available from these mice and 20 µL was extracted and analysed in an analogous manner 
to the previous study. While plasma concentrations of ceramide 42:1 were unaffected, 
ceramides 40:1 and 42:2 were both significantly increased with high fat diet (Figure 5.14B). 
This shows that high fat diet stimulates an increase in ceramide 40:1 concentration in the 
muscle and a concomitant increase in circulation.  
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5.4.7 Long chain ceramides are increased in the skeletal muscle of mice fed a western 
diet 
In Chapter 3, phospholipid changes observed in C2C12 myotubes and primary HSkMCs 
exposed to palmitate more closely resembled changes observed in the skeletal muscle of mice 
in response to a western-style, compared with a high-fat diet. Previous literature has also 
suggested that a western diet (WD) is a more representative model for obesity and insulin 
A 
Figure 5.14: Long chain ceramides are increased in plasma of mice fed a high-fat 
diet in a second in vivo study 
Mice were fed either a chow or high-fat diet (HFD) for 14 weeks. (A) Liquid 
chromatography-mass spectrometry analysis of ceramides extracted from gastrocnemius 
tissue. (B) LC-MS analysis of ceramides extracted from plasma. Species were analysed 
using a Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are 
expressed as mean ± SEM (Chow: n = 10, HFD: n = 13).  
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resistance in humans 278. Here, ceramides were analysed from 8 mice fed WD and 8 mice fed 
a low fat control diet for 12 weeks. Approximately 25 mg of gastrocnemius tissue was 
extracted using a modified Bligh and Dyer extraction, and the organic phase was analysed by 
LC-MS. Peaks were annotated using accurate mass and peaks were normalised to a relevant 
internal standard and dry protein pellet weight.  
Mice fed a western diet had increased concentrations of ceramide 40:1 and 42:1 compared to 
mice fed a low fat, control diet (Figure 5.15A). Furthermore, ceramide 36:1 was also 
increased suggesting a general upregulation in longer chain ceramides, although ceramide 
38:1 was unchanged (Figure 5.15B). These results highlight that dietary mouse models of 
obesity and insulin resistance do have increased skeletal muscle ceramides. Furthermore, 
these results reinforce the evidence in Chapter 3 supporting a WD mouse model as a better 
model for saturated fatty acid exposure in vitro. Unfortunately, plasma from this study was 
not available for analysis, so the effect of WD on circulating concentrations of ceramides 
could not be investigated.  
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5.4.8 Long chain ceramides are increased in skeletal muscle biopsies from diabetic 
patients 
With ceramides increased in C2C12 myotubes and primary HSkMCs following palmitate 
treatment, as well as the gastrocnemius of WD and high fat diet-fed mice, the relevance of 
these results to human disease was assessed through the analysis of human skeletal muscle 
biopsies. Previous literature has shown that ceramides increase in obese, insulin resistant 
patients 352. Biopsies of the pectoralis major muscle were taken from patients undergoing 
routine pacemaker surgery. Patients spanned a wide-range of BMIs and were a mix of non-
A 
Figure 5.15: Long chain ceramides are increased in the skeletal muscle of mice fed a 
western diet 
Mice were fed either a western diet (WD) for 14 weeks. (A) and (B) Liquid 
chromatography-mass spectrometry analysis of ceramides extracted from gastrocnemius 
tissue. Species were analysed using a Student’s t-test. * P ≤ 0.05, ** P < 0.01, *** P < 
0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n = 8).  
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diabetic and type 2 diabetic patients. Metabolites were extracted from approximately 20 mg 
of tissue and the organic phase was analysed using LC-MS. Peaks were annotated using 
accurate mass and normalised to both a relevant internal standard and dry protein pellet 
weight.  
Correlation between concentrations of ceramides 40:1 and 42:1 and BMI were assessed using 
linear regression analysis. Gradients of each regression line were not significantly non-zero, 
whilst R2 values were low, indicating that ceramide concentrations did not explain the 
variation in the model (Figure 5.16A). Ceramide 40:1 and 42:1 were not significantly 
changed between diabetic and non-diabetic patients, when considered separately. However, 
when analysed across groups using two-way ANOVA, long-chain ceramides were found to 
be increased in the skeletal muscle of diabetic patients, suggesting long-chain ceramides are 
associated with insulin resistance (Figure 5.16B). 
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Figure 5.16: Long chain ceramides are increased in skeletal muscle biopsies of 
diabetic patients 
Liquid chromatography-mass spectrometry analysis of skeletal muscle biopsies collected 
from patients during pacemaker fitting. (A) Linear regression analysis of long-chain 
ceramide concentrations against patient BMI. (B) Concentration of long-chain ceramides 
in non-diabetic controls and patients with type 2 diabetes. Species were analysed using a 
two-way ANOVA test with Sidak’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** 
P < 0.001, **** P < 0.0001. Data are expressed as mean (10-90th percentile) (non-
diabetic: n = 53, diabetic: n = 22). 
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5.5 Discussion 
This chapter sought to define the mechanisms linking palmitate exposure with the induction 
of ER stress in skeletal muscle. Previous work had suggested that the induction of ER stress 
may be coordinated between tissues, with constitutive activation of Xbp1 in pomc neurons 
activating the UPR in the liver 150. Here, we have identified long chain ceramides as cell non-
autonomous mediators that propagate ER stress signalling from palmitate-treated myotubes to 
untreated myotubes – the first isolation of a signal of this nature.  
The results are in keeping with evidence implicating ceramides in the induction of ER stress 
and being associated with lipotoxicity in general. Inhibition of ceramide synthesis in 
pancreatic β-cells reduced palmitate-induced ER stress 338. Both pharmacological inhibition 
of ceramide synthase, using fumonisin B1, and siRNA-mediated knockdown of ceramide 
synthases 5 and 6 highlighted the importance of C14 ceramide in myristate-induced ER stress 
in intestinal epithelial cells 339. Furthermore, exogenous treatment with short chain ceramide 
analogues, which are rapidly converted to longer chain, physiological ceramides, increased 
ER stress in the hypothalamus and human adenoid cystic carcinoma cells 344,345. Infusion of a 
short-chain ceramide analogue in the hypothalamus of rats increased ceramides and induced 
hypothalamic ER stress, while the thermogenic capacity of brown adipose tissue was 
reduced. This highlighted how dysregulated sphingolipid metabolism and ER stress in one 
tissue can impact on the function of a distal tissue 353.  
Palmitate treatment also increased intracellular ceramide concentrations, suggesting that 
increased secretion of ceramides resulted from elevated ceramide synthesis. Similar results 
have been observed in acute models of palmitate treatment 354. Ceramides are synthesised via 
two pathways – the de novo and salvage pathways. Since the de novo pathway condenses 
serine with palmitoyl-CoA, it is likely that palmitate stimulates ceramide synthesis in this 
manner via an increase in substrate. Indeed, myotubes treated acutely with palmitate 
synthesise ceramides analogously 354. However, further work is required to confirm the 
importance of the de novo pathway in chronic culture models.  
Synthesis of ceramides via the de novo pathway is supported by the narrow spectrum of 
ceramide species detected. Primarily, the ceramides that were synthesised and secreted from 
myotubes comprised long-chain acyl chains, typically 20 carbons or longer. This specificity 
likely arises due to expression differences in ceramide synthase isoforms. There are six 
isoforms – termed ceramide synthase 1-6 – and each has a preference for different acyl chains 
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355. The synthesis of long-chain ceramides is favoured by ceramide synthase 2, which has a 
particularly high activity for fatty acids containing 22 and 24 carbons 356. Ceramide synthase 
2 is well-expressed in skeletal muscle, although the expression levels of ceramide synthase 1, 
which favours the formation of C18 ceramide, and ceramide synthase 4, which produces C20 
ceramide, are higher 356. This suggests that there is an alteration in the regulation of ceramide 
synthase 2 that leads to the preferential formation of long-chain ceramides following 
palmitate treatment. Previous studies have shown that acute palmitate treatment stimulates 
the expression of ceramide synthase 2 in both C2C12 myotubes and cardiomyocytes, 
suggesting one possible regulatory step that explains the results of this chapter 357,358. 
Analysis of skeletal muscle from mice fed a western diet showed an increase in long chain 
ceramides. Furthermore, these ceramides were also increased in skeletal muscle biopsies 
taken from type 2 diabetic patients. This confirms that results from cultured myotubes 
translate to in vivo models; increased ceramides are a feature of dyslipidaemia. This 
corresponds well with previous studies demonstrating an increase in ceramide content in 
skeletal muscle biopsies taken from obese insulin-resistant individuals 352. Similarly, obese 
insulin-resistant humans who took part in an 8-week endurance fitness program had reduced 
ceramide concentrations in skeletal muscle, concomitant with improvements in glucose 
tolerance 359. 
One difference between the in vitro and in vivo ceramide profiles was the detection of C16 
ceramide (ceramide 34:1). While concentrations of C16 ceramide were high in cultured 
myotubes following palmitate treatment, the species was not detected in skeletal muscle from 
in vivo studies. Previous studies have detected C16 in both murine and human skeletal 
muscle, so the reason underpinning its absence in the in vivo experiments in this thesis is 
unclear 69,360,361. However, these studies also place greater importance on long-chain, rather 
than C16, ceramides in skeletal muscle metabolic disease, in keeping with the results of this 
chapter. 
Murine dietary models of obesity also exhibited elevated plasma ceramides, a result in 
keeping with previous research. Haus and colleagues correlated plasma ceramides with 
insulin resistance and plasma TNFα concentration, implicating ceramides in both 
inflammation and dysregulated insulin signalling 72. Raised plasma ceramide concentrations 
highlight the potential for ceramides to act as signalling molecules, transported to distal 
tissues separate from their site of synthesis. The capacity for plasma ceramides to act as 
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bioactive signalling mediators was highlighted in a study in which ceramides contained in 
low-density lipoprotein (LDL) were infused into lean mice, impairing glucose uptake and 
increasing markers of insulin resistance in skeletal muscle 86.  
To demonstrate the capacity for exogenous ceramides to induce ER stress, an 
ethanol:dodecane vehicle was required, due the poor aqueous solubility of ceramides. 
However, the vehicle for intercellular trafficking of ceramides is unclear. Ceramides secreted 
from hepatocytes were packaged into LDL, but myotubes do not synthesise LDL 86. A similar 
mechanism of transport, using a vehicle comprising a lipid membrane remains likely. 
Exosomes are membrane-bound vesicles that have an increasingly important role in cell 
signalling 362. Ceramides are enriched in the membrane of exosomes, and so future work 
should look to the potential of exosomes as a vehicle for ceramide signalling between 
myotubes 363.  
 
Conclusion 
Experiments in this chapter have identified long chain ceramides as cell non-autonomous 
signals, which propagate palmitate-induced ER stress between myotubes. This is the first 
identification of a signal of this nature. Furthermore, LC-MS analysis showed increased 
ceramide concentrations were also a feature of murine in vivo models of obesity and type 2 
diabetic patients.  
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Ceramides are synthesised in a Perk-dependent manner 
via the de novo pathway and enriched in secreted 
exosomes  
 
6.1 Introduction 
Cell non-autonomous signalling has recently emerged as a mechanism controlling the 
induction of ER stress in distal tissues, but the nature of these signals has remained elusive 
146. In Chapter 5, long-chain ceramides were identified as cell non-autonomous signals that 
propagate myotube UPR activation following chronic palmitate treatment. However, the 
pathways regulating this process are unclear. 
Increases in intracellular ceramide concentrations suggested that the stimulation of ceramide 
secretion resulted from elevated synthesis. Ceramides are synthesised via two principal 
pathways – the de novo and salvage pathways (Figure 6.1). The de novo pathway takes place 
at the ER. The initial step involves serine palmitoyl transferase (SPT), which condenses 
serine and palmitoyl-CoA, forming 3-keto-sphinganine 364. This is then reduced to 
sphinganine by 3-ketosphinganine reductase. Ceramide synthase adds a fatty acid chain to 
sphinganine, forming a dihydroceramide that is then reduced to a ceramide by 
dihydroceramide desaturase. The salvage pathway, on the other hand, takes place in late 
endosomes and lysosomes, and involves the breakdown of complex sphingolipids, such as 
sphingomyelin and glucosylceramides, to form ceramides 365. Previous literature has shown 
that acute palmitate treatment increases ceramide synthesis via the de novo pathway, with the 
increase in substrate availability elevating flux through SPT 354. 
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Following synthesis, experiments in Chapter 5 showed that ceramides were secreted from 
myotubes into the culture media. The poor aqueous solubility of ceramides in these 
experiments suggests the need for a suitable vehicle. In C. elegans, a constitutively active 
Xbp1 in neurons induced ER stress in distal tissues, and was found to be dependent on the 
release of small clear vesicles 149. Furthermore, hepatocytes treated with palmitate release 
ceramide-enriched extracellular vesicles via Ire1 363. Extracellular vesicles, such as exosomes 
and microvesicles, are membrane-bound particles that can transfer proteins, RNA and small 
molecules, including lipids, between cells in both a paracrine and endocrine manner 366. 
Indeed, increases in ceramides can trigger membrane budding and exosome secretion, while 
inhibition of neutral sphingomyelinase 2, an enzyme important in the generation of ceramide 
via the salvage pathway, prevented exosome release 367.  
Figure 6.1 Ceramide synthesis pathways 
Diagram depicting the two main pathways in the synthesis of ceramides – the de novo 
and salvage pathways. Also shown are the actions of three de novo pathway inhibitors: 
myriocin, which inhibits serine palmitoyltransferase, fumonisin B1, which inhibits 
ceramide synthase, and Fenretinide, which inhibits dihydroceramide desaturase. 
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6.2 Aims and Objectives 
The aim of this chapter was to investigate the mechanisms underpinning the propagation of 
ER stress between myotubes. The following set of objectives were designed to achieve this:  
1) Use pharmacological inhibition to understand the pathways of importance in ceramide 
synthesis following palmitate treatment of myotubes. 
2) Identify the mode of intercellular signal transport. 
3) Combine mass spectrometry and pharmacological inhibition to investigate the 
mechanisms of ceramide-induced ER stress. 
 
  
  Chapter 6 
 
165 
 
6.3 Materials and Methods 
6.3.1 C2C12 culture 
C2C12 cells were cultured as described in Chapter 2 Materials and Methods (Section 2.1.1 
C2C12 myoblast culture and differentiation). Pharmacological inhibitors (detailed in section 
6.3.7 Pharmacological inhibitors) were used for the final 24 hours of experiments. Cells were 
differentiated and treated in collagen I-coated 12-well plates.  
 
6.3.2 Primary human skeletal muscle cell culture 
Primary human skeletal muscle cells (HSkMCs) were cultured as described in Chapter 2 
Materials and Methods (Section 2.1.2 Primary human skeletal muscle cell culture and 
differentiation). Pharmacological inhibitors (detailed in section 6.3.7 Pharmacological 
inhibitors) were used for the final 24 hours of experiments. Cells were treated in collagen I-
coated 12-well plates.  
 
6.3.3 AML-12 cell culture 
Alpha mouse liver 12 (AML-12) cells were cultured in 1:1 Dulbecco's modified Eagle's 
medium and Ham's F12 medium, supplemented with 10% FBS, 1% penicillin/streptomycin, 
1% Insulin-Transferrin-Selenium (ITS; 10 mg/L, 5.5 mg/L and 6.7 µg/L respectively) and 
dexamethasone (100 µM). Cells were grown to confluence in collagen-I coated 12-well plates 
(Corning). Conditioned media from C2C12 myotubes was transferred on to confluent AML-
12 hepatocytes for 10 hours.  
 
6.3.4 Production of conditioned media and conditioned media transfer experimentation 
Myocytes were treated with 200 µM palmitate or the BSA vehicle during 6 days of 
differentiation. At the end of this period culture media was switched to serum-free media, 
free from any agonists, for 24 hours, allowing for the accumulation of secreted factors from 
the myocytes. This conditioned media was then transferred on to untreated myocytes for 10 
hours.  
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6.3.5 Exosome purification 
Exosomes were purified using Total Exosome Isolation Reagent (from cell culture media) 
(Thermo Fisher), following the manufacturer’s protocol. Briefly, conditioned media was 
harvested from myocytes and centrifuged (2,000 x g, 30 minutes) to remove cell debris. The 
supernatant was transferred to a fresh tube, and 0.5 volumes of the Total Exosome Isolation 
Reagent was added. Samples were vortexed well and incubated overnight at 5 ºC. Samples 
were subsequently centrifuged (10,000 x g, 60 minutes, 5 ºC) and the supernatant discarded. 
The pelleted exosomes were resuspended in serum-free media for conditioned media transfer 
to untreated myocytes, or extracted using a modified Bligh and Dyer extraction protocol 
detailed in Chapter 2 Materials and Methods (Section 2.5.1 Cell metabolite extraction for 
mass spectrometry) for LC-MS analysis.  
 
6.3.6 Conjugation of palmitate to BSA 
Palmitate was bound to BSA following the protocol summarised in Chapter 2 Materials 
and Methods (2.1.3 Conjugation of palmitate to BSA).  
 
6.3.7 Pharmacological inhibitors 
Fumonisin B1, Fenretinide, AMG PERK 44 and 4µ8c were purchased from Tocris 
Bioscience, and dissolved in DMSO to a concentration of 20 mM. The inhibitors were diluted 
into culture media to a final concentration of 10 µM, or 5µM in the case of Fenretinide. 
Myriocin was purchased from Sigma Aldrich, and dissolved in DMSO, forming a stock 
solution of 10 mM, and diluted into culture media to a final concentration of 10 µM.  
 
6.3.8 Cell harvesting 
Cells were harvested and pelleted as described in Chapter 2 Materials and Methods 
(section 2.1.4 Cell harvesting). Cell counts were performed using a Scepter automated cell 
counter (Millipore). 
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6.3.9 RNA isolation and purification 
RNA was extracted and purified from cells using an RNeasy mini kit (Qiagen), as outlined in 
Chapter 2 Materials and Methods (Section 2.4.1 RNA isolation and purification). 
 
6.3.10 cDNA synthesis  
RNA concentrations were standardised and cDNA then synthesised using a RT2 first strand 
kit (Qiagen), following the manufacturer’s instructions as set out in Chapter 2 Materials 
and Methods (Section 2.4.2 cDNA synthesis). 
 
6.3.11 Reverse transcription polymerase chain reaction 
Transcript levels were analysed using the StepOnePlus Real-Time PCR system, as described 
in Chapter 2 Materials and Methods (Section 2.4.3 Reverse transcription quantitative 
polymerase chain reaction).  
 
6.3.12 Metabolite extraction from cells 
Metabolites were extracted from cells using a modified Bligh and Dyer method, described in 
Chapter 2 Materials and Methods (Section 2.5.1 Cell metabolite and lipid extraction for 
mass spectrometry).  
 
6.3.13 Metabolite extraction from media 
1 mL of serum-free cell culture media was collected. 800 µL of methanol/chloroform (1:1) 
was added to each sample and mixed well by vortexing. Samples were centrifuged (16,100g, 
20 minutes), and the organic layer subsequently separated and dried down under nitrogen gas. 
Dried samples were stored at -80 ºC. 
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6.3.14 Liquid chromatography-mass spectrometry analysis of lipids 
The dried-down organic fraction was dissolved in 50 µl methanol/chloroform (1:1), and 
diluted into 190 µl IPA/ACN/H2O (2:1:1). Samples were then analysed using an Orbitrap 
Elite mass spectrometer, using a method with two scan events as described in Chapter 2 
Materials and Methods (Section 2.6 Liquid chromatography-mass spectrometry open 
profiling of lipids). Chromatogram files were converted using MSConvert (Proteowizard), 
and processed using XCMS within an R script. Peaks were normalised to a relevant internal 
standard and then either cell number, for in vitro experiments, or dry protein pellet weight, 
for the analysis of skeletal muscle tissue.  
 
6.3.15 Statistics 
Statistical significance was assessed using either a one-way ANOVA with Tukey’s multiple 
comparisons test, two-way ANOVA with Sidak’s multiple comparisons test or Student’s t-
test, as detailed in each figure. In each case, n ≥ 3 and the significance level was set to P ≤ 
0.05. All univariate analysis was conducted using GraphPad (version 6) software. 
 
  
  Chapter 6 
 
169 
 
6.4 Results 
6.4.1 Chronic palmitate increases synthesis of ceramides via the de novo pathway 
Ceramides are synthesised via two principal pathways – the de novo and salvage pathways – 
with previous literature implicating the former in ceramide synthesis following acute 
exposure to palmitate 354.  To investigate whether chronic palmitate-induced increases in 
ceramide synthesis are also dependent on de novo synthesis, the initial formation of 3-
ketosphinganine was prevented using myriocin, an inhibitor of SPT 368. C2C12 myotubes 
were grown to confluence, and differentiated for 6 days. During this period, cells were treated 
with either 200 µM palmitate or the BSA vehicle control. Cells were also co-treated with 
either 10 µM myriocin or the vehicle control for the final 24 hours. Cells were harvested, and 
metabolites extracted using a modified Bligh and Dyer extraction. The organic phase was 
analysed by LC-MS. Peaks were annotated using accurate mass, and peak intensity was 
normalised to a relevant internal standard and cell number. Palmitate treatment increased the 
concentrations of ceramides 34:1, 40:1 and 42:1, compared to cells treated with the vehicle 
control. However, myriocin treatment greatly reduced concentrations of ceramides in all cells 
regardless of palmitate exposure (Figure 6.2A). This highlights that palmitate-induced 
increases in ceramides are dependent on flux through SPT.  
To confirm the dependency on the de novo pathway, ceramide synthase was inhibited using 
fumonisin B1 369. C2C12 myotubes were treated with 200 µM palmitate or the BSA vehicle 
control during a 6-day differentiation period, as well as 10 µM fumonisin B1 (FB1) or the 
DMSO vehicle control for the final 24 hours. Cells were harvested and extracted using a 
modified Bligh and Dyer extraction. The organic phase was analysed by LC-MS, with peaks 
normalised to a relevant internal standard and cell number. As with myriocin treatment, 
inhibition of ceramide synthase with FB1 ablated concentrations of ceramides 34:1, 40:1 and 
42:1 in both palmitate- and BSA-treated cells (Figure 6.2B). These results highlight the 
importance of the de novo pathway in chronic palmitate-induced ceramide synthesis.  
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Figure 6.2: Chronic palmitate stimulates ceramide synthesis via the de novo pathway 
C2C12 myotubes were treated with either 200 µM palmitate, or the vehicle control, 
during a 6-day differentiation period. Cells were also co-cultured with (A) 10 µM 
myriocin, (B) 10 µM fumonisin B1 (FB1), or the vehicle control for the final 24 hours. 
Metabolites were extracted from cells and ceramides were analysed by liquid 
chromatography-mass spectrometry (LC-MS). Species were analysed using a one-way 
ANOVA with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001. Data are expressed as mean ± SEM (n = 3).  
 
A 
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6.4.2 Chronic palmitate treatment increases ceramide synthase 2 expression in skeletal 
myocytes 
There are six identified isoforms of ceramide synthase, termed ceramide synthase 1-6. The 
enzymes vary in their acyl chain specificity, and, therefore, produce a different subset of 
(dihydro)ceramides 355. Ceramide synthase 2 (Cers2) preferentially synthesises longer chain 
ceramides, including ceramides 40:1 (C22) and 42:1 (C24). Since inhibition of ceramide 
synthase reduced ceramide concentrations, the effect of chronic palmitate treatment on the 
expression of Cers2 was investigated. C2C12 myotubes were treated with either 100 or 200 
µM palmitate, or the BSA vehicle control, throughout a 6-day differentiation period. RNA 
was harvested, and the expression of Cers2 measured using RT-qPCR. The results showed 
that chronic 200 µM palmitate increased the expression of Cers2 1.5-fold, suggesting that 
palmitate-induced increases in longer chain ceramides is partially as a result of increased 
ceramide synthase 2 (Figure 6.3A).  
This mechanism was also investigated in primary HSkMCs, which were treated with 50 or 
100 µM palmitate for 6 days during differentiation. RNA was harvested and expression of 
CERS2 analysed by RT-qPCR. Treatment of primary HSkMCs with 100 µM palmitate 
increased the expression of CERS2 1.4-fold, demonstrating that palmitate-induced increases 
in ceramide synthesis in human myocytes is also partially dependent on elevated 
concentrations of ceramide synthase 2, rather than simply increased substrate availability 
(Figure 6.3B).  
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Figure 6.3: Chronic palmitate increases the expression of ceramide synthase 2 in 
mouse and human skeletal myocytes 
(A) C2C12 myotubes were treated with either 100 or 200 µM palmitate, or the vehicle 
control, during a 6-day differentiation period. RNA was harvested and expression of 
Cers2 was analysed by RT-qPCR. (B) Primary human skeletal muscle cells were treated 
with 50 or 100 µM palmitate, or the vehicle control, for 6 days during differentiation. 
RNA was harvested and expression of CERS2 was analysed by RT-qPCR. Species were 
analysed using a one-way ANOVA test with Tukey’s multiple comparison test. * P ≤ 
0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n 
= 4).  
 
B 
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6.4.3 Pharmacological inhibition of Perk reduces palmitate-induced long chain 
ceramide synthesis 
As shown in Chapter 3, chronic palmitate treatment increases not only the concentration of 
ceramides, but also the expression of UPR target genes. Therefore, the dependence of 
ceramide synthesis on specific arms of the UPR was investigated using pharmacological 
inhibition of Ire1 and Perk. C2C12 myotubes were grown to confluence and differentiated for 
6 days. During this period, cells were treated with 200 µM palmitate or the BSA vehicle 
control. For the final 24 hours, cells were also cultured with either 10 µM 4µ8c, an inhibitor 
of Ire1, 10 µM AMG PERK 44, which inhibits Perk, or the DMSO vehicle control. Cells 
were harvested and metabolites extracted using a modified Bligh and Dyer method. The 
organic phase was analysed using LC-MS, with peaks normalised to a relevant internal 
standard and cell number.  
Inhibition of Ire1 had no effect on the concentrations of ceramides 34:1, 40:1 and 42:1, 
regardless of palmitate treatment (Figure 6.4A). However, treatment with AMG PERK 44 
attenuated palmitate-induced increases in ceramides 40:1 and 42:1, suggesting a role for Perk 
in the stimulation of ceramide synthesis (Figure 6.4B). Ceramide 34:1concentrations, 
however, were unaffected by inhibition of Perk, suggesting the effect is limited to longer 
chain ceramides. BSA-treated cells were also unaffected by Perk inhibition. This suggests 
little regulation of ceramide concentrations by Perk under resting conditions, but a specific 
involvement of Perk in the elevation of long chain ceramide concentrations induced by 
palmitate. These results highlight an important role for the Perk arm of the UPR in mediating 
palmitate-induced increases in ceramide synthesis, which is a previously unknown link 
between the induction of ER stress and the generation of lipotoxic intermediates.  
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Figure 6.4: Pharmacological inhibition of Perk reduces concentrations of long-chain 
ceramides 
C2C12 myotubes were treated with either 200 µM palmitate, or the vehicle control, 
during a 6-day differentiation period. Cells were also co-cultured with (A) 10 µM 4µ8c 
(IRE1i), (B) 10 µM AMG PERK 44 (Perki), or the vehicle control for the final 24 hours. 
Metabolites were extracted from cells and ceramides were analysed by liquid 
chromatography-mass spectrometry. Species were analysed using a one-way ANOVA 
with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 
0.0001. Data are expressed as mean ± SEM (n = 3).  
 
A 
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6.4.4 Ceramides are increased in isolated exosomes from media 
Results so far have unveiled a mechanism by which palmitate stimulates synthesis of 
ceramides via the de novo pathway, and is dependent on the activation of the Perk arm of the 
UPR. Ceramides can then be secreted by activated myotubes, propagating ER stress 
signalling in a cell non-autonomous manner. However, a mechanism of release and 
trafficking between cells is not yet understood. Extracellular vesicles, such as exosomes, are 
important mediators of intercellular signalling 362. A number of studies have shown the 
importance of ceramide species in the biogenesis of exosomes 363,367. To investigate a role for 
exosomes in ceramide trafficking and ER stress activation, C2C12 myotubes were treated 
with 200 µM palmitate, or the BSA vehicle control, for 6 days during differentiation. 
Following this, culture media was switched to serum-free media, free of palmitate or BSA, 
for 24 hours. The conditioned media was then harvested and exosomes purified for analysis. 
Metabolites were extracted from exosomes using a modified Bligh and Dyer method, and the 
organic phase was analysed by LC-MS. Peaks were normalised to a relevant internal 
standard. Ceramides 34:1, 40:1 and 42:1 were all detected within exosomes purified from 
C2C12 conditioned media (Figure 6.5A). Furthermore, these species were all increased 
following chronic palmitate treatment, suggesting that exosomes are the vehicle for ceramide 
transport between cells. 
The ability for ceramide-enriched exosomes to induce ER stress was also tested. Purified 
exosomes were reconstituted in serum-free media and transferred on to untreated C2C12 
myotubes for 10 hours. The induction of ER stress was assessed using RT-qPCR of target 
UPR genes (Atf3, Atf4, Hspa5 and Edem1). Purified exosomes from palmitate-treated 
myotubes were unable to induce expression of ER stress genes when considered individually. 
However, when analysed as a group using two-way ANOVA, these exosomes were able to 
increase the expression of the UPR gene panel (Figure 6.5B), suggesting that ceramide-
enriched exosomes are capable of propagating ER stress to untreated myotubes.  
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B 
Figure 6.5: Exosomes purified from conditioned media of C2C12 myotubes treated 
with palmitate are enriched in long chain ceramides  
C2C12 myotubes were treated with 200 µM palmitate or the vehicle control for 6 days 
during differentiation. Conditioned media was collected following a switch to serum-free 
media for 24 hours and exosomes were subsequently purified from the media. (A) 
Ceramides were analysed using liquid chromatography-mass spectrometry. (B) Exosomes 
were reconstituted in serum-free media and transferred to untreated myotubes for 10 
hours. The induction of ER stress was assessed using RT-qPCR of a target panel of UPR 
genes (Atf3, Atf4, Hspa5 and Edem1). Species were analysed using a two-way ANOVA 
with Sidak’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 
0.0001. Data are expressed as mean ± SEM (n = 4).  
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Experiments were also repeated in primary HSkMCs to confirm that the results were not an 
artefact of immortalised cells. HSkMCs were grown to confluence and treated with 100 µM 
palmitate or the BSA vehicle throughout a 6-day differentiation period. Culture media was 
then switched to basal media, free of any agonists, for 24 hours. Exosomes were then purified 
from conditioned media for downstream applications. Since primary HSkMCs are cultured at 
a much lower cell number, purification of exosomes could not provide a detectable level of 
ceramides as analysed by LC-MS. However, purified exosomes were also reconstituted in 
basal media and transferred on to untreated, differentiated HSkMCs for 10 hours. RNA was 
harvested and the induction of ER stress was assessed using RT-qPCR. Exosomes purified 
from HSkMCs treated with palmitate increased the expression of ATF3 and ATF4 1.2-fold, 
while HSPA5 narrowly missed out on significance (p=0.07), relative to exosomes purified 
from BSA-treated myocytes (Figure 6.6). EDEM1 expression, however, was unaffected by 
palmitate treatment. These results show that exosomes purified from palmitate-treated 
HSkMCs are capable of increasing transcription of some UPR target genes in untreated 
myocytes, and suggest that ceramides may propagate ER stress signalling via exosome-
mediated transport. However, expression of ER stress genes was weaker in both C2C12 
myotubes and primary HSkMCs than observed in previous conditioned media experiments, 
possibly as a result of a low yield of exosomes during their isolation. 
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6.4.5 Treatment with Fenretinide increases concentrations of dihydroceramides and the 
induction of ER stress  
Following the identification of mechanisms underpinning palmitate-induced ceramide 
synthesis and secretion, culminating in the propagation of ER stress signalling, the final set of 
experiments sought to understand the manner by which ceramides can activate UPR 
signalling. Initially, LC-MS was used to profile the effects of exogenous ceramide treatment 
on the lipidome. C2C12 cells were grown to confluence and differentiated for 6 days. For the 
final 10 hours, cells were treated with either 10 µM C22 ceramide (40:1), 10 µM C24 
ceramide (42:1), a combination of the both, or the ethanol/dodecane (98:2) vehicle. Cells 
were then harvested and metabolites extracted using a modified Bligh and Dyer method. The 
organic phase was analysed by LC-MS, with peaks normalised to a relevant internal standard 
and cell number.  
Treatment of C2C12 myotubes with each ceramide increased the concentrations of that 
ceramide intracellularly, suggesting that the ceramides are taken up from the culture media 
Figure 6.6: Exosomes purified from palmitate-treated myocytes increase ER stress in 
untreated myocytes  
Primary human skeletal muscle cells were treated with 100 µM palmitate or the vehicle 
control for 6 days during differentiation. Exosomes purified from conditioned media were 
reconstituted in fresh basal media, prior to transfer to untreated myocytes for 10 hours. 
Induction of endoplasmic stress was assessed using RT-qPCR of a panel of UPR genes 
(ATF3, ATF4, HSPA5 and EDEM1). Species were analysed using a one-way ANOVA 
with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, **** P < 
0.0001. Data are expressed as mean ± SEM (n=4).  
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(Figure 6.7A). Furthermore, increases in ceramide 34:1 suggest that the C22 and C24 
ceramides are recycled to increase concentrations of other ceramides. Combined treatment 
with C22 and C24 ceramides increased concentrations of ceramide 34:1, 40:1 and 42:1 in line 
with the individual treatments. 
Consistent with the concept of recycling, concentrations of dihydroceramides (DHCers) were 
also increased with ceramide treatment. Treatment with C22 ceramide increased the cognate 
dihydroceramide 40:0, while C24 ceramide raised concentrations of dihydroceramide 42:0 
(Figure 6.7B). Similarly, both ceramide treatments also raised dihydroceramide 34:0. 
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Figure 6.7: Long chain ceramides increase intracellular concentrations of ceramides 
and dihydroceramides in C2C12 myotubes 
C2C12 myoblasts were differentiated for 6 days. During the final 10 hours, myotubes 
were treated with either 10 µM C22:0 ceramide, 10 µM C24:0 ceramide, a combination of 
both, or the vehicle control. (A) Ceramides and (B) dihydroceramides were analysed by 
liquid chromatography-mass spectrometry. Species were analysed using a one-way 
ANOVA with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001. Data are expressed as mean ± SEM (n = 3).  
A 
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Experiments were repeated in primary HSkMCs to confirm results are consistent between 
models. HSkMCs were treated with either 10 µM C22 ceramide (40:1), 10 µM C24 ceramide 
(42:1), a combination of the both, or the ethanol/dodecane (98:2) vehicle for the final 10 
hours of a 6-day differentiation period. Metabolites were extracted using a modified Bligh 
and Dyer method, and the organic phase was analysed using LC-MS. Peaks were normalised 
to a relevant internal standard and cell number. As observed in C2C12 myotubes, treatment 
with either C22 or C24 ceramide increased the concentrations of ceramide 40:1 and 42:1, 
respectively, while combined treatment increased both the ceramides (Figure 6.8A). 
However, ceramide 34:1 was largely unaffected, and C24 ceramide in fact decreased 
concentrations of ceramide 34:1.  
Changes in dihydroceramide 40:0 were also analogous to results observed in C2C12 
myotubes (Figure 6.8B). However, dihydroceramide 34:0 was unaffected by ceramide 
treatment, while dihydroceramide 42:0 was only increased by combined C22 and C24 
ceramide treatment. These results show that ceramide treatment of both murine and primary 
human myocytes increase not only ceramide but also concentrations of dihydroceramides, a 
set of sphingolipids that are normally considered as ceramide precursors in de novo synthesis.  
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Recent work has demonstrated a role for dihydroceramide accumulation in the induction of 
ER stress. Inhibition of dihydroceramide desaturase in a gastric carcinoma cell line led to the 
accumulation of dihydroceramides, concomitant with cell cycle arrest and the induction of 
ER stress 370. Furthermore, an increase in the dihydroceramide:ceramide ratio increases ER 
stress and apoptosis in glioma cells 371. To investigate if dihydroceramides may mediate lipid-
induced ER stress, C2C12 cells were grown to confluence and differentiated for 6 days, 
A 
Figure 6.8: Long chain ceramides increase intracellular concentrations of ceramides 
and dihydroceramides in primary human skeletal myocytes 
Primary human skeletal muscle cells were differentiated for 6 days. During the final 10 
hours, myotubes were treated with either 10 µM C22:0 ceramide, 10 µM C24:0 ceramide, 
a combination of both, or the vehicle control. (A) Ceramides and (B) dihydroceramides 
were analysed by liquid chromatography-mass spectrometry. Species were analysed using 
a one-way ANOVA with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** 
P < 0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n = 3).  
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during which they were treated with either 200 µM palmitate or the vehicle control. For the 
final 24 hours, cells were co-cultured with either 5 µM Fenretinide, an inhibitor of 
dihydroceramide desaturase, or the DMSO vehicle control. Cells were harvested and 
metabolites were extracted using a modified Bligh and Dyer method. Peaks were normalised 
to a relevant internal standard and cell number. RNA was also collected, and the induction of 
ER stress assessed using RT-qPCR.  
LC-MS analysis demonstrated that Fenretinide treatment slightly reduced palmitate-induced 
increases of ceramide 34:1 and 42:1, while ceramide 40:1 was unchanged (Figure 6.9A). 
Concentrations of dihydroceramide 34:0, 40:0 42:0, however, were greatly increased, 
highlighting effective inhibition of dihydroceramide desaturase (Figure 6.9B). This 
inhibition also increased palmitate-induced levels of Atf3 (10-fold compared to palmitate-
treated cells), Atf4 (1.7-fold compared to palmitate-treated cells) and Hspa5 (3.1-fold 
compared to palmitate-treated cells), although Edem1 expression was unaffected (Figure 
6.9C). These results implicate dihydroceramides in mediating palmitate-induced ER stress, 
and suggest that increases in dihydroceramides following exogenous ceramide treatment may 
have mechanistic importance.  
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Figure 6.9: Inhibition of dihydroceramide desaturase increases concentrations of 
dihydroceramides and exacerbates palmitate-induced ER stress 
C2C12 myoblasts were treated with 200 µM palmitate or the vehicle control during a 6-day 
differentiation period. During the final 24 hours, myotubes were treated with either 5 µM 
Fenretinide, or the vehicle control. (A) Ceramides and (B) dihydroceramides were analysed 
by liquid chromatography-mass spectrometry. (C) Induction of ER stress was analysed by 
RT-qPCR of a UPR gene panel (Atf3, Atf4, Hspa5 and Edem1). Species were analysed 
using a one-way ANOVA with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, 
*** P < 0.001, **** P < 0.0001. Data are expressed as mean ± SEM (n = 3).  
B 
C 
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6.4.6 Conditioned media from palmitate-treated myocytes activates ER stress in AML-
12 hepatocytes  
This chapter has focused on the identification of ceramides, packaged in exosomes, as cell 
non-autonomous signals that propagate ER stress activation. However, all experiments have 
considered ceramides as paracrine mediators, increasing UPR signalling in neighbouring 
skeletal myocytes. Yet, ceramides 40:1 and 42:2, were both increased in the plasma of mice 
fed a high-fat diet, suggesting that ceramides may be endocrine signalling compounds. 
Therefore, we hypothesised that conditioned media derived from skeletal myocytes could 
activate ER stress in other tissue types. To investigate this, conditioned media was collected 
from C2C12 myotubes treated chronically with either 200 µM palmitate or the BSA vehicle 
control, as previously described. This conditioned media was then transferred on to untreated 
AML-12 hepatocytes, and the induction of ER stress assessed using RT-qPCR. Conditioned 
media from myotubes treated with palmitate increased expression of Atf3 (2.7-fold), Atf4 (4-
fold), Hspa5 (1.9-fold), and Edem1 (1.2-fold), indicating the induction of ER stress (Figure 
6.10). These results show that secreted factors from stressed myotubes can induce ER stress 
in cell types of distal tissues. While the nature of this signal is not clear, it is feasible that long 
chain ceramides may also induce ER stress in hepatocytes and, therefore, have the capacity to 
act as endocrine signals.   
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Figure 6.10: Conditioned media from palmitate-treated C2C12 myotubes induces 
ER stress in untreated AML-12 hepatocytes 
C2C12 cells were treated with 200 µM palmitate or the BSA vehicle control during a 6-
day differentiation period. Subsequently, media was switched to serum-free media for 24 
hours. This conditioned media was then transferred to untreated AML-12 hepatocytes for 
10 hours and RT-qPCR was used to analyse the expression of key unfolded protein 
response genes (Atf3, Atf4, Hspa5 and Edem1). Each gene was analysed using a one-way 
ANOVA with Tukey’s multiple comparison test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001. Data are expressed as mean ± SEM (n = 4).  
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6.5 Discussion 
This chapter aimed to improve mechanistic understanding of ceramide-mediated intercellular 
propagation of ER stress signalling. Co-treating myotubes with palmitate and inhibitors of 
ceramide synthase or SPT reduced ceramide concentrations, indicating that chronic 
palmitate-stimulated synthesis of ceramides is via the de novo pathway. This is in line with 
previous work using acute models of palmitate exposure, which resulted in an increase in flux 
through SPT 354. Here, however, palmitate treatment increased expression of Cers2, a 
ceramide synthase isoform that preferentially incorporates long-chain acyl chains, providing 
an additional level of regulation in the de novo pathway. Previous work has highlighted that 
acute palmitate also stimulates the transcription of Cers2 in myotubes 358. The importance of 
Cers2 in the development of insulin resistance has been questioned, with one study showing 
that haploinsufficiency for Cers2 increased susceptibility to diet-induced insulin resistance in 
mice as a result of compensatory increases in C16 ceramide 372. While this study suggested 
that Cers6-generated C16 ceramide is important in the dysregulation of insulin signalling, 
overexpression of Cers6 in myotubes improved insulin sensitivity in another study 373. These 
contradictory results show the difficulty in studying ceramide synthase isoforms, namely due 
to compensatory changes following genetic ablation. The effects of altering ceramide 
concentrations are likely to be context-dependent, and more nuanced models, such as tissue-
specific and inducible genetic knockout mice, may be required to understand the importance 
of specific ceramide synthase isoforms in dyslipidaemia and the development of insulin 
resistance.  
The poor solubility of ceramides in water suggested the need for effective packaging of the 
sphingolipids for extracellular transport a paracrine signal. Exosomes purified from 
conditioned media were enriched in ceramides, providing a mechanism of transport between 
cells. Our understanding of the importance of exosomes in cell-cell signalling has increased 
greatly in recent years, with their role in transporting cargo including proteins, lipids and 
nucleic acids well-documented 362,374,375. Inhibition of neutral sphingomyelinase in Oli-neu 
cells reduced exosome secretion, demonstrating an important role for ceramides in exosome 
release 367. Furthermore, exosomes enriched in C16 and C24 ceramide were shown to 
mediate Tnfα-induced cell death in human oligodendroglioma cells 376. The results in this 
chapter, in combination with previous work, highlight the importance of ceramides in both 
exosome biogenesis and signalling.  
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Ceramide-enriched exosomes were also secreted from hepatocytes treated with palmitate, 
capable of increasing macrophage chemotaxis 363. Both exosome secretion and ceramide 
concentrations were reduced in hepatocytes derived from IRE1-null mice, showing an 
interaction between exosome signalling and ER stress. However, this study showed that 
exosomes were enriched in C16 ceramide, rather than longer chain species, suggesting tissue-
differences in the regulation of ceramide synthesis. The importance of C16 ceramide is well-
documented in development of insulin resistance in the liver and adipose tissue 377. However, 
a role for C16 ceramide is less convincing in skeletal muscle, supported by results in this 
thesis. Future work should focus on understanding if longer chain ceramides in skeletal 
muscle function in an analogous manner to C16 ceramide in other insulin-sensitive tissues, or 
if ceramide signalling is chain length specific.  
With previous work showing the importance of ceramide-enriched exosomes in the liver 
microenvironment, the potential for myocyte-derived exosomes isolated in this chapter to 
function in an endocrine manner should be pursued in further research. Indeed, results from 
this chapter showed that conditioned media from palmitate-treated myotubes could induce 
ER stress in AML-12 hepatocytes, showing that a myotube-derived signal could act on 
different cell types. Although the nature of this signal is unclear, possible candidates include 
the long chain ceramides enriched in exosomes. Previous studies have suggested a role for 
ceramides in saturated fatty acid-induced ER stress in the liver, strengthening this hypothesis 
378.  
The importance of ER stress in skeletal muscle lipid-induced insulin resistance has been 
debated 258,259,379. However, in this chapter, inhibition of Perk activity decreased 
concentrations of long-chain ceramides. With strong evidence supporting a role for ceramides 
in the development of insulin resistance, this data suggests a novel mechanistic link between 
increased ER stress and insulin sensitivity 58,380. These results should be followed up using 
siRNA-mediated knockdown of Perk to confirm that decreases in ceramides are not an off-
target effect of the inhibitor. Experiments should also probe the mechanism between Perk and 
ceramide synthesis. Ceramide 34:1 concentrations were unaffected by inhibition of Perk, 
suggesting a mechanism focusing on ceramide synthase 2, which specifically incorporates 
longer chain acyl-CoA moieties into ceramides 355.  
Preliminary work to isolate the mechanism underpinning ceramide-induced ER stress focused 
on the role of dihydroceramides, which increased following exogenous ceramide treatment. 
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Inhibition of dihydroceramide desaturase 1 (Des1) increased the dihydroceramide:ceramide 
ratio, and activated ER stress. A role for dihydroceramide accumulation in ER stress has also 
been reported in gastric carcinoma cells 370. However, conversion of ceramide to 
dihydroceramide has previously not been reported, and experiments should focus on 
understanding whether the increases in dihydroceramides result from increases in sphingosine 
via the salvage pathway or reverse activity of Des1. Mitigating these results is the evidence 
supporting inhibition of Des1 as a therapeutic intervention in metabolic disease, in which 
Fenretinide improved ameliorated lipid-induced insulin resistance in cultured myotubes and 
mice fed a high-fat diet 381,382. Much work is required to delineate the importance of 
dihydroceramides in ER stress induction, including siRNA knockdown of Des1 to rule out 
potential drug-induced ER stress. 
 
Conclusion 
Experiments in this chapter have shown that palmitate-stimulated synthesis of ceramides is 
via the de novo pathway, in part due to an increase in expression of Cers2.  This synthesis 
was reduced following inhibition of the Perk arm of the UPR, implicating ER stress in the 
regulation of lipotoxic mediators. Exosomes purified from the conditioned media of 
palmitate-treated myotubes were enriched with long chain ceramides, providing a mechanism 
for ceramide secretion. Conditioned media transfer on to hepatocytes indicates the presence 
of potential endocrine mediators of UPR activation. 
  
 
Chapter 7  
 
Summary and Discussion 
 
7.1 General Discussion 
The increase in the number of individuals with T2DM places a strain on global healthcare 
systems. To develop improved therapeutic approaches for this growing epidemic, we need to 
better understand the mechanisms underpinning the aetiology of metabolic dysfunction in 
T2DM. Obesity is the leading independent risk factor. Recently circulating FFA-induced 
endoplasmic reticulum stress has emerged as a mechanism linking obesity-mediated 
dyslipidaemia with the development of insulin resistance 40,57. This thesis sought to use 
lipidomic tools to profile metabolic perturbations linking palmitate-induced lipotoxicity to 
ER stress in skeletal muscle 276.  
This thesis compared acute models of palmitate-induced ER stress, typically favoured in the 
literature 54,103,257–260, with a chronic palmitate exposure model developed in C2C12 
myotubes. The chronic model demonstrated greater metabolic disruption in a background of 
UPR activation more reflective of in vivo scenario 275. In particular, chronic palmitate 
stimulated catabolism of PUFA-containing PCs in a cPLA2-dependent manner, a metabolic 
signature that translated to in vivo models of obesity and the clinic. While similar correlations 
between PUFA-containing PCs and insulin resistance had previously been documented in 
human studies 292, this work suggests palmitate as a driver of this process.  
Little previous research has focused on the functional consequences of palmitate-induced 
phospholipid remodelling within skeletal muscle. The enhanced catabolism of PCs following 
palmitate exposure is likely to have a profound effect on membrane properties such as 
fluidity, but this thesis hypothesised that phospholipid remodelling would also provide an 
increase in free PUFAs as a substrate for bioactive eicosanoid synthesis and inflammatory 
signalling 294. The importance of myocyte-derived eicosanoids in metabolic disease is under-
investigated. Here, a targeted LC-MS/MS method was employed to profile an array of 
eicosanoids. The results suggested that myocytes predominantly synthesise and secrete 
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lipoxygenase-derived eicosanoids, and their release was increased in response to both acute 
and chronic palmitate exposure. Pharmacological inhibition of 15-LOX in both C2C12 
myotubes and primary HSkMCs amplified expression of key inflammatory cytokines Ccl2 
and Il6, which suggests a role for 15-LOX-derived eicosanoids in the control of inflammatory 
cytokine synthesis. Previous studies have also shown a role for eicosanoids in the promotion 
of inflammation and insulin resistance. Treatment of myotubes with LTB4 increased 
inflammatory signalling and reduced insulin-stimulated glucose uptake, while inhibition of 
the LTB4 receptor protected mice from insulin resistance 311. 12-LOX-KO mice were 
protected from high-fat diet-induced increases in inflammatory cytokine concentrations in 
adipose tissue, while markers of insulin sensitivity were increased in skeletal muscle 296. 
Similarly, treating adipocytes with LOX-derived 12-HETE increased expression of 
inflammatory cytokines 383. However, results from this thesis suggest 15-LOX-derived 
eicosanoids restrict the synthesis of inflammatory cytokines, acting to fine-tune the 
inflammatory response stimulated by palmitate. This is the first demonstration that skeletal 
muscle-derived eicosanoids may be beneficial to metabolic-associated inflammation. With 
previous studies emphasising 5- and 12-LOX derived eicosanoids in the development of 
inflammation and insulin resistance, results here suggest an alternative subset of 
metabolically-beneficial eicosanoids. Therefore, increasing the activity of 15-LOX, or 
treatment with 15-LOX products, may reduce palmitate-induced inflammation in skeletal 
muscle, a mechanism well described for the development of insulin resistance 299.  
Chronic low-grade inflammation, typified by enhanced tissue macrophage infiltration, is a 
hallmark of the metabolic syndrome 91,254. This thesis further investigated the interaction 
between palmitate-exposed myotubes and macrophages in the setting of enhanced eicosanoid 
signalling. Previously, conditioned media transfer experiments had suggested that palmitate-
treated myocytes secrete signals capable of increasing macrophage activation 321. This thesis 
sought to better understand bi-directional signalling by employing a co-culture system. 
Myotubes chronically treated with palmitate signalled to increase macrophage activation. The 
use of serum-free media ensured that these effects were independent of palmitate itself, and 
instead were a result of secreted factors from the myotubes. However, pharmacological 
inhibition of either cPLA2, 12-LOX or 15-LOX did not dampen the expression of these 
markers, suggesting that the effects on macrophage activation are likely to be independent of 
eicosanoids.  
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Instead, myocyte-derived eicosanoids appear important in the transmission of ER stress from 
myotubes to macrophages. Co-culture of palmitate-treated myotubes with macrophages 
increased macrophage expression of UPR target genes, and this response was attenuated with 
inhibition of cPLA2. While a role for eicosanoids in the regulation of ER stress has been 
shown previously 297, as far as the author is aware, this thesis is the first to suggest they 
function in propagating the activation of the UPR between different cell types. Here, 
inhibition of 12- and 15-LOX did not impact on the propagation of ER stress, suggesting that 
an alternative subset of eicosanoids, or a separate cPLA2-dependent product such as 
lysophosphatidylcholines, are involved in this signalling. The consequences of this activation 
of the UPR are unclear, but literature suggests ER stress can impact on both the polarisation 
and function of macrophages 384.  
Using the co-culture system, the reciprocal assessment of bi-directional crosstalk between 
myotubes and macrophages was explored. RT-qPCR profiling of C2C12 myotubes 
subsequent to co-culture showed no difference in UPR target gene expression in response to 
palmitate. This suggests that macrophage-derived factors may facilitate the suppression of ER 
stress in skeletal muscle. While the results are preliminary, this could have interesting 
implications for our understanding of the role the immune system plays in the metabolic 
syndrome. The importance of macrophage activation in this process also warrants further 
investigation. 
This thesis also highlighted eicosanoid lipids as regulators of UPR signalling in myotube 
monocultures. Inhibition of 12-LOX exacerbated palmitate-induced ER stress in myotubes, 
suggesting a role for this subset of eicosanoids in the control of skeletal muscle UPR 
activation. This is in apparent disagreement with previous literature showing that inhibition 
of 12-LOX ameliorates chemical-induced ER stress in adipocytes 326. However, the study by 
Cole and colleagues utilised both different tissue types and different inducers of ER stress, 
making comparisons difficult. Furthermore, they also show an increase in the expression of 
Hspa5 and Atf4 in 12-LOX-KO mice, in line with the results of this thesis. A possible role for 
eicosanoids in the regulation of ER stress has been suggested in other papers as well, namely 
with the demonstration that pharmacological inhibition of 5-LOX reduces lipid-induced ER 
stress in C2C12 myotubes 297. However, this is the first demonstration that a subset of 
eicosanoid species may function to ameliorate UPR activation. By increasing the activity of 
12-LOX or by isolating specific 12-LOX-derived species, it may be possible to reduce the 
induction of ER stress. These results provided functional validation for not only alterations in 
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eicosanoid secretion but also remodelling of phospholipids observed within in vitro and in 
vivo models of metabolic disease. In addition to a pivotal role in inflammatory signalling, 
these investigations show myocyte-derived eicosanoids are important in the control of ER 
stress, providing a novel insight into the regulation of UPR activation by lipid mediators.  
Furthermore, this thesis identified the first cell non-autonomous signal functioning in cell-cell 
activation of the UPR (Figure 7.1) 146. Conditioned media from palmitate-treated myotubes 
induced ER stress in untreated myotubes, indicating the presence of a signal-molecule. This 
induction was unaffected by boiling of the media, suggesting the signal was likely to be non-
protein. LC-MS lipidomic profiling of the media identified candidate signals, and long-chain 
ceramides were observed to be paracrine/autocrine mediators of ER stress. These results also 
translated to primary HSkMCs, suggesting a conserved mechanism in human cells. These 
results build on previous studies that suggested the presence of cell non-autonomous signals 
in UPR regulation 150. A recent study demonstrated retromer-dependent Wnt signalling in the 
cell non-autonomous regulation of the mitochondrial unfolded protein response in C. elegans, 
a pathway activated in response to an accumulation of unfolded proteins in the mitochondria 
385,386. However, this thesis is the first to show the importance of lipid, rather than protein, 
signalling in the cell non-autonomous regulation of ER stress activation. Previous studies 
have emphasised the correlation between plasma ceramide concentrations, insulin resistance 
and metabolic disease 72,387,388. Furthermore, ceramides contained within LDL have been 
shown to target skeletal muscle and promote insulin resistance, showing the capacity for 
circulating ceramides to elicit signalling changes within myocytes 389. The results in this 
thesis, providing the first identification of a cell non-autonomous signal, are crucial for our 
understanding of protein homeostasis and suggest that a cell autonomous viewpoint of ER 
stress is insufficient. Furthermore, these results place ceramides at the centre of lipotoxicity 
and the control of ER stress in metabolic disease. 
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Long chain ceramides were also increased in the skeletal muscle of in vivo models of obesity 
and T2DM analysed in this thesis. In particular, a western diet-fed mouse model best 
reflected the effects of palmitate in culture, while the high-fat diet mouse studies proved 
inconsistent. Phospholipid remodelling was similarly inconsistent in mice fed a high fat diet, 
but western diet-fed mice exhibited the PC catabolism observed in vitro. The reasons 
underpinning this observation are unclear but are likely to reflect differences in the diet and 
whole-body physiology. The western diet is high in sucrose, as well as fat, and mice fed this 
diet have increased de novo lipogenesis (DNL) 291. With palmitate the major product of DNL, 
western diet-fed mice may be exposed to more palmitate than mice fed a high fat diet. 
Furthermore, previous work has shown that palmitate deriving from DNL is more 
hepatotoxic than dietary palmitate 390. This toxicity difference may also be important in 
skeletal muscle metabolism, explaining differences observed between the western diet and 
Figure 7.1 Long chain ceramides are cell non-autonomous signals that propagate 
endoplasmic reticulum stress between myocytes 
Exogenous palmitate induces endoplasmic reticulum (ER) stress in myocytes. This 
includes the activation of the PERK arm of the unfolded protein response, which 
enhances de novo synthesis of long-chain ceramides from palmitoyl-CoA. Ceramides are 
then packaged into exosomes and secreted from the cell of synthesis. Uptake of ceramide-
enriched exosomes stimulates the synthesis of dihydroceramides and the induction of ER 
stress 405.  
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high-fat diet murine studies. These results raise questions with regards to in vivo dietary 
models of obesity. Results not only differed between the studies using a western diet and 
those using a high fat diet, but also between the two high fat diets. There were profound 
differences between the two high fat diets, including proportions of protein and carbohydrate. 
Furthermore, the source of fat in diet F3282 was lard, while fat content in D12492 derived 
from both lard and soybean oil. This is likely to lead to differences in the fatty acid profile of 
each diet, clearly impacting on the mouse lipidome. A standardised high fat diet, and 
associated protocols such as duration of feeding, would help comparisons between different 
studies both within the same research group and across separate groups 391. Furthermore, as 
our mechanistic knowledge of diet, obesity and insulin resistance improves, we can tailor the 
composition of the high fat diet to optimise the induction of metabolic pathologies. Previous 
studies have highlighted the benefits of using a western diet compared to a high-fat diet for 
mouse models of insulin resistance, lipid metabolic dysfunction and contractile dysfunction, 
suggesting that future studies could focus on this dietary intervention 278,392.  
With the identification of ceramides as secreted signals, questions remained about the 
mechanism of cell-cell transport. The poor aqueous solubility of ceramides suggested a 
requirement for a vehicle. Exosomes have emerged as important mediators of paracrine and 
endocrine signalling 362. Here, purified exosomes from the media of palmitate-treated cells 
were enriched in long chain ceramides. Treating myotubes with these exosomes increased the 
expression of UPR target genes, suggesting exosomes function as the extracellular vehicle for 
ceramides. These results are consistent with the demonstration that palmitate treatment of 
hepatocytes increased the secretion of ceramide-enriched exosomes 363. However, the 
ceramide-content of exosomes has canonically been viewed as secretion mechanism, 
especially since inhibition of neutral sphingomyelinase 2 prevents the release of exosomes in 
an oligodendroglial cell line 367. Research has predominantly focused on the protein and RNA 
content of exosomes, but the results of this thesis highlight the importance of exosome lipid 
composition in cell-cell communication 366. Exosomal-dependent lipid signalling may 
represent an important mechanism underpinning the progression of metabolic disease, 
requiring the focus of future research. 
Lipidomic tools were employed to investigate the mechanism by which exogenous ceramide 
enhanced ER stress. LC-MS profiling of ceramide-treated cells showed an increase in 
dihydroceramides, canonically viewed as precursors to ceramides in the de novo synthesis 
pathway 364. Previous literature has suggested a role for dihydroceramide accumulation in ER 
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stress 370. Here, inhibition of dihydroceramide desaturase increased dihydroceramide 
concentrations concomitant with the exacerbation of palmitate-induced ER stress, suggesting 
a similar mechanism. The means by which dihydroceramides may activate UPR signalling is 
unclear, but may relate to alterations in membrane structure 393,394. Conversely, inhibition of 
dihydroceramide desaturase also inhibits lipid-induced insulin resistance in murine models of 
obesity, while knockdown of dihydroceramide desaturase ameliorated palmitate-induced ER 
stress in C2C12 myotubes 381. This appears contrary to a role for dihydroceramides in the 
activation of the UPR, given the mechanistic links between ER stress and the development of 
insulin resistance 154. Further work is required to understand the importance of 
dihydroceramides in palmitate-induced ER stress, and the consequences for insulin 
sensitivity. 
 
7.2 Future Directions 
The results of this thesis may be expanded upon in a number of ways. Chapter 4 showed 
lipoxygenase-derived eicosanoids signal in the regulation of skeletal muscle ER stress. 
Knockdown of lipoxygenase isoforms with siRNA would complement the use of 
pharmacological inhibitors, and confirm that the exacerbation of palmitate-induced ER stress 
is not a result of off-target drug effects. Further work should then focus on the identification 
of important eicosanoid species that drive the signalling events observed. The effects of 
candidate eicosanoids could be interrogated with the induction of ER stress profiled 
transcriptionally using a method similar to that in Chapter 5. Eicosanoids predominantly 
stimulate intracellular signalling by binding to G protein-coupled receptors (GPCRs) 395. 
Therefore, the effects of individual species could be confirmed by ablating receptor function 
or using a high throughput GPCR-reporter linked screen 396,397.  
Furthermore, the results of macrophage co-culture with myotubes in Chapter 4 could also be 
developed. In this thesis, macrophage activation was assessed using transcriptional markers. 
This analysis, would be complemented by flow cytometry-based cell sorting using protein 
markers such as CD64, CD80, CD11 and CD209 398. Not only would this provide a more 
detailed assessment of macrophage activation, but the technique would also provide 
information on single-cell macrophage phenotypes. Co-cultured macrophages exhibited 
increased expression of both M1 and M2 markers. Flow cytometry would help ascertain if a 
mixed population of cells were present or if these increases represented an alternative 
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macrophage activation state. Flow cytometry work should also be combined with metabolic 
phenotyping of macrophages. For example, M1 macrophages are characterised by elevated 
glycolysis, while M2 macrophages have increased fatty acid β-oxidation and arginase-driven 
production of ornithine 399.   
Chapter 4 demonstrated that macrophages suppress palmitate-induced ER stress in C2C12 
myotubes. Future work should confirm this observation in an experiment using palmitate 
treatment of myotubes with and without co-cultured macrophages. In such an experiment, 
myotubes would be treated chronically with palmitate or the BSA vehicle, as described 
throughout this thesis. For the final 24 hours, media would be switched to serum-free media 
and half of the replicates in each treatment group co-cultured with macrophages, while the 
other half would be macrophage-free. Comparisons between the treatment groups would 
highlight any protective effect of macrophage co-culture on the activation of myotube UPR 
signalling. Furthermore, it is important that experiments are extended in to human primary 
tissue cultures to confirm this is not an artefact of immortalised murine cell lines. An 
improved characterisation of macrophage phenotypes will aid in the identification of 
mechanisms underpinning the macrophage-mediated suppression of ER stress – namely if 
macrophage phenotype affects their capacity to ameliorate myotube stress. If macrophage 
activation does influence this process, experiments could focus on manipulating macrophages 
in vivo using candidate signal-derived treatments and assess the impact on diet-induced ER 
stress in murine models of obesity. The impact on insulin sensitivity and glucose homeostasis 
should also be considered. This is a potentially interesting field of research with little or no 
literature suggesting a role for macrophages in the control of UPR signalling in peripheral 
tissues.  
Chapter 5 identified the first paracrine mediator of ER stress 146. To conclusively confirm 
long chain ceramides as a paracrine mediator of ER stress, conditioned media transfer 
experiments should use media from cells co-treated with palmitate and an inhibitor of 
ceramide synthesis, such as myriocin, which should show ameliorated induction of ER stress. 
This pharmacological approach could also be complemented with siRNA knockdown of 
ceramide synthase 2, allowing for the investigation specifically of long chain ceramides. This 
method was recently employed in the investigation of long-chain ceramides in cardiomyocyte 
lipotoxicity 357. However, previous literature has shown that knockdown of ceramide 
synthase isoforms is compensated for with upregulation of alternative isoforms 400. Future 
experiments should also seek to confirm ceramides as paracrine mediators in vivo. This could 
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be achieved by treating mice with ceramide species, but this is complicated by the solubility 
of ceramides, preventing their introduction via drinking water or injection without a toxic 
vector. Instead, a short-chain ceramide analogue has been used in previous studies, which is 
rapidly converted into more physiological ceramides 344,401.  
Experiments in this thesis have predominantly focused on the metabolic consequences of 
lipotoxicity and ceramide signalling in skeletal muscle. However, previous studies have 
highlighted the importance of ceramides for the development of insulin resistance and 
metabolic dysfunction in other tissue types, including adipose and liver. Indeed, 
overexpression of hepatic acid ceramidase, which catalyses the breakdown of ceramides, 
prevents hepatic steatosis and improves insulin sensitivity in both the liver and adipose tissue 
402. These results implicate ceramides in the progression of metabolic disease in tissues other 
than skeletal muscle. Further work should, therefore, seek to understand if ceramides may act 
as paracrine mediators within adipose and the liver as well. Indeed, hepatocytes treated with 
palmitate secrete ceramide-enriched extracellular vesicles 363. However, this study 
highlighted an enrichment in C16 ceramide only, while synthesis was dependent on Ire1, 
suggesting alternative mechanisms to those uncovered in skeletal muscle within this thesis.  
The identification of exosomes as a vehicle for secreted ceramides is an interesting area for 
further research. Understanding of the role exosomes play in cell-cell signalling is improving 
but the mechanisms relating to their release and uptake are poorly described. Previous work 
has suggested a role for ceramides in exosome budding, but this is via neutral 
sphingomyelinase, a member of the salvage pathway 367. This thesis demonstrates that 
ceramides synthesised via the de novo pathway go on to induce ER stress, suggesting an 
alternative mechanism. Proteomic profiling of both myotubes and purified exosomes may 
provide an insight into mediators of exosome release, tissue targeting and uptake. Once 
mechanisms are identified, the role ceramide enriched exosomes play in whole body glucose 
homeostasis and dyslipidaemia can be investigated via pharmacological inhibition or genetic 
ablation of key mediators.  
Inhibition of Perk reduced concentrations of long chain ceramides following exposure of 
myotubes to palmitate. This identified a novel link between ER stress and the synthesis of 
ceramides. These results should first be confirmed using genetic ablation of this arm of the 
UPR, as well as translation in primary HSkMCs. Perk-dependent regulation of sphingolipid 
synthesis could also be pursued in vivo using a Perk-null mouse model, challenged with a 
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western diet. Using glucose uptake assays in vitro, and insulin tolerance tests and OGTTs in 
vivo could be used to assay the importance of Perk signalling and ceramide accumulation in 
the development of insulin resistance and T2DM.  
Finally, the role ceramide-enriched exosomes play in endocrine signalling could be 
investigated. Conditioned media from palmitate-treated myotubes induced ER stress in 
hepatocytes, while ceramides were increased in the plasma of mice fed a high fat diet, 
suggesting their transport between tissues in vivo. Further work could employ conditioned 
media transfer from myotubes to other cells of interest, including adipocytes and pancreatic 
β-cells, followed by the profiling of UPR activation. The induction of ER stress in these 
tissues has important consequences in cellular pathology and dysfunctional insulin signalling. 
A role for long chain ceramides could then be confirmed by exposing cells to exogenous 
ceramide or purified exosomes. Similarly, ceramide-enriched exosomes may be important in 
associated pathologies of the metabolic syndrome such as endothelial dysfunction, for which 
ER stress represents a potential mechanism 403. Features of dysfunctional endothelial cells in 
culture include increased inflammatory signalling, expression of adhesion molecules and 
elevated rates of apoptosis, which can then be assayed following conditioned media transfer, 
or treatment with ceramide-enriched exosomes 404. Isolating and profiling exosomes in 
plasma collected from murine in vivo models of metabolic disease and clinical samples to 
assess ceramide enrichment would increase translation from culture experiments. 
Improvements in our understanding of mechanisms of exosome release and uptake could also 
aid in in vivo assessment of the role ceramide-enriched exosomes play in endocrine 
signalling. Once identified, use of genetic models in which constituents of pathways involved 
in exosome release are knocked out specifically in skeletal muscle would be important in the 
investigation of their biological and pathophysiological significance.  
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7.3 Conclusions 
To conclude, this thesis employed lipidomic techniques to gain a deeper understanding of 
palmitate-induced ER stress and lipotoxicity in skeletal muscle and its contribution to 
dyslipidaemia. Combining LC-MS and GC-MS analysis with RT-qPCR of key UPR target 
genes demonstrated the importance of phospholipid remodelling in the production of 
bioactive lipid signalling molecules. In particular, chronic palmitate stimulated the 
breakdown of PUFA-containing PCs to generate lipoxygenase-derived eicosanoids, a 
metabolic phenotype also observed in skeletal muscle tissue of in vivo models of obesity and 
T2DM. The secretion of eicosanoids synthesised by lipoxygenase isoforms were increased 
following both acute and chronic palmitate treatment and may have important paracrine roles. 
Inhibition of key lipoxygenase isoforms implicated a subset of eicosanoids in the control of 
UPR activation in both myotubes and co-cultured macrophages, highlighting previously 
unknown paracrine mechanisms that may be important in lipotoxicity and the progression of 
metabolic disease.  
Furthermore, this thesis has also identified exosome-packaged long-chain ceramides as cell 
non-autonomous signals propagating ER stress between myotubes. Chronic palmitate 
treatment increases the synthesis of ceramides via ceramide synthase 2, and the ceramides are 
packaged into exosomes and secreted into the culture media. Ceramides were also increased 
in the skeletal muscle and plasma of in vivo models of obesity. The Perk arm of the UPR 
links ER stress to the synthesis of ceramides, while the accumulation of dihydroceramides 
may represent a potential mechanism linking exogenous ceramides with the induction of ER 
stress. This work is the first identification of non-autonomous signals of its kind and has 
important implications for our understanding of ER stress regulation in metabolic disease.  
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